
<html lang="en"     class="pb-page"  data-request-id="00a2865b-e539-4e7a-930c-83cfca5c96a0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00610;issue:issue:10.1021/jmcmar.2016.59.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Liping H.  Pettus" /></meta><meta name="dc.Creator" content="Kristin L.  Andrews" /></meta><meta name="dc.Creator" content="Shon K.  Booker" /></meta><meta name="dc.Creator" content="Jie  Chen" /></meta><meta name="dc.Creator" content="Victor J.  Cee" /></meta><meta name="dc.Creator" content="Frank  Chavez, Jr." /></meta><meta name="dc.Creator" content="Yuping  Chen" /></meta><meta name="dc.Creator" content="Heather  Eastwood" /></meta><meta name="dc.Creator" content="Nadia  Guerrero" /></meta><meta name="dc.Creator" content="Bradley  Herberich" /></meta><meta name="dc.Creator" content="Dean  Hickman" /></meta><meta name="dc.Creator" content="Brian A.  Lanman" /></meta><meta name="dc.Creator" content="Jimmy  Laszlo, III" /></meta><meta name="dc.Creator" content="Matthew R.  Lee" /></meta><meta name="dc.Creator" content="J. Russell  Lipford" /></meta><meta name="dc.Creator" content="Bethany  Mattson" /></meta><meta name="dc.Creator" content="Christopher  Mohr" /></meta><meta name="dc.Creator" content="Yen  Nguyen" /></meta><meta name="dc.Creator" content="Mark H.  Norman" /></meta><meta name="dc.Creator" content="David  Powers" /></meta><meta name="dc.Creator" content="Anthony B.  Reed" /></meta><meta name="dc.Creator" content="Karen  Rex" /></meta><meta name="dc.Creator" content="Christine  Sastri" /></meta><meta name="dc.Creator" content="Nuria  Tamayo" /></meta><meta name="dc.Creator" content="Paul  Wang" /></meta><meta name="dc.Creator" content="Jeffrey T.  Winston" /></meta><meta name="dc.Creator" content="Bin  Wu" /></meta><meta name="dc.Creator" content="Tian  Wu" /></meta><meta name="dc.Creator" content="Ryan P.  Wurz" /></meta><meta name="dc.Creator" content="Yang  Xu" /></meta><meta name="dc.Creator" content="Yihong  Zhou" /></meta><meta name="dc.Creator" content="Andrew S.  Tasker" /></meta><meta name="dc.Creator" content="Hui-Ling  Wang" /></meta><meta name="dc.Description" content="The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in pr..." /></meta><meta name="Description" content="The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in pr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 22, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00610" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00610" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00610" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00610" /></link>
        
    
    

<title>Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00610" /></meta><meta property="og:title" content="Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0018.jpeg" /></meta><meta property="og:description" content="The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis. The three isoforms of Pim protein appear largely redundant in their oncogenic functions. Thus, a pan-Pim kinase inhibitor is highly desirable. However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low Km for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concentrations. Herein, we report a series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors. In particular, compound 17 is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma, with 93% tumor growth inhibition at 50 mg/kg QD upon oral dosing." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis. The three isoforms of Pim protein appear largely redundant in their oncogenic functions. Thus, a pan-Pim kinase inhibitor is highly desirable. However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low Km for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concentrations. Herein, we report a series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors. In particular, compound 17 is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma, with 93% tumor growth inhibition at 50 mg/kg QD upon oral dosing." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0018.jpeg" /></meta><meta name="twitter:title" content="Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00610"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00610">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00610&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00610&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00610&amp;href=/doi/10.1021/acs.jmedchem.6b00610" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6407-6430</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00609" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00623" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liping+H.++Pettus">Liping H. Pettus</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kristin+L.++Andrews">Kristin L. Andrews</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shon+K.++Booker">Shon K. Booker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Chen">Jie Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor+J.++Cee">Victor J. Cee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Chavez%2C++Jr.">Frank Chavez, Jr.</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuping++Chen">Yuping Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heather++Eastwood">Heather Eastwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nadia++Guerrero">Nadia Guerrero</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bradley++Herberich">Bradley Herberich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean++Hickman">Dean Hickman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+A.++Lanman">Brian A. Lanman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jimmy++Laszlo%2C++III">Jimmy Laszlo, III</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Lee">Matthew R. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Russell++Lipford">J. Russell Lipford</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bethany++Mattson">Bethany Mattson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Mohr">Christopher Mohr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yen++Nguyen">Yen Nguyen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+H.++Norman">Mark H. Norman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Powers">David Powers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+B.++Reed">Anthony B. Reed</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Rex">Karen Rex</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Sastri">Christine Sastri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nuria++Tamayo">Nuria Tamayo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Wang">Paul Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+T.++Winston">Jeffrey T. Winston</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Wu">Bin Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tian++Wu">Tian Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+P.++Wurz">Ryan P. Wurz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Xu">Yang Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihong++Zhou">Yihong Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+S.++Tasker">Andrew S. Tasker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Ling++Wang">Hui-Ling Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>â </sup>Department of Therapeutic DiscoveryâMedicinal Chemistry, <sup>â¡</sup>Molecular Structure, <sup>Â§</sup>Pharmacokinetics and Drug Metabolism, <sup>â¥</sup>Oncology Research, <sup>â¥</sup>Pharmaceutics, <sup>#</sup>Discovery Technologies, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 805-447-6964. Fax: 805-480-1337. E-mail: <a href="/cdn-cgi/l/email-protection#e68a968392929395a6878b818388c885898b"><span class="__cf_email__" data-cfemail="9cf0ecf9e8e8e9efdcfdf1fbf9f2b2fff3f1">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00610&amp;href=/doi/10.1021%2Facs.jmedchem.6b00610" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6407â6430</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 10, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 April 2016</li><li><span class="item_label"><b>Published</b> online</span>22 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 July 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00610" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00610</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6407%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLiping%2BH.%2BPettus%252C%2BKristin%2BL.%2BAndrews%252C%2BShon%2BK.%2BBooker%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D13%26contentID%3Dacs.jmedchem.6b00610%26title%3DDiscovery%2Band%2BOptimization%2Bof%2BQuinazolinone-pyrrolopyrrolones%2Bas%2BPotent%2Band%2BOrally%2BBioavailable%2BPan-Pim%2BKinase%2BInhibitors%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6430%26publicationDate%3DJuly%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00610"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2588</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00610" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Liping&quot;,&quot;last_name&quot;:&quot;H. Pettus&quot;},{&quot;first_name&quot;:&quot;Kristin&quot;,&quot;last_name&quot;:&quot;L. Andrews&quot;},{&quot;first_name&quot;:&quot;Shon&quot;,&quot;last_name&quot;:&quot;K. Booker&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;J. Cee&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Chavez&quot;},{&quot;first_name&quot;:&quot;Yuping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Heather&quot;,&quot;last_name&quot;:&quot;Eastwood&quot;},{&quot;first_name&quot;:&quot;Nadia&quot;,&quot;last_name&quot;:&quot;Guerrero&quot;},{&quot;first_name&quot;:&quot;Bradley&quot;,&quot;last_name&quot;:&quot;Herberich&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;Hickman&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;A. Lanman&quot;},{&quot;first_name&quot;:&quot;Jimmy&quot;,&quot;last_name&quot;:&quot;Laszlo&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Lee&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Russell Lipford&quot;},{&quot;first_name&quot;:&quot;Bethany&quot;,&quot;last_name&quot;:&quot;Mattson&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Mohr&quot;},{&quot;first_name&quot;:&quot;Yen&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;H. Norman&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Powers&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;B. Reed&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Rex&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Sastri&quot;},{&quot;first_name&quot;:&quot;Nuria&quot;,&quot;last_name&quot;:&quot;Tamayo&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;T. Winston&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Tian&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;P. Wurz&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Yihong&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;S. Tasker&quot;},{&quot;first_name&quot;:&quot;Hui-Ling&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;6407-6430&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00610&quot;},&quot;abstract&quot;:&quot;The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis. The three isoforms of Pim protein appear largely redundant in their oncogenic functions. Thus, a pan-Pim kinase inhibitor is highly desirable. However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low Km for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concentrations. Herein, we report a series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors. In particular, compound 17 is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma, with 93% tumor growth inhibition at 50 mg/kg QD upon oral dosing.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00610&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00610" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00610&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00610" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00610&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00610" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00610&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00610&amp;href=/doi/10.1021/acs.jmedchem.6b00610" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00610" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00610" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00610%26sid%3Dliteratum%253Aachs%26pmid%3D27285051%26genre%3Darticle%26aulast%3DPettus%26date%3D2016%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2BQuinazolinone-pyrrolopyrrolones%2Bas%2BPotent%2Band%2BOrally%2BBioavailable%2BPan-Pim%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D13%26spage%3D6407%26epage%3D6430%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/13" title="Go to Volume 59, Issue 13"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/jmcmar.2016.59.issue-13/20160714/jmcmar.2016.59.issue-13.largecover.jpg" alt="Go to Volume 59, Issue 13"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis. The three isoforms of Pim protein appear largely redundant in their oncogenic functions. Thus, a pan-Pim kinase inhibitor is highly desirable. However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low <i>K</i><sub>m</sub> for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concentrations. Herein, we report a series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors. In particular, compound <b>17</b> is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma, with 93% tumor growth inhibition at 50 mg/kg QD upon oral dosing.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The proviral integration site of Moloney murine leukemia virus proteins 1, 2, and 3 (Pim-1, Pim-2, and Pim-3) are a family of constitutively active serine/threonine kinases that are involved in the survival and proliferation of hematopoietic cells in response to cytokines, stress, and growth factors signaling downstream of JAK/STAT and NF-ÎºB activation.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The signaling pathway of the Pim kinases parallels that of the PI3K/Akt/mTOR axis and both pathways share overlapping targets, such as Bcl-2-associated death promoter (BAD) and the protein synthesis regulator eIF4E-BP1.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Phosphorylation of BAD increases Bcl-2 activity and thus promotes cell survival, whereas phosphorylation of eIF4E-BP1 releases eIF4E to promote mRNA translation and cellular growth. The Pim-1, -2, and -3 proteins are expressed at low levels in normal tissues but overexpressed in hematologic and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, prostate cancer, and gastric and liver carcinomas.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Pim triple knockout mice are small but viable, fertile, and show subtle hematologic changes.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Therefore, the inhibition of the Pim kinases presents a promising clinical pathway to treat Pim overexpressing forms of cancers.</div><div class="NLM_p">The kinase domains of the Pim family are structurally unique in the hinge region of the ATP-binding pocket, which contains a tertiary amide (proline) not found in other kinases.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> This unique hinge region feature can be exploited to achieve selectivity against other protein kinases. The three isoforms of Pim kinases share a high level of sequence homology within the family (>61%) and appear largely redundant in their oncogenic functions.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Thus, a pan-Pim kinase inhibitor is highly desirable. Among the three isoforms, Pim-2 has the lowest <i>K</i><sub>m</sub> (â¼4 Î¼M) for ATP, about 100- and 10-fold lower than those of Pim-1 and Pim-3, respectively.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Hence, cell active pan-Pim inhibitors have been more challenging to identify than Pim-1 or Pim-3 inhibitors. Many research groups have disclosed ATP-competitive Pim kinase inhibitors of diverse chemical scaffolds with a wide range of cell potency.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10-13)</a> In particular, shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a> are the structures of three clinical molecules, <b>27</b> (PIM447),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>28</b> (SGI-1776),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and <b>29</b> (AZD-1208),<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> as well as <b>30</b>, the macrocyclic inhibitor from Amgen.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> While basic Pim inhibitors <b>27</b> (Pim-2 <i>K</i><sub>i</sub> = 18 pM) and <b>29</b> (Pim-2 <i>K</i><sub>i</sub> = 160 pM) were very potent in enzymatic assays, they displayed >1000-fold enzyme to cell shift. On the other hand, neutral Pim inhibitor <b>30</b> had only about 100-fold enzyme to cell shift but the flat molecule had limited solubility in aqueous medium (40 and 295 Î¼M in PBS (pH 7.4) and FaSIF (pH 6.8), respectively. Herein, we describe the development of a novel series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors that led to the identification of compound <b>17</b>, which is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and potency of publicly disclosed Pim kinases inhibitors. *Data from ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">14</a>; <sup>#</sup>data from ref <a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">18</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We recently disclosed a highly potent and selective series of 2-aryl-6,7-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-ones, exemplified by <b>1</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), as pan-Pim kinase inhibitors.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> Compound <b>1</b> was potent in both biochemical (IC<sub>50</sub> = 0.3 nM for both Pim-1 and Pim-2) and cellular (KMS-12 BM, IC<sub>50</sub> = 23 nM) assays. In addition, <b>1</b> was efficacious in a KMS-12 BM multiple myeloma xenograft model in mice (78% TGI @ 50 mg/kg QD oral dosing). Although <b>1</b> possessed desirable pharmacokinetic (PK) properties in rat (CL = 0.4 L/h/kg, <i>V</i><sub>ss</sub> = 1.0 L/kg, <i>T</i><sub>1/2</sub> = 3.5 h, %<i>F</i> = 37), it had rapid intravenous (IV) clearance (CL = 3.4 L/h/kg, over liver blood flow) and a short half-life (<i>T</i><sub>1/2</sub> = 0.6 h) in dog. Therefore, this compound was not suitable for further advancement as safety studies in a nonrodent species (such as dog) would have been difficult. We sought to improve the PK profile of this series while maintaining the good potency in vitro and in vivo. The rat and dog plasma protein binding unbound fractions (<i>f</i><sub>u</sub>) of <b>1</b> were measured (using rapid equilibrium dialysis) to be 1.7% and 6.0%, respectively, which calculated the unbound clearance CL<sub>u</sub> of <b>1</b> in rat and dog to be 23.5 and 56.6 L/h/kg, respectively. The intrinsic clearance (CL<sub>int</sub>) of <b>1</b> in rat liver microsomes (RLM) and dog liver microsomes (DLM) was 189 and 203 Î¼L/min/mg, respectively.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The CL<sub>int</sub> of <b>1</b> in rat hepatocytes and dog hepatocytes was 39 and 32 Î¼L/min/10<sup>6</sup> cells, respectively. The in vitro and in vivo pharmacokinetics data of <b>1</b> in rat and dog appeared to be poorly correlated. Although metabolic pathways besides hepatic oxidations might be involved, we decided to look for clues in the microsomal stability first. Metabolite identification studies showed that when <b>1</b> was incubated with RLM, compound <b>2</b> (derived from hydroxylation of the <i>t</i>-butyl group) was the major metabolite. When <b>1</b> was incubated with DLM, compound <b>3</b> (formed from dehydrogenation of the 6,7-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one) was the major metabolite. With this information in hand, we prepared a series of analogues designed to block these oxidations, focusing initially on replacement of the 6,7-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one with a metabolically more stable bicycle and, subsequently, on the left-hand portion of the molecule, modifying the amino-quinoxaline.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. In Vitro Metabolism of Compound <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84686" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84686" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> In Vitro SAR</h3><div class="NLM_p">In biochemical assays, the compounds were evaluated for their ability to inhibit the phosphorylation of a BAD peptide at serine 112 (S112) by full-length recombinant human Pim-1 and Pim-2 proteins. Our experience across multiple scaffolds in the Pim program had been that Pim-3 activity was in general comparable to that of Pim-1.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Therefore, the Pim-3 enzyme assay was not routinely performed. In cell-based assays, the compounds were measured for their ability to inhibit the phosphorylation of BAD at S112 in KMS-12 BM cells in the presence of 20% fetal bovine serum (FBS) using flow cytometry. KMS-12 BM is a multiple myeloma cell line with endogenous Pim-1, -2, and -3 proteins and a relatively high level of Pim-2 expression.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For an initial assessment of metabolism, the compounds were evaluated in RLM and HLM, and the data, reported as intrinsic clearance (CL<sub>int</sub>), were used to prioritize potent compounds for additional PK studies.</div><div class="NLM_p">In the initial phase of this investigation, we focused our SAR work on the right-hand portion of compound <b>1</b>, searching for a more metabolically stable replacement for the 6,7-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one motif. As observed previously in our SAR development for compound <b>1</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> the C7-F in <b>1</b> offered about 3-fold improvement in enzyme and cellular potency over a C7-H in <b>4</b> (structure and data are shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), whereas in vitro and in vivo metabolic stability in rats was comparable. For this part of SAR investigation, to facilitate syntheses, we elected to keep the left-hand portion of the analogues constant as 3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl and compare their data to that of compound <b>4</b>, then make a C7-F analogue on an optimized right-hand piece. Moving the pyrrole-nitrogen in <b>4</b> to the bridgehead position in <b>5</b> (KMS-12 BM, IC<sub>50</sub> = 4.56 Î¼M, RLM CL<sub>int</sub> = 205 Î¼L/min/mg) or homologating the [5,6]-fused bicycle in <b>4</b> to the [5,7]-fused bicycle in <b>6</b> (KMS-12 BM, IC<sub>50</sub> = 1.63 Î¼M, RLM CL<sub>int</sub> = 169 Î¼L/min/mg) resulted in much weaker cellular potency and higher rat microsomal turnover when compared to <b>4</b> (KMS-12 BM, IC<sub>50</sub> = 110 nM, RLM CL<sub>int</sub> = 86 Î¼L/min/mg). Contraction of the [5,6]-fused bicycle in <b>4</b> to the [5,5]-fused bicycle gave rise to compound <b>7</b> and, through substitutions at C6â² (R<sup>1</sup> and R<sup>2</sup>), a set of 5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-ones, <b>8</b>, <b>9</b>, <b>10</b>, <b>11</b>, and <b>12</b>. Compared to <b>4</b>, the 5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-ones <b>7</b>, <b>8</b>, <b>9</b>, <b>10</b>, and <b>11</b> have improved cellular potency, with pBAD IC<sub>50</sub> values of 44, 65, 30, 22, and 78 nM, respectively. Interestingly, between the set of enantiomers <b>8</b> and <b>9</b>, the (<i>R</i>)-6â²-Me enantiomer (<b>9</b>) was not only more potent in both enzymatic and cell-based assays but also had lower microsomal turnover. The [5,5]-fused bicycles, <b>7</b>, <b>9</b>, <b>10</b>, and <b>11</b>, were further profiled in rat IV/PO PK. Among these four compounds, the C6â²-unsubstituted analogue <b>7</b> had the highest RLM turnover (CL<sub>int</sub> = 96 Î¼L/min/mg) and the highest IV clearance (1.6 L/h/kg). The (<i>R</i>)-6â²-(2-aminoethyl) analogue <b>10</b> had poor rat PK profile, with moderate clearance (CL = 1.4 L/h/kg), high volume of distribution (<i>V</i><sub>ss</sub> = 21.2 L/kg), and low bioavailability (%<i>F</i> < 1), a feature common to other basic amine-derived Pim inhibitors from our Pim program.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In rat PK, both compound <b>9</b> (CL = 0.5 L/h/kg, %<i>F</i> = 62) and 6-spirocyclopropane <b>11</b> (CL = 0.6 L/h/kg, %<i>F</i> = 100) had similar IV clearance to that of <b>4</b> (CL = 0.7 L/h/kg, %<i>F</i> = 6) but with much higher oral bioavailability. Expansion of the 6-spirocyclopropane in <b>11</b> (Pim-2 IC<sub>50</sub> = 0.5 nM, KMS-12 BM IC<sub>50</sub> = 78 nM) to a 6-spiropyran in <b>12</b> (Pim-2 IC<sub>50</sub> = 117 nM, KMS-12 BM IC<sub>50</sub> = 5.76 Î¼M) resulted in a significant loss of potency. Chlorination at pyrrole-C3â² in <b>9</b> (KMS-12 BM, IC<sub>50</sub> = 30 nM, RLM CL<sub>int</sub> = 50 Î¼L/min/mg) provided <b>13</b> (KMS-12 BM, IC<sub>50</sub> = 407 nM, RLM CL<sub>int</sub> = 143 Î¼L/min/mg) that had weaker potency and higher microsomal turnover. Lastly, the replacement of pyrrole in <b>7</b> with a thiophene gave rise to 5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one <b>14</b> and 4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one <b>15</b>, which displayed reduced potency and microsomal stability when compared to pyrrole <b>7</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Potency, Microsomal Stability, and Rat PK Data of Compounds <b>1</b>, <b>4</b>â<b>15</b>, and <b>26</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Average of at least two determinations unless indicated by *(<i>n</i> = 1); for full statistical information, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">In vitro microsomal stability (<i>n</i> = 1) measurements were conducted in the presence of NADPH at 37 Â°C for 30 min at a final compound concentration of 1 Î¼M.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Dosed at 2 mg/kg, vehicle 100% DMSO.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Dosed at 5 mg/kg.</p></div><div class="footnote" id="t1fn5"><sup>Table e1</sup><p class="last">Vehicle 10% Soluplus, 40% PEG 400, 50% DI water/MSA, pH 2.2.</p></div><div class="footnote" id="t1fn6"><sup>Table e2</sup><p class="last">Vehicle 15% HPBCD, 2% HPMC, 1% Pluronic F68, pH 2.2 water/MSA.</p></div><div class="footnote" id="t1fn7"><sup>Table f</sup><p class="last">Vehicle 40% PEG 400 in DI water, pH 2.2 water/MSA.</p></div><div class="footnote" id="t1fn8"><sup>Table g</sup><p class="last">Vehicle 1% Tween 80, 2% HPMC, pH 2.2 water/MSA.</p></div><div class="footnote" id="t1fn9"><sup>Table h</sup><p class="last">NT = not tested.</p></div></div><div></div></div><div class="NLM_p">From <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, in terms of cellular potency and rat PK profile, the best replacement for the [5,6]-fused bicycle in <b>4</b> is the (<i>R</i>)-6â²-Me-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one motif in <b>9</b>. Further substitution of a C7-F in <b>9</b> provided analogue <b>26</b>, which exhibited improved enzyme potency (IC<sub>50</sub> = 0.1 nM for both Pim-1 and Pim-2) but similar cellular potency (IC<sub>50</sub> = 29 nM) and rat PK profile (IV CL = 0.5 L/h/kg, %<i>F</i> = 54). Compounds <b>9</b> and <b>26</b>, with DLM of 88 and 105 Î¼L/min/mg, respectively, were further profiled in dog IV PK (dosing, 0.3 mg/kg; vehicle, 50% PEG 400 and 50% water). Although <b>9</b> (CL = 1.6 L/h/kg, <i>V</i><sub>ss</sub> = 1.7 L/h, <i>T</i><sub>1/2</sub> = 0.6 h) and <b>26</b> (CL = 1.5 L/h/kg, <i>V</i><sub>ss</sub> = 1.7 L/h, <i>T</i><sub>1/2</sub> = 1.1 h) had improved dog IV PK properties over compound <b>1</b> (CL = 3.4 L/h/kg, <i>V</i><sub>ss</sub> = 8.7 L/h, <i>T</i><sub>1/2</sub> = 0.6 h), their IV CL values were still high. Metabolite identification studies of compound <b>9</b> in dog hepatocytes showed that there was extensive hydroxylation on the quinoxaline bicycle. Subsequently, we focused our SAR work on the left-hand portion of <b>9</b>, seeking a replacement for the amino-quinoxaline motif to improve in vivo stability while maintaining the desirable Pim potency. Our strategy was to focus on bicycles with reduced electron density relative to the amino-quinoxaline scaffold in <b>9</b>.</div><div class="NLM_p"><a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> summarizes our efforts to replace the amino-quinoxaline in compound <b>9</b> while keeping the right-hand portion constant as (<i>R</i>)-6â²-Me-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one. Compared to <b>9</b>, pyrido-pyrimidinone <b>16</b> had weaker potency (Pim-2 IC<sub>50</sub> = 2.1 nM, KMS-12 BM IC<sub>50</sub> > 2000 nM) and lower solubility in aqueous medium. Interestingly, the regioisomeric quinazolinone <b>17</b> had not only improved potency (Pim-2 IC<sub>50</sub> = 0.2 nM, KMS-12 BM IC<sub>50</sub> = 31 nM) but also greater aqueous solubility. Compared to the C7-H analogue <b>17</b>, the C7-F analogue <b>18</b> displayed marginally improved enzyme potency (IC<sub>50</sub> = 0.1 nM for both Pim-1 and Pim-2) but similar cellular potency (IC<sub>50</sub> = 26 nM); on the other hand, the N-7 analogue <b>19</b> displayed greatly reduced enzyme (Pim-2 IC<sub>50</sub> = 7.4 nM) and cellular potency (IC<sub>50</sub> = 1642 nM), as did the CH<sub>2</sub>-linker analogue <b>20</b> (Pim-2 IC<sub>50</sub> = 4.9 nM, KMS-12 BM IC<sub>50</sub> = 5690 nM). Compared to <b>9</b>, benzo-thiadiazine-dioxide <b>21</b> had improved aqueous solubility but reduced enzyme potency, with Pim-1 and Pim-2 IC<sub>50</sub>s of 6.5 and 5.2 nM, respectively.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency, cLogP, and Aqueous Solubility for Compounds <b>9</b>, <b>16</b>â<b>25</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0016.gif" alt="" id="GRAPHIC-d3161e1178-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Average of at least two determinations; for full statistical information, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">cLogP values were calculated via a Pipeline Pilot Web Port interface (Biovia, Inc.) to the Daylight software suite (v. 4.81, Daylight Chemical Information Systems, Inc.).</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last"><i>n</i> = 1 for pH solubility data, PBS = phosphate-buffered saline, FaSIF = fasted state simulated intestinal fluid.</p></div></div><div></div></div><div class="NLM_p">Next, we probed the SAR surrounding the <i>t</i>-butylamino motif in compound <b>17</b> with alkylamino-quinazolinones <b>22</b>â<b>25</b> (while keeping cLogP < 4). Although the structural difference was very subtle between <b>22</b> and <b>17</b>, the methylcyclopropylamino <b>22</b> had better cellular potency (IC<sub>50</sub> = 11 nM) than the <i>t</i>-butylamino analogue <b>17</b> (IC<sub>50</sub> = 31 nM) and was 3 times more soluble in FaSIF (pH 6.8) medium. Hydroxylation of the <i>t</i>-butyl group in <b>17</b> provided compound <b>23</b>, which displayed a 4-fold loss of potency in enzymatic and cellular assays. The tertiary amino quinazolinones, <i>t</i>-butylmethylamino analogue <b>24</b> and 2,2-dimethylpyrrolidine-derived <b>25</b> were 5-fold and 3-fold weaker, respectively, in both enzymatic and cellular assays than <b>17.</b></div><div class="NLM_p">The compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> displayed a wide range of enzyme (Pim-2 IC<sub>50</sub>) to cell (KMS-12 BM IC<sub>50</sub>) shift, from 30-fold for compounds <b>9</b> and <b>22</b> to >1000-fold for compounds <b>16</b> and <b>20</b>. Compounds <b>16</b> and <b>20</b> had no aqueous solubility, which may explain the extremely large cell shift. On the other hand, <b>9</b> and <b>22</b> were among the more aqueous soluble compounds in the table. There appeared to be little correlation between cell shift and calculated lipophilicity (cLogP).</div><div class="NLM_p">From <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, the amino-quinazolinones <b>17</b>, <b>18</b>, and <b>22</b>, with cellular IC<sub>50</sub> < 50 nM, were evaluated in a panel of in vitro assays and in vivo pharmacokinetics and drug metabolism (PKDM) tests. The results are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. All three compounds had rat plasma protein free unbound fractions of about 6% and appeared to be Pgp substrates as judged by the efflux ratio (ER) in LLC-PK1 cells overexpressed with rat and human P-glycoproteins. However, <b>17</b> stood out from the group as having the best permeability (<i>P</i><sub>app</sub> = 44 Ã 10<sup>â6</sup> cm/s), the lowest rat IV clearance (0.3 L/h/kg), and the highest oral bioavailability (%<i>F</i> = 39). Therefore, <b>17</b> was subjected to additional PKDM and safety profiling. It had moderate dog IV clearance (0.8 L/h/kg) with <i>V</i><sub>ss</sub> of 1 L/kg and <i>T</i><sub>1/2</sub> of 0.7 h and good oral bioavailability (44%). The dog plasma protein binding unbound fractions (<i>f</i><sub>u</sub>) of <b>17</b> was measured (using rapid equilibrium dialysis) to be 11%. The unbound clearance CL<sub>u</sub> of <b>17</b> in dog was 7.3 L/h/kg, which was significantly lower than that of our starting point for this series, the quinoxaline-pyrrolo-pyridinone <b>1</b> (dog IV CL<sub>u</sub> = 56.6 L/h/kg). Compound <b>17</b> had intrinsic clearance (CL<sub>int</sub>) of 12, 12, and 3 Î¼L/min/10<sup>6</sup> cells, in rat, dog, and human hepatocytes, respectively. With the low turnover in microsomes and hepatocytes across species (rat, dog, and human), along with low IV clearance in rat and moderate IV clearance in dog, compound <b>17</b> had a low projected human clearance (0.034 L/h/kg, â¼3% of liver blood flow).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In addition, <b>17</b> had minimal inhibition toward CYPs (with IC<sub>50</sub> values of >50, >50, 31, and >50 Î¼M for 3A4, 1A2, 2C19, and 2D6, respectively) and no activity for human pregnane X receptor (hPXR) at 10 Î¼M.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro and in Vivo PKDM Data for Compounds <b>17</b>, <b>18</b>, and <b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0017.gif" alt="" id="GRAPHIC-d3161e1404-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Determination of fraction unbound (fu) in plasma protein using rapid equilibrium dialysis (RED (compound concentration @ 5 Î¼M) (<i>n</i> = 1), R = rat, H = human.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">In vitro microsomal stability (<i>n</i> = 1) measurements were conducted in the presence of NADPH at 37 Â°C for 30 min at a final compound concentration of 1 Î¼M.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Dosed at 2 mg/kg, vehicle 100% DMSO.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Dosed at 5 mg/kg.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">NT = not tested.</p></div></div><div></div></div><div class="NLM_p">In a hERG binding assay, <b>17</b> had an IC<sub>50</sub> of >30 Î¼M. For broader selectivity against receptors and ion channels, <b>17</b> was tested at 10 Î¼M against 147 targets provided by Cerep, with only one target showing percent of control (POC) < 10%.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> For kinase selectivity, <b>17</b> was tested at 1 Î¼M in a customized KINOME<i>scan</i> panel containing 100 nonmutant kinases offered by DiscoveRx. The S(35), S(10), and S(1) selectivity scores were determined to be 0.07, 0.06, and 0.03, respectively. At 1 Î¼M, <b>17</b> hit six kinases with POC < 10%: CLK4 (0.2%), YSK4 (0.4%), p38Î³ (0.9%), Pim-1 (1.3%), CSNK2A1 (3.5%), and DYRK1A (6%). For pan-Pim kinase activities, the <i>K</i><sub>d</sub> values of <b>17</b> for Pim-1, Pim-2, and Pim-3 were determined by DiscoveRx to be 1.3, 1.7, and 1.2 nM, respectively.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">The X-ray structure of <b>17</b> bound to Pim-1 protein (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ">5IPJ</a>) was obtained and is presented in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. This structure reveals a number of key interactions between <b>17</b> and Pim-1 protein, which contribute to its potency and kinase selectivity. The high kinome selectivity found in <b>17</b> is largely due to the unique tertiary amide Pro123 as the linker residue in Pim-1 as it accommodates the C5-H in quinazolinone. Two water molecules bridge the carbonyl oxygen (C4 = O) in <b>17</b> and the carbonyl oxygen of Pro123, which are 4.7 Ã apart. The C6-H in <b>17</b> forms a H-bonding (3.1 Ã) interaction with the carbonyl oxygen of Glu121. Additional favorable hydrophobic contacts are observed between the (<i>R</i>)-C6â²-Me in the [5,5]-fused ring with the Phe49 and Ile185 (shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b), and the <i>t</i>-butyl group fills a small lipophilic pocket under the P-loop of Pim-1. The carbonyl oxygen (C4â² = O) of pyrrolone engages in a H-bonding (2.8 Ã) with the conserved catalytic Lys67. The dihedral angle between the pyrrole and quinazolinone is 0Â° degrees; the combination of two factors, the intramolecular H-bond from the pyrrole-NH to the quinazolinone-N1 and the relatively small size of a 5-membered pyrrole ring, helps to keep it coplanar with respect to the quinazolinone scaffold.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of <b>17</b>/Pim-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ">5IPJ</a>). (a) Inhibitor <b>17</b> occupies the ATP-binding site; hydrogen bond contacts are shown with dashed lines; the red dots represent water molecules; the top of the ATP-binding pocket is omitted for clarity. (b) CPK (CoreyâPaulingâKoltun) rendering of <b>17</b> illustrating that the alkyl substituents form a complementary hydrophobic surface to Leu44, Gly45, Val52, Phe49, and Ile185. The figures were generated with the PyMOL Molecular Graphics System, version 1.7.0.1 SchrÃ¶dinger, LLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a three-day luminescent KMS-12 BM cell viability assay, compound <b>17</b> had an IC<sub>50</sub> value of 260 nM. Given the promising potency, kinase selectivity, and metabolic profile of <b>17</b>, it was progressed to a mouse KMS-12 BM xenograft model (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Dosed orally once daily (QD) at 10, 25, and 50 mg/kg, <b>17</b> resulted in a dose-dependent decrease in tumor growth compared to the vehicle control group, with 50 mg/kg dose achieving 93% tumor growth inhibition (TGI). There was no appreciable difference in TGI between 50 and 100 mg/kg doses, probably due to the solubility limited exposure at the top dose of 100 mg/kg (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). No overt toxicity was observed based on body weight and overall appearance of the treated animals. On the last day of the xenograft study, a terminal pharmacodynamic (PD) study was conducted to measure the effect of <b>17</b> on the inhibition of BAD phosphorylation. In the PD models, we typically observed a maximum inhibition of 60â70% pBAD for selective Pim kinase inhibitors; the remainder of BAD phosphorylation was attributed to AKT (PKB).<a onclick="showRef(event, 'ref18 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref29">(18, 29)</a> As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, except for the 100 mg/kg dose, there was a dose- and exposure-dependent decrease in pBAD levels, with 50 mg/kg dose achieving near-maximal suppression for at least 12 h. The EC<sub>50</sub> for pBAD inhibition was determined to be 254 nM of total plasma <b>17</b>. As the fraction unbound of <b>17</b> in mouse plasma protein is 0.084, this corresponds to an unbound plasma concentration of 21.4 nM, similar to the measured in vitro KMS-12 BM pBAD IC<sub>50</sub> of 31 nM (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) The effect of <b>17</b> on tumor growth in mouse KMS-12 BM xenograft model. (b) The concentration of <b>17</b> in plasma. Data represent the mean (<i>n</i> = 10) Â± SEM for the xenograft study and (<i>n</i> = 2/time point) for the concentration of <b>17</b> in plasma. Statistical significance (*) was determined by repeated measures analysis of variance (RMANOVA) followed by Dunnettâs post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>17</b> on BAD phosphorylation in terminal KMS-12 BM xenograft tumors. Data represent the mean (<i>n</i> = 2) Â± standard deviation. Bars represent levels of pBAD and are expressed as percent of vehicle (POV) of pBAD/total BAD (tBAD). Red dots represent the mean total plasma concentration of <b>17</b>. Statistical significance was evaluated by analysis of variance (ANOVA), followed by the Bonferroni/Dunn post hoc test. * <i>p</i> < 0.0001, ** <i>p</i> < 0.001, *** <i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The structures of four commonly used intermediates are shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>: 8-bromo-<i>N</i>-(<i>tert</i>-butyl)-3-methylquinoxalin-2-amine (<b>AQ1</b>), <i>N</i>-(<i>tert</i>-butyl)-3-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-amine (<b>AQ2</b>), 2-bromo-1-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)ethanone (<b>AQ3</b>), and pyrrolopyrrolone boronic ester <b>BE1</b>. The syntheses of intermediates <b>AQ1</b>, <b>AQ2</b>, and <b>AQ3</b> have been disclosed.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> For the synthesis of boronic ester <b>BE1</b>, the chemistry toward pyrrolopyrrolone fused bicycle previously reported by Vanotti and co-workers<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> was modified. It is worth pointing out that erosion of chiral purity occurred during the removal of tosyl protecting group in <b>BE1e</b> using K<sub>2</sub>CO<sub>3</sub> in MeOH. Chiral supercritical fluid chromatography (SFC) was used to purify the crude product (74% <i>ee</i>) and provided pyrrolopyrrolone <b>BE1f</b> in >99% <i>ee</i>. Subsequent C2-H activation of <b>BE1f</b> in the presence of iridium(I) catalyst and (BPin)<sub>2</sub> afforded the boronic ester <b>BE1</b>, which was used as crude without further purification.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Structures of Amino-quinoxaline Intermediates <b>AQ1</b>, <b>AQ2</b>, and <b>AQ3</b>, and Synthesis of Boronic Ester <b>BE1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) CDI, THF, (2) mono-<i>t</i>-butyl malonate, MgCl<sub>2</sub>, KO<i>t</i>Bu, 75%; (b) NH<sub>4</sub>OAc, NH<sub>3</sub> in MeOH, chloroacetaldehyde, 63%; (c) NaO<i>t</i>Bu, <i>p</i>TsCl, THF, 70%; (d) TFA, DCM, 50 Â°C; (e) T3P, DIPEA, EtOAc >95% (2 steps); (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, SFC chiral purification, 73%; (g) (BPin)<sub>2</sub>, bis(1,5-cyclooctadiene)di-Î¼-methoxydiiridium(I), 4,4â²-di-<i>t</i>-butyl-2,2â²-dipyridyl, MTBE.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, the synthetic routes to compounds <b>5</b> and <b>6</b> are outlined. Commercially available <b>5a</b> was alkylated with 1,2-dibromoethane to give <b>5b</b>, which was treated with (2,4-dimethoxyphenyl)methanamine to provide pyrrolopyrazinone <b>5c</b>. Commercially available <b>6a</b> was brominated with 1,3-dibromo-5,5-dimethylhydantoin to afford 2-bromo-6,7-dihydro-1<i>H</i>-indol-4(5<i>H</i>)-one (<b>6b</b>), which was treated with hydroxylamine hydrochloride/NaOAc followed by thionyl chloride to afford the [5,7]-fused bicycle <b>6c</b>. The Suzuki coupling reactions of boronic ester <b>AQ2</b> (structure shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) with <b>5c</b> (followed by protecting group removal) and <b>6c</b> provided compounds <b>5</b> and <b>6</b>, respectively.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, DMF, 1,2-dibromoethane, 0â70 Â°C, 46%; (b) (2,4-dimethoxyphenyl)methanamine, DMSO, 150 Â°C, 85%; (c) <b>AQ2</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>3</sub>PO<sub>4</sub>, 135 Â°C; (d) TFA, DCM, 22% (2 steps); (e) 1,3-dibromo-5,5-dimethylhydantoin, DMF, 60 Â°C, 83%; (f) hydroxylamine hydrochloride, NaOAc, MeOH, 50 Â°C; (g) SOCl<sub>2</sub>, 55% (2 steps); (h) <b>AQ2</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>3</sub>PO<sub>4</sub>, 105 Â°C, 96%.</p></p></figure><div class="NLM_p">The general synthetic route to aminoquinoxaline-pyrrolopyrrolones <b>7</b>â<b>12</b> is shown in <a class="ref internalNav" href="#sch4A" aria-label="Scheme 4">Scheme 4</a>. Alkylation of Î²-keto ester <b>7a</b> and <b>9a</b>â<b>12a</b> with 2-bromo-1-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)ethanone (<b>AQ3</b>) and subsequent ring formation in the presence of AcONH<sub>4</sub>/HOAc in EtOH afforded pyrroles <b>7b</b> and <b>9b</b>â<b>12b</b>, with erosion of chirality for <b>9b</b> and <b>10b</b>. Saponification of <b>7b</b> and <b>9b</b>â<b>12b</b> with LiOH followed by Boc removal with HCl provided the <i>o</i>-aminomethyl-pyrrole-carboxylic acids <b>7c</b> and <b>9c</b>â<b>12c</b>, which were treated with an activating agent (PyBop or HATU or EDCI) to form the pyrrolo-pyrrolones <b>7</b>, <b>9d</b>, <b>10d</b>, <b>11</b>, and <b>12</b>. Chiral SFC purification of <b>9d</b> (about 85% <i>ee</i>) provided (<i>S</i>)-Me <b>8</b> (minor) and (<i>R</i>)-Me <b>9</b> (major). Benzyl ether <b>10d</b> was converted to amine <b>10e</b> (>90% <i>ee</i>) in a four-step sequence: removal of benzyl protecting group with BCl<sub>3</sub> followed by conversion of the resulting alcohol to a methanesulfonate, azidation, and reduction with PMe<sub>3</sub>. Amine <b>10e</b> (about 90% <i>ee</i>) was subjected to chiral SFC purification to afford (<i>R</i>)-CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub><b>10</b> (99% <i>ee</i>). Lastly, compound <b>13</b> was derived from the treatment of <b>9</b> with <i>N</i>-chlorosuccinimide.</div><figure id="sch4A" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0008.jpeg" id="GRAPHIC-d3161e2046-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Aminoquinoxaline-pyrrolopyrrolones <b>7</b>â<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch4A"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>AQ3</b>, K<sub>2</sub>CO<sub>3</sub>, THF, EtOH, RT; (b) AcONH<sub>4</sub>, EtOH, AcOH, 50 Â°C; (c) LiOH then HCl; (d) PyBop or HATU or EDCI, DIPEA; (e) 1) BCl<sub>3</sub>; 2) MsCl, Et<sub>3</sub>N; 3) NaN<sub>3</sub>; 4) PMe<sub>3</sub>; (f) NCS, CHCl<sub>3</sub>, 70%.</p></p></figure><div class="NLM_p">As the program progressed, we found a more convergent route to prepare the aminoquinoxaline-pyrrolopyrrolones, exemplified by the synthesis of <b>26</b> shown in <a class="ref internalNav" href="#sch4B" aria-label="Scheme 5">Scheme 5</a>. Compound <b>26</b> was derived from the Suzuki coupling reaction of chiral boronic ester <b>BE1</b> and bromo-quinoxaline <b>26g</b>, which in turn was synthesized from the commercially available 2-bromo-1,3-difluoro-4-nitrobenzene (<b>26a</b>) in six steps.</div><figure id="sch4B" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0009.jpeg" id="GRAPHIC-d3161e2112-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Aminoquinoxaline-pyrrolopyrrolone <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch4B"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (NH<sub>4</sub>)<sub>2</sub>CO<sub>3</sub>, Et<sub>3</sub>N, DMF, 97%; (b) Pt/C, H<sub>2</sub>, EtOH, 99%; (c) ethyl 2-bromopropionate, 120 Â°C, 96%; (d) H<sub>2</sub>O<sub>2</sub>, NaOH, 85 Â°C, 80%; (e) POCl<sub>3</sub>, 90 Â°C, 49%; (f) <i>t</i>-butylamine, DMSO, 100 Â°C, 83%; (g) <b>BE1</b>, XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, 54%.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch5" aria-label="Scheme 6">Scheme 6</a>, 2-formylthiophene-3-carboxamide <b>14a</b> was converted to thienopyrrolone <b>14b</b> via a three-step sequence: reduction with NaBH<sub>4</sub> followed by mesylate formation with MsCl and pyrrolone formation in the presence of LiHMDS. Bromination of <b>14b</b> with NBS followed by removal of the <i>t</i>-butyl group with acid gave bromo-thienopyrrolone <b>14d</b>. In a similar fashion, <b>15d</b> was constructed, except that the removal of <i>t</i>-butyl group required high temperature (130 Â°C in microwave). The Suzuki coupling reactions of boronic ester <b>AQ2</b> with bromo-thienopyrrolones <b>14d</b> and <b>15d</b> gave quinoxaline-thienopyrrolones <b>14</b> and <b>15</b>, respectively.</div><figure id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>14</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) NaBH<sub>4</sub>, (2) MsCl, DIPEA, (3) LiHMDS, 77% for <b>14b</b> and 60% for <b>15b</b>; (b) NBS, 34%; (c) H<sub>2</sub>SO<sub>4</sub>, 25%; (d) <b>AQ2</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>3</sub>PO<sub>4</sub>, 26% for <b>14</b> and 52% for <b>15</b>; (e) Br<sub>2</sub>, HOAc; (f) H<sub>2</sub>SO<sub>4</sub>, 130 Â°C, 68% for two steps.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch6" aria-label="Scheme 7">Scheme 7</a>, compounds <b>16</b>, <b>19</b>, <b>20</b>, and <b>21</b> were derived from the Suzuki coupling reaction of boronic ester <b>BE1</b> with bromo-pyridopyrimidinone <b>16b</b>, chloro-pyridopyrimidinone <b>19b</b>, bromo-quinazolinone <b>20b</b>, and bromo-benzothiadiazine-1,1-dioxide <b>21e</b>, respectively. Given that boronic ester <b>BE1</b> decomposed readily at high temperatures, this type of Suzuki coupling reaction was typically run at 40â45 Â°C in an oil bath for 1â3 h(s) in the presence of XPhos Pd G2, in yields ranging from 21% to 71%.</div><figure id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>16</b>, <b>19</b>, <b>20</b>, and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) diethyl methylmalonate, 220 Â°C; (b) BOP, <i>t</i>-butyl amine, DBU, 21%; (c) <b>BE1</b>, XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, 40% for <b>16</b>, 21% for <b>19</b>, 62% for <b>20</b>, 71% for <b>21</b>; (d) triphosgene, MeNH<sub>2</sub>, 44%; (e) BOP, <i>t</i>-butyl amine, 41%; (f) T3P, CH<sub>3</sub>NH<sub>2</sub>, 62%; (g) <i>t</i>-butylacetyl chloride, 100 Â°C, quant; (h) NaNO<sub>2</sub>, concentrated HCl, CuSO<sub>4</sub>; (i) CH<sub>3</sub>NH<sub>2</sub>, DIPEA, 26% for two steps; (j) Pt/C, H<sub>2</sub>, MeOH, 95%; (k) <i>t</i>-butyl nitrite, TMSN<sub>3</sub>, MeCN, 20%; (l) PPh<sub>3</sub>, <i>t</i>-butyl isocyanate, DBU, 120 Â°C, 45%.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch7" aria-label="Scheme 8">Scheme 8</a>, commercially available <i>o</i>-amino-benzoic acids <b>17a</b> and <b>18a</b> were converted to chloro-quinazolinones <b>17d</b> and <b>18d</b>, respectively, via methyl amide formation in the presence of T3P, followed by hydroxy-quinazolinone formation using triphosgene and chlorination using POCl<sub>3</sub>. Displacement of the C2âCl in <b>17d</b> and <b>18d</b> with amines gave amino-quinazolinones <b>17e</b>, <b>18e</b>, and <b>25e</b>, which were coupled with boronic ester <b>BE1</b> to afford compounds <b>17</b>, <b>18</b>, and <b>25</b>, respectively. Alternatively, <i>o</i>-amino-benzoic acid <b>22a</b> was converted to chloro-quinazolinone <b>22d</b> via sulfinyl-/sulfonyl-quinazolinone formation, followed by hydrolysis with LiOH and chlorination using POCl<sub>3</sub>. In a similar fashion, displacement of the C2-Cl in <b>22d</b> with amines gave amino-quinazolinones <b>22e</b> and <b>23e</b>, which were coupled with boronic ester <b>BE1</b> to afford compounds <b>22</b> and <b>23</b>, respectively. The displacement of C2-Cl in <b>22d</b> with <i>N</i>,2-dimethylpropan-2-amine was not successful, probably due to the steric hindrance of the amine. Therefore, amino-quinazolinone <b>24f</b> was prepared from the reaction of <b>22d</b> with <i>t</i>-butylamine followed by methylation of the resulting <b>24e</b> with NaH/MeI. Finally, the Suzuki coupling of <b>24f</b> with boronic ester <b>BE1</b> afforded compound <b>24</b>.</div><figure id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0012.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>17</b>, <b>18</b>, and <b>22</b>â<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeNH<sub>2</sub>, T3P, EtOAc; 92% for <b>17b</b>, 78% for <b>18b</b>; (b) triphosgene, DIPEA, >95% for both <b>17c</b> and <b>18c</b>; (c) POCl<sub>3</sub>, DIPEA, 84% for <b>17d</b>, 80% for <b>18d,</b> 77% for <b>22d</b>; (d) HNRR<sup>2</sup>; (e) <b>BE1</b>, XPhos Pd G2 or Pd<sub>2</sub>(dba)<sub>3</sub>/X-phos, K<sub>3</sub>PO<sub>4</sub>; (f) (1) MeNCS, (2) MeI, K<sub>2</sub>CO<sub>3</sub>, 97%; (g) <i>m</i>CPBA; (h) LiOH, 94% for two steps; (i) NaH, MeI, 85%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of potent and selective pan-Pim inhibitors was developed from the quinoxaline-pyrrolopyridinones, exemplified by compounds <b>1</b> and <b>4</b>. Although <b>1</b> was efficacious in a mouse KMS-12 BM xenograft model (78% TGI @ 50 mg/kg QD oral dosing), it had rapid dog intravenous (IV) clearance (CL and CL<sub>u</sub> were 3.38 and 56.6 L/h/kg, respectively). Metabolite identification studies of compound <b>1</b> in dog microsomes indicated that dehydrogenation of the pyrrolopyridinone was the major metabolic pathway. Efforts to seek a more metabolically stable replacement for the pyrrolopyridinone motif in <b>1</b> and <b>4</b> led us to quinoxaline-pyrrolopyrrolones <b>9</b> (dog IV CL = 1.60 L/h/kg) and <b>26</b> (dog IV CL = 1.47 L/h/kg), which displayed some improvement in metabolic stability. Subsequent efforts (guided by the results from metabolite identification studies of compound <b>9</b>) to seek a metabolically more stable replacement for the quinoxaline motif in <b>9</b> and <b>26</b> led us to quinazolinone-pyrrolopyrrolone <b>17</b> (dog IV CL and CL<sub>u</sub> were 0.84 and 7.3 L/h/kg, respectively). Compound <b>1</b>7 was efficacious in a mouse KMS-12 BM xenograft model (93% TGI @ 50 mg/kg QD oral dosing). However, the low solubility of <b>17</b> in aqueous (such as PBS and FaSIF) medium could become a potential roadblock for further development of this compound. Our continued efforts toward the development of selective and orally bioavailable pan-Pim kinase inhibitors with improved drug-like properties will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Biology</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Pim-1 and Pim-2 Enzyme Assays</h4><div class="NLM_p last">The assay for the determination of Pim activity was based on the formation of phosphorylated biotinylated-BAD peptide at the serine 112 residue (S112) and employed homogeneous time-resolved fluorescence (HTRF) technology to detect the product in a 384-well plate format. The phosphorylation of biotinylated-BAD (S112) peptide by full length recombinant Pim-1 or Pim-2 protein was detected with streptavidin:allophycocyanin conjugate and an europium (Eu) labeled antibody directed against phosphorylated-BAD (S112). Excitation of Eu by a high energy laser light (337 nm) led to a transfer of energy to the APC molecule and resulted in an emission at 665 nm. The fluorescence was directly proportional to the amount of phosphorylated BAD peptide present in the reaction. Compounds were prepared in DMSO by conducting 3-fold serial dilutions to give a 22-point dosing curve having a high dose of 1 Î¼M. A reference compound was included on each assay plate [Costar 3658] in order to validate that plate; on one plate of every assay run, two additional reference compounds were included. The reaction buffer consisted of 45 mM Hepes, pH 7.0, 15 mM NaCl, and 1 mM MgCl<sub>2</sub>. The quench/detection buffer consisted of 50 mM Tris, 100 mM NaCl, 0.05% BSA, 0.1% Tween, and 3 mM EDTA, biotinylated BAD peptide (Biopeptide), 10 mM ATP (Sigma), labeled pBAD (S112) mAb (Cell Signaling and PerkinElmer) [with 0.05% BSA and 2 mM DTT added], and streptavidin:allophycocyanin [PerkinElmer], and final concentrations, either Pim-1 enzyme [5 pM] or Pim-2 enzyme [0.5 pM], DMSO [1%], BAD-LANCE-conjugated BAD (S112) [0.5 Î¼M], ATP [1.5 Î¼M], streptavidin:allophycocyanin [0.002 mg/mL], and biotinylated-BAD (S112) mAb [100 pM]. Initial incubations were carried out at RT (22 Â°C) for 30 min for both Pim-1 and Pim-2. Pim enzyme was added to compound in buffer, and plates were incubated for 30 min. Biotinylated BAD and ATP were added, and plates were incubated for 1 h. A mixture of labeled pBAD (S112) mAb and quench/detection buffer were added and incubated for 2 h. Fluorescence was measured by an HTRF Envision microplate reader. For each plate, percent of control (POC) values were calculated for each well. Values for the IC<sub>50</sub> were estimated using a standard three- or four-parameter logistic model.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> KMS-12 BM pBAD Assay</h4><div class="NLM_p last">The flow cytometry assay for determination of the Pim activity in the KMS-12 BM cell line (DSMZ catalogue no. ACC 551) measured levels of phospho-BAD normalized against total BAD protein levels. Protocols: compounds were initially diluted in DMSO by conducting 2-fold serial dilutions to give a 22-point dosing curve having a high dose of 30 Î¼M. Exponentially growing KMS-12 BM cells (50 Î¼L, between 0.5 and 1.5 Ã 10<sup>6</sup>/mL, DSMZ) in assay media (RPMI/20% heat inactivated FBS/1Ã NaPyruvate/1Ã NEAA/1Ã PSG (pen/strep glutamine)) were added to a 384-well plate containing 200 nL of compound. The cell plates were then incubated with compound for 110 min at 37 Â°C, 5% CO<sub>2</sub>. BD Phosflow Lyse/Fix (BD Biosciences) was diluted to 2Ã with assay media. Then 50 Î¼L of the diluted BD Phosflow Lyse/Fix was added to each well. The cell plates were incubated for 15 min at RT. The plates were spun for 15 s at 2 K RPM then aspirated. Staining Media (1Ã PBS with 0.5% FBS) was added (80 Î¼L). The plates again were spun for 15 s at 2 K RPM then aspirated. BD Perm/Wash Buffer (1Ã, 50 Î¼L, BD Biosciences) was added. The cell plates were then incubated for >30 min at RT in the dark. The plates were spun for 15 s at 2 K RPM and then aspirated. Staining media (1Ã PBS with 0.5% FBS) was added (80 Î¼L). The plates were spun for 15 s at 2 K RPM and then aspirated and additional staining media (1Ã PBS with 0.5% FBS) was added (80 Î¼L). The plates were spun for 15 s at 2 K RPM and then aspirated. Rabbit antihuman pBAD Ser112 Ab (Cell Signaling) was diluted in staining media (1:120). The diluted pBAD Ab (10 Î¼L) was added to each well. The cell plates were incubated for >1 h at RT. The plates were spun for 15 s at 2 K RPM then aspirated. Staining media (1Ã PBS with 0.5% FBS) was added (80 Î¼L). Goat anti-rabbit Alexa-647 (Invitrogen) was diluted in staining media (1:4000). The diluted goat anti-rabbit Alexa-647 (70 Î¼L) was added to each well. The cell plates were then incubated for >30 min at RT in the dark. The plates were spun for 15 s at 2 K RPM and then aspirated. Staining media (1Ã PBS with 0.5% FBS) was added (80 Î¼L). The plates were spun for 15 s at 2 K RPM and then aspirated and additional staining media (1Ã PBS with 0.5% FBS) was added (80 Î¼L). The plates were spun for 15 s at 2 K RPM and then aspirated. Staining Media (1Ã PBS with 0.5% FBS) was added (30 Î¼L). The plates were read on a BD LSRII, and results were calculated according to the assay protocols ((%Phosphoprotein = ((2 Ã Phospho signal)/(Phospho signal + Total signal)) Ã 100)).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> KMS-12 BM Cell Viability Assay</h4><div class="NLM_p last">KMS-12 BM cells were seeded into 96-well tissue culture plates at 5000 cells/well in full growth medium, RPMI1640/20% heat-inactivated FBS and were allowed to acclimate overnight in an incubator (37 Â°C; 5% CO<sub>2</sub>) prior to treatment. The following day, cells were treated with compounds that had been serially diluted first in DMSO and then into full growth medium, which was then added onto the cells to achieve a doseâresponse curve with a final high dose of 10 Î¼M. DMSO alone was used as a control in all viability assays. Cellular viability was assessed after 72 h of treatment using the CellTiter-Glo luminescent viability assay reagent (Promega Inc.). Plates were read on the EnVision Multilabel plate reader (PerkinElmer), and IC<sub>50</sub> values were calculated using the statistical curve-fitting program XLFit (IDBS software).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> KMS-12 BM Xenograft Efficacy</h4><div class="NLM_p last">Animals were cared for in accordance to the <i>Guide for the Care and Use of Laboratory Animals</i> (eighth edition, National Research Council (US)). All research protocols were approved by the Institutional Animal Care and Use Committee. The efficacy <b>17</b> on TGI in vivo was evaluated in KMS-12 BM tumors in female SCID-bg mice. Mice were injected with 10<sup>6</sup> KMS-12 BM cells at a ratio of 1:1 cell culture media to Matrigel. Animals were randomized into treatment groups by tumor size and treated when tumors measured approximately 200 mm<sup>3</sup>. Compounds were administered by PO at 10, 25, 50, or 100 mg/kg once daily. Vehicle: 25% PEG 400, 10% Kollidon VA 64, 0.1% ascorbic acid, pH 1.5 with MSA. Animals were weighed, and tumor volumes were collected twice per week. The tumor volume was calculated as <i>L</i> Ã <i>W</i> Ã <i>H</i> and expressed in mm<sup>3</sup>. Tumor volume data represent the mean volume (<i>n</i> = 10) Â± standard error. Statistical significance was determined by repeated measures followed by Dunnettâs post hoc analysis. Statistical calculations were made through the use of JMP software v8.0.2 interfaced with SAS v9.1 (SAS Institute, Inc., Cary, NC).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> KMS-12 BM Terminal PD Studies</h4><div class="NLM_p last">The ability of <b>17</b> to impact Pim-dependent phosphorylation of BAD (Ser-112) in vivo was determined at the end of the KMS-12-BM tumor xenograft study. On the last day, mice were dosed and tumors were harvested at 1, 4, 8, 12, and 24 h post dose (<i>n</i> = 2/time point). Tumor lysates were generated and analyzed by MSD as per manufacturerâs recommendation for levels of phosphorylated BAD. Bars represent levels of phosphorylated BAD and are expressed as percent of vehicle; dots represent total plasma concentration (Î¼M).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all reagents were commercially available and used as received. All final compounds possessed purity â¥95% as determined by high performance liquid chromatography (HPLC). The HPLC methods used the following conditions: Zorbax SB-C18 column (50 mm Ã 3.0 mm, 3.5 Î¼m) at 40 Â°C with a 1.5 mL/min flow rate; solvent A of 0.1% TFA in water, solvent B of 0.1% TFA in MeCN; 0.0â3.0 min, 5â95% B in A; 3.0â3.5 min, 95% B in A; 3.5â3.51 min, 5% B in A. Flow from the UV detector was split (50:50) to the MS detector, which was configured with APIES as ionizable source. <sup>1</sup>H NMR spectra were recorded on a 400 MHz Bruker NMR spectrometer at ambient temperature. Data are reported as follows: chemical shift (ppm, Î´ units) from an internal standard, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad), coupling constant (Hz), and integration. All microwave-assisted reactions were performed in sealed reaction vials using a Personal Chemistry Emrys Optimizer microwave synthesizer. Analytical thin-layer chromatography (TLC) was performed using JT Baker silica gel plates precoated with a fluorescent indicator. Silica gel chromatography was performed using either an ISCO Companion or Biotage medium pressure liquid chromatography system.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 7-(2-(Pyrrolidine-1-carbonyl)quinolin-8-yl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>5</b>)</h4><div id="sec5_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> Step 1</h5><div class="NLM_p last">To a solution of methyl 4-bromo-1<i>H</i>-pyrrole-2-carboxylate (<b>5a</b>, Combi-Blocks, 5.15 g, 25.20 mmol) in DMF (25 mL) at 0 Â°C was added sodium hydride (60% wt in mineral oil, 1.81 g, 45.40 mmol), and the resulting mixture was stirred at 0 Â°C for 15 min. 1,2-Dibromoethane (4.79 mL, 55.50 mmol) was added, and the reaction mixture was stirred at RT for 10 min then heated in an oil bath at 70 Â°C for 2 h. After cooling to RT, it was treated with ice-cold NH<sub>4</sub>Cl solution (10 mL), extracted with 2 Ã 75 mL of EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. Purification on a silica gel column (15â35% EtOAc in hexanes) gave methyl 4-bromo-1-(2-bromoethyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>5b</b>, 3.60 g, 11.58 mmol, 46% yield) as an off-white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.41 (1H, d, <i>J</i> = 2.0 Hz), 6.92 (1H, d, <i>J</i> = 1.8 Hz), 4.65 (2H, t, <i>J</i> = 6.5 Hz), 3.75 (5H, m). <i>m</i>/<i>z</i> (ESI, +ve) 311.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Step 2</h5><div class="NLM_p last">(2,4-Dimethoxyphenyl)methanamine (4.36 mL, 28.9 mmol) was added to a stirred solution of methyl 4-bromo-1-(2-bromoethyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>5b</b>, 3.60 g, 11.58 mmol) in DMSO (15 mL) at RT. The reaction mixture was heated at 150 Â°C in an oil bath for 5 h. After it was cooled to RT, the brown mixture was partitioned between 10 mL of 2.0 N HCl and 200 mL of EtOAc. The layers were separated; the organic solution was washed with 2 N HCl (5 mL) followed by brine (5 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Purification on a silica gel column (25â75% EtOAc in hexanes) gave 7-bromo-2-(2,4-dimethoxybenzyl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>5c</b>, 3.61 g, 9.88 mmol, 85% yield) as an off-white crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.15 (1H, d, <i>J</i> = 1.8 Hz), 7.11 (1H, d, <i>J</i> = 8.2 Hz), 6.68 (1H, d, <i>J</i> = 1.8 Hz), 6.59 (1H, d, <i>J</i> = 2.3 Hz), 6.50 (1H, dd, <i>J</i> = 8.3, 2.4 Hz), 4.53 (2H, s), 4.12 (2H, dd, <i>J</i> = 6.7, 5.2 Hz), 3.81 (3H, s), 3.76 (3H, s), 3.57 (2H, dd, <i>J</i> = 6.7, 5.0 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 365/367 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Step 3</h5><div class="NLM_p last">A mixture of <i>N</i>-(<i>tert</i>-butyl)-3-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-amine (<b>AQ2</b>, 187 mg, 0.55 mmol), dicyclohexyl(2â²,4â²,6â²-triisopropyl-[1,1â²-biphenyl]-2-yl)phosphine (13 mg, 0.027 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (12 mg, 0.014 mmol), 7-bromo-2-(2,4-dimethoxybenzyl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>5c</b>, 167 mg, 0.46 mmol), and potassium phosphate (291 mg, 1.37 mmol) in 2 mL of dioxane and 0.5 mL of water was heated in a microwave at 135 Â°C for 45 min. The reaction mixture was treated with 2 mL of 1 N NaOH and extracted with EtOAc (2 Ã 5 mL). The organic extracts were concentrated. Purification of the brown residue on a silica gel column (eluted with 25â75% EtOAc in hexanes) afforded 7-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-2-(2,4-dimethoxybenzyl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>5d</b>, 60 mg) as a brown amorphous solid. <i>m</i>/<i>z</i> (ESI, +ve) 500.1 (M + H)<sup>+</sup>. The crude brown amorphous solid in 0.5 mL of TFA and 0.5 mL of DCM was heated in an oil bath at 60 Â°C for 30 min. The resulting dark-red mixture was concentrated, and the residue was partitioned between 5 mL of 1 N NaOH and 50 mL of EtOAc. The organic layer was washed with 5 mL of brine and concentrated. The residue was purified on a silica gel column (1â5% MeOH in EtOAc) to give 7-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>5</b>) (35 mg, 22% yield) as a yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.81 (1H, d, <i>J</i> = 1.4 Hz), 7.70 (1H, m), 7.65 (1H, br), 7.56 (1H, m), 7.30 (1H, t, <i>J</i> = 7.7 Hz), 7.26 (1H, d, <i>J</i> = 1.6 Hz), 5.83 (1H, s), 4.15 (2H, m), 3.55 (2H, m), 2.54 (3H, s), 1.55 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 350.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-5,6,7,8-tetrahydropyrrolo[3,2-<i>c</i>]azepin-4(1<i>H</i>)-one (<b>6</b>)</h4><div id="sec5_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Step 1</h5><div class="NLM_p last">1,3-Dibromo-5,5-dimethylhydantoin (532 mg, 1.86 mmol) was added to a solution of 6,7-dihydro-1<i>H</i>-indol-4(5<i>H</i>)-one (<b>6a</b>, Combi-blocks, 503 mg, 3.72 mmol) in DMF (13 mL) at â60 Â°C, and the resulting mixture was stirred at â60 Â°C for 10 min. The mixture was then concentrated in vacuo (65 Â°C, 24 Torr), and the residual oil was chromatographically purified (silica gel, 0â80% EtOAc/hexanes). The isolated product was taken up in EtOAc (100 mL) and sequentially washed with saturated (satd) aqueous NaHCO<sub>3</sub> (3 Ã 40 mL) and brine (40 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to provide 2-bromo-6,7-dihydro-1<i>H</i>-indol-4(5<i>H</i>)-one (<b>6b</b>, 664 mg, 3.10 mmol, 83% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.43 (1H, br s), 6.51 (1H, d, <i>J</i> = 2.3 Hz), 2.79 (2H, t, <i>J</i> = 6.2 Hz), 2.48 (2H, t, <i>J</i> = 6.6 Hz), 2.15 (2H, quin, <i>J</i> = 6.3 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 214.1/216.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Step 2</h5><div class="NLM_p last">A solution of 2-bromo-6,7-dihydro-1<i>H</i>-indol-4(5<i>H</i>)-one (<b>6b</b>) (222 mg, 1.04 mmol), hydroxylamine hydrochloride (80 mg, 1.14 mmol), and sodium acetate (94 mg, 1.14 mmol) in MeOH (28 mL) was stirred under argon at 50 Â°C for 22 h. The reaction mixture was then concentrated in vacuo, and the residue was partitioned between satd aqueous NaHCO<sub>3</sub> (40 mL) and EtOAc (60 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (60 mL). The combined extracts were dried over sodium sulfate, filtered, and concentrated in vacuo to provide 2-bromo-6,7-dihydro-1<i>H</i>-indol-4(5<i>H</i>)-one oxime (273 mg) as an off-white solid. . Major isomer: <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm: (â¼2:1 mixture of oxime isomers) Î´ ppm 7.99 (1 H, br s), 6.36 (1H, br s), 2.71 (2H, br s), 2.63 (2H, br s), 1.89â1.98 (2H, m). Minor isomer: <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.14 (1H, br s), 6.97 (1H, br s), 2.70 (2H, m), 2.47 (2H, br s), 1.99 (2H, br s). <i>m</i>/<i>z</i> (ESI, +ve) 228.9/231.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Step 3</h5><div class="NLM_p last">Thionyl chloride (0.06 mL, 0.90 mmol) was added to a solution of 2-bromo-6,7-dihydro-1<i>H</i>-indol-4(5<i>H</i>)-one oxime (186 mg, 0.81 mmol) in THF (8.0 mL) at 25 Â°C, and the resulting solution was stirred at 25 Â°C for 18 h. The reaction mixture was then diluted with EtOAc (40 mL), sequentially washed with satd aqueous NaHCO<sub>3</sub> (2 Ã 30 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Chromatographic purification of the residue (silica gel, 0â10% MeOH/DCM) furnished 2-bromo-5,6,7,8-tetrahydropyrrolo[3,2-<i>c</i>]azepin-4(1<i>H</i>)-one (<b>6c</b>, 102 mg, 0.44 mmol, 55% yield) as a light-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.59 (1 H, br s), 7.36 (1H, t, <i>J</i> = 4.5 Hz), 6.27 (1H, d, <i>J</i> = 2.7 Hz), 3.12 (2H, m), 2.82 (2H, t, <i>J</i> = 6.6 Hz), 1.86 (2H, m). <i>m</i>/<i>z</i> (ESI, +ve) 228.9/231.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Step 4</h5><div class="NLM_p last">A mixture of <i>N</i>-(<i>tert</i>-butyl)-3-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-amine (<b>AQ2</b>) (341 mg, 0.66 mmol), 2-bromo-5,6,7,8-tetrahydropyrrolo[3,2-<i>c</i>]azepin-4(1<i>H</i>)-one (<b>6c</b>) (84.0 mg, 0.37 mmol), potassium phosphate (420 mg, 1.98 mmol), dicyclohexyl(2â²,4â²,6â²-triisopropyl-[1,1â²-biphenyl]-2-yl)phosphine (X-Phos) (17.5 mg, 0.037 mmol), and tris(dibenzylideneacetone)dipalladium (0) (16.8 mg, 0.018 mmol) in a mixture of dioxane (3.0 mL) and water (0.60 mL) was stirred under argon at 105 Â°C for 1.5 h. The reaction mixture was subsequently diluted with DCM (10 mL) and concentrated onto silica gel. Chromatographic purification (silica gel, 0â100% EtOAc/hexanes, then 0â10% MeOH/DCM) furnished 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6,7,8-tetrahydropyrrolo[3,2-<i>c</i>]azepin-4(1<i>H</i>)-one (<b>6</b>) (128 mg, 0.35 mmol, 96% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.77 (1H, br s), 7.83 (1H, dd, <i>J</i> = 7.4, 1.0 Hz), 7.56 (1H, dd, <i>J</i> = 7.8, 1.0 Hz), 7.32 (2H, t, <i>J</i> = 7.7 Hz), 7.09 (1H, d, <i>J</i> = 2.7 Hz), 6.01 (1H, s), 3.21 (2H, dd, <i>J</i> = 8.5, 4.6 Hz), 3.02 (2H, t, <i>J</i> = 6.5 Hz), 2.55 (3H, s), 1.97 (2H, m), 1.58 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 364.2 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-6-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>)</h4><div id="sec5_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Step 1</h5><div class="NLM_p last"><i>Flask A</i>: To a solution of mono-<i>t</i>-butyl malonate (29.3 mL, 190 mmol) and anhydrous magnesium chloride (18.12 g, 190 mmol) in 400 mL of THF in a three-neck 3 L round-bottomed flask (RBF) with temperature probe and mechanical stirrer at 2 Â°C was added potassium <i>t</i>-butoxide (1.0 M solution in THF; 190 mL, 190 mmol) slowly dropwise via addition funnel such that the temperature did not exceed 10 Â°C. The mixture became cloudy over the addition and was easy to stir. The ice bath was removed, and the reaction was stirred at ambient temperature for 3 h. <i>Flask B</i>: To a solution of Boc-<span class="smallcaps smallerCapital">d</span>-alanine (30.00 g, 159 mmol) in 300 mL of THF at RT under N<sub>2</sub> (fitted with N<sub>2</sub> inlet and gas outlet to bubbler) was added 1,1â²-carbonyldiimidazole (0.93 g, 5.71 mmol) in three portions separated by 5 min. Gas evolution was observed. The reaction was stirred for 3 h. The contents in <i>flask B</i> were added via an additional funnel to <i>flask A</i>, and the resulting cloudy white mixture was stirred for 39 h at RT. The resulting white suspension was cooled in an ice bath, and 500 mL of 1 N HCl was added at a rate such that the internal temperature did not exceed 20 Â°C. Then 0.8 L Et<sub>2</sub>O was added and the mixture transferred to a separatory funnel. The layers were separated, and the organic layer was washed sequentially with 200 mL of 1 N HCl, 200 mL of water, 2 Ã 200 mL of satd aqueous NaHCO<sub>3</sub>, and 200 mL of brine. It was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting clear colorless oil was seeded with small crystals of the desired product and was further concentrated on a rotovap to give a white solid. The material was dried in vacuo for 2 h to give (<i>R</i>)-<i>tert</i>-butyl 4-((<i>tert</i>-butoxycarbonyl)amino)-3-oxopentanoate (<b>BE1a</b>) (34.3 g, 119 mmol, 75% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 5.15 (1H, br), 4.30â4.51 (1H, m), 3.38â3.58 (2H, m), 1.48 (9H, s), 1.46 (9H, s), 1.37 (3H, d, <i>J</i> = 7.2 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 310.1 (M + Na)<sup>+</sup>.</div></div><div id="sec5_2_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 2</h5><div class="NLM_p last">(<i>R</i>)-<i>tert</i>-Butyl 4-((<i>tert</i>-butoxycarbonyl)amino)-3-oxopentanoate (<b>BE1a</b>; 34.3 g, 119 mmol) was treated with NH<sub>4</sub>OAc (92.0 g, 1194 mmol) and NH<sub>3</sub> (2 M in MeOH; 597 mL, 1194 mmol). To the resulting slurry was added chloroacetaldehyde (50% in water; 154 mL, 1194 mmol) in portions. The temperature of the reaction rose to 42 Â°C, and the reaction was cooled with ice, briefly, to 38 Â°C. When no further exotherm was noted, the clear light-yellow reaction was placed on a rotovap in a 50 Â°C water bath. After 40 min, the reaction was dark brown. The reaction was heated for an additional 100 min. The reaction was concentrated in vacuo and treated with dichloromethane and satd aqueous NaHCO<sub>3</sub> with rapid stirring (<i>Caution: gas evolution</i>). The reaction was transferred to a 5 L bottle, and solid NaHCO<sub>3</sub> was added. When gas evolution was no longer observed, the material was transferred to a separatory funnel. <i>Note</i>: a large amount of brown solids precipitated from the mixture, so MeOH (20 mL) was added to the mixture to dissolve the solids. The water layer was extracted with 3 Ã 250 mL of dichloromethane, and the combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting thick brown oil was dissolved in â¼150 mL of dichloromethane, filtered, and purified by silica gel chromatography (1500 g ISCO RediSep gold column using 0â30% EtOAc/hexanes) to afford (<i>R</i>)-<i>tert</i>-butyl 2-(1-((<i>tert</i>-butoxycarbonyl)amino)ethyl)-1<i>H</i>-pyrrole-3-carboxylate (<b>BE1b</b>) (23.41 g, 75 mmol, 63% yield) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 9.30 (1H, br), 6.53 (2H, dt, <i>J</i> = 13.9, 2.8 Hz), 6.10 (1H, br), 5.15 (1H, br), 1.57 (9H, s), 1.53 (3H, d, <i>J</i> = 6.8 Hz), 1.43 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 333.1 (M + Na)<sup>+</sup>.</div></div><div id="sec5_2_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 3</h5><div class="NLM_p last">A 1 L three-necked RBF was charged with (<i>R</i>)-<i>tert</i>-butyl 2-(1-((<i>tert</i>-butoxycarbonyl)amino)ethyl)-1<i>H</i>-pyrrole-3-carboxylate (<b>BE1b</b>; 20.06 g, 64.6 mmol) and 200 mL of THF, fitted with an addition funnel and temperature probe, and cooled in an ice bath to 2 Â°C. Sodium <i>tert</i>-butoxide (2 M in THF; 33.9 mL, 67.8 mmol) was added via addition funnel at such a rate that the temperature of the reaction did not exceed 4 Â°C. After the addition was complete, the dark-brown reaction mixture was stirred for 5 min. A solution of <i>p</i>-toluenesulfonyl chloride (12.94 g, 67.9 mmol) in 50 mL of THF was then added via addition funnel at such a rate that the temperature of the reaction did not exceed 7 Â°C. After the addition was complete, the reaction was stirred 30 min. The reaction was treated with 30 mL of water and 100 mL of EtOAc and 30 mL of satd aqueous NaHCO<sub>3</sub>. The layers were separated and the organic washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give 29 g of a tan solid. The material was stirred in 75 mL MeOH for 15 min and then placed in the freezer. The slurry was filtered by rinsing with 2 Ã 50 mL of ice-cold MeOH. The solid was collected and dried in vacuo to give (<i>R</i>)-<i>tert</i>-butyl 2-(1-((<i>tert</i>-butoxycarbonyl)amino)ethyl)-1-tosyl-1<i>H</i>-pyrrole-3-carboxylate (<b>BE1c</b>) (21.0 g, 45.2 mmol, 70% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.89 (2H, d, <i>J</i> = 7.0 Hz), 7.30 (2H, d, <i>J</i> = 8.2 Hz), 7.23 (1H, d, <i>J</i> = 3.5 Hz), 6.82 (1H, br), 6.55 (1H, d, <i>J</i> = 3.3 Hz), 5.84 (1H, d, <i>J</i> = 7.0 Hz), 2.40 (3H, s), 1.55 (9H, s), 1.32â1.44 (12H, m). <i>m</i>/<i>z</i> (ESI, +ve) 487.1 (M + Na)<sup>+</sup>.</div></div><div id="sec5_2_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 4</h5><div class="NLM_p last">To a solution of (<i>R</i>)-<i>tert</i>-butyl 2-(1-((<i>tert</i>-butoxycarbonyl)amino)ethyl)-1-tosyl-1<i>H</i>-pyrrole-3-carboxylate (<b>BE1c</b>; 25.11 g, 54.0 mmol) in 120 mL of dichloromethane was added TFA (120 mL) slowly in portions (<i>Caution: gas evolution was observed</i>). After complete addition, the dark-brown reaction mixture was stirred for 5 min, then fitted with a water-cooled reflux condenser and drying tube and was placed in a preheated 50 Â°C oil bath for 3 h. The reaction was cooled and concentrated in vacuo, and the solid material was dried in vacuo for 48 h to give (<i>R</i>)-2-(1-aminoethyl)-1-tosyl-1<i>H</i>-pyrrole-3-carboxylic acid trifluoroacetate salt (<b>BE1d</b>) (22.83 g, 54.1 mmol, 100% yield). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) Î´ ppm 7.89 (2H, d, <i>J</i> = 8.4 Hz), 7.57 (1H, d, <i>J</i> = 3.5 Hz), 7.52 (2H, d, <i>J</i> = 8.2 Hz), 6.79 (1H, d, <i>J</i> = 3.5 Hz), 5.28 (1H, q, <i>J</i> = 6.8 Hz), 2.47 (3H, s), 1.32 (3H, d, <i>J</i> = 6.8 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 309.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Step 5</h5><div class="NLM_p last">To a slurry of (<i>R</i>)-2-(1-aminoethyl)-1-tosyl-1<i>H</i>-pyrrole-3-carboxylic acid trifluoroacetate salt (<b>BE1d</b>, 22.83 g, 54.1 mmol) in 150 mL of EtOAc at 0 Â°C was added DIPEA (28.2 mL, 162 mmol). After 10 min, 1-propanephosphonic acid cyclic anhydride (T3P) (50 wt % solution in EtOAc; 35.0 mL, 59.5 mmol) was added. After 10 min, the heterogeneous reaction was warmed to RT. After 4 h, the reaction mixture was dark brown and homogeneous. It was treated with 400 mL of satd aqueous NaHCO<sub>3</sub> and transferred to a separatory funnel. The layers were separated, and the organic layer was washed with 1Ã satd aqueous NaHCO<sub>3</sub>, then brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered through a glass frit, and concentrated in vacuo to give (<i>R</i>)-6-methyl-1-tosyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1e</b>) (16.5 g, 56.8 mmol, quantitative yield) as a tan foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.73 (2H, m), 7.35 (2H, d, <i>J</i> = 8.0 Hz), 7.16 (1H, d, <i>J</i> = 3.3 Hz), 6.48 (1H, d, <i>J</i> = 3.1 Hz), 5.75 (1H, br s), 4.68 (1H, q, <i>J</i> = 6.5 Hz), 1.62 (3H, d, <i>J</i> = 6.7 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 291.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step 6</h5><div class="NLM_p last">To a stirred solution of (<i>R</i>)-6-methyl-1-tosyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1e</b>; 15.6 g, 53.7 mmol) in 250 mL of MeOH under nitrogen in an ice/water bath was added K<sub>2</sub>CO<sub>3</sub> (14.85 g, 107 mmol). The slurry was stirred at RT overnight. Then 100 g of silica gel was added and the reaction was concentrated in vacuo. A dichloromethane-wetted pad of silica gel (4 cm) was poured in a 15 cm diameter fritted funnel, and the dried silica gel/reaction mixture was placed on the silica gel pad and covered with 4 cm of sand. One L fractions collected: no. 1, 1 L of dichloromethane; no. 2, 1 L of 10% MeOH/dichloromethane; no. 3, 1 L of 10% MeOH/dichloromethane; no. 4, â¼750 mL of 10% MeOH/dichloromethane; no. 5, 1 L of 10% MeOH/dichloromethane. Fractions 3â5 were combined and concentrated in vacuo to give 7.7 g (74% <i>ee</i>) as a tan solid. The material was further purified by chiral SFC (mobile phase CO<sub>2</sub>/15% MeOH (20 mM NH<sub>3</sub>), chiral column ASH (250 mm Ã 30 mm), wavelength 256 nm, flow rate 120 mL/min). The second eluting peak was collected and concentrated in vacuo to give (<i>R</i>)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1f</b>) (5.3 g, 39.0 mmol, 73% yield, 99% <i>ee</i>) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) Î´ ppm 6.84 (1H, d, <i>J</i> = 2.9 Hz), 6.23 (1H, d, <i>J</i> = 2.9 Hz), 4.53 (1H, q, <i>J</i> = 6.7 Hz), 1.41 (3H, d, <i>J</i> = 6.8 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 137.1</div></div><div id="sec5_2_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step 7</h5><div class="NLM_p last">A glass pressure vessel was charged with (<i>R</i>)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1g</b>) (2.50 g, 18.36 mmol) and bis(pinacolato) diboron (5.13 g, 20.20 mmol) in MTBE (70 mL) followed by bis(1,5-cyclooctadiene)di-Î¼-methoxydiiridium(I) (0.36 g, 0.55 mmol) and 4,4â²-di-<i>tert</i>-butyl-2,2â²-dipyridyl (0.29 g, 1.10 mmol). The mixture was bubbled with argon for 3 min, then sealed and heated in an oil bath at 55 Â°C for 2 h. After the reaction mixture was cooled to RT, it was filtered through a plug of aluminum oxide (Sigma-Aldrich; neutral, activated, Brockmann I) and washed with dichloromethane (1200 mL) and then 5â10% MeOH in dichloromethane (1500 mL). The fractions containing the desired product (as judged by LCMS) were combined and concentrated to give (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>) (5.86 g) as a brown solid. <i>m</i>/<i>z</i> (ESI, +ve ion) 263.0 (M + H)<sup>+</sup>. The crude material was used without further purification. <sup>1</sup>H NMR indicated the desired boronic ester:starting material:pinacol to be about 1:0.08:0.22. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.68 (1H, br), 7.62 (1H, s), 6.49 (1H, s), 4.40 (1H, m), 1.28 (12H, s), 1.17 (3H, d, <i>J</i> = 5.9 Hz).</div></div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>7</b>)</h4><div id="sec5_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step 1</h5><div class="NLM_p last">To a 25 mL round-bottomed flask was added ethyl 4-((<i>tert</i>-butoxycarbonyl)amino)-3-oxobutanoate (<b>7a</b>) (0.47 g, 1.91 mmol), potassium carbonate (0.41 g, 2.97 mmol), 2-bromo-1-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)ethanone (<b>AQ3</b>) (0.40 g, 1.19 mmol), THF (3 mL), and EtOH (3 mL). The reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with satd NH<sub>4</sub>Cl (5 mL) and extracted with EtOAc (10 mL). The organic extract was washed with water (5 mL), dried over sodium sulfate, and concentrated to give ethyl 4-((<i>tert</i>-butoxycarbonyl)amino)-2-(2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-2-oxoethyl)-3-oxobutanoate as a light-yellow oil and used without further purification. <i>m</i>/<i>z</i> (ESI, +ve) 501.3 (M + H)<sup>+</sup>. To a 15 mL glass tube was added the light-yellow oil containing ethyl 4-((<i>tert</i>-butoxycarbonyl)amino)-2-(2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-2-oxoethyl)-3-oxobutanoate, ammonium acetate (0.36 g, 4.71 mmol), EtOH (2 mL), and AcOH (1 mL). The tube was sealed and heated at 50 Â°C for 3 h. The reaction mixture was allowed to cool to RT and was concentrated to half of its volume. The mixture was diluted with EtOAc (10 mL) and water (5 mL). The organic extract was washed with NaOH (1 N, 5 mL), water (5 mL), brine (5 mL), dried over sodium sulfate, and concentrated. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a Redi-Sep prepacked silica gel column (24 g), eluting with a gradient of 0â30% EtOAc in hexanes to give ethyl 2-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylate (<b>7b</b>) (0.33 g, 59% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.64 (br, 1H), 7.82 (dd, <i>J</i> = 1.17, 7.43 Hz, 1H), 7.58â7.64 (m, 1H), 7.41 (d, <i>J</i> = 2.74 Hz, 1H), 7.35 (s, 1H), 6.94 (br s, 1H), 4.53 (d, <i>J</i> = 5.28 Hz, 2H), 4.21 (q, <i>J</i> = 7.04 Hz, 2H), 2.56 (s, 3H), 1.58 (s, 9H), 1.39 (s, 9H), 1.30 (t, <i>J</i> = 7.10 Hz, 3H). <i>m</i>/<i>z</i> (ESI, +ve) 482.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step 2</h5><div class="NLM_p last">A glass microwave reaction vessel was charged with ethyl 2-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylate (<b>7b</b>) (0.27 g, 0.56 mmol), lithium hydroxide monohydrate (0.12 g, 2.82 mmol), dioxane (3 mL), and water (1 mL). The reaction mixture was stirred and heated in an Initiator microwave reactor (Personal Chemistry) at 110 Â°C for 3 h. The reaction mixture was acidified with HCl (1 N, 5 mL), and the precipitated orange solid was filtered, washed with water, ether, and dried in a vacuum oven at 50 Â°C for 3 h. The resulting orange solid was suspended in dioxane (2 mL), treated with HCl (2 mL of 4 N in dioxane), and stirred at RT for 4 h. The mixture was concentrated to half of its volume, and the orange solid obtained was filtered, washed with ether, and dried to give 2-(aminomethyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylic acid hydrochloride (<b>7c</b>), which was used as crude material and based on theoretical yield.</div></div><div id="sec5_2_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step 3</h5><div class="NLM_p last">To a 100 mL round-bottomed flask was added 2-(aminomethyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylic acid hydrochloride (<b>7c</b>) (0.21 g, 0.55 mmol), DCM (10 mL), DMF (10 mL), diisopropylethylamine (0.29 mL, 1.65 mmol), and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (0.34 g, 0.66 mmol) (PyBop). The reaction mixture was stirred at RT for 30 min, concentrated to half of its volume, and diluted with EtOAc (10 mL). The organic extract was washed with satd NaHCO<sub>3</sub> (5 mL), dried over sodium sulfate, and concentrated. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a Redi-Sep prepacked silica gel column (12 g), eluted first with 30% EtOAc in hexanes and then with a gradient of 0â4% 2 M NH<sub>3</sub>/MeOH in DCM to provide 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>7</b>) (97 mg, 52% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.08 (br, 1H), 7.82 (d, <i>J</i> = 7.24 Hz, 1H), 7.63 (d, <i>J</i> = 8.02 Hz, 1H), 7.53 (s, 1H), 7.37 (t, <i>J</i> = 7.73 Hz, 1H), 6.94 (s, 1H), 6.02 (s, 1H), 4.29 (s, 2H), 2.58 (s, 3H), 1.55 (s, 9H). <i>m</i>/<i>z</i> (ESI, +ve) 336.2 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (6<i>S</i>)-2-(3-(<i>tert</i>-Butylamino)-2-methyl-5-quinoxalinyl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>8</b>), and (6<i>R</i>)-2-(3-(<i>tert</i>-Butylamino)-2-methyl-5-quinoxalinyl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>9</b>)</h4><div id="sec5_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Step 1</h5><div class="NLM_p last">At RT, a solution of (<i>R</i>)-ethyl-4-((<i>tert</i>-butoxycarbonyl)amino)-3-oxopentanoate (<b>9a</b>) (5.38 g, 20.77 mmol) in 20 mL of THF and 20 mL of DMF was treated with 2-bromo-1-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)ethanone (<b>AQ3</b>) (5.44 g, 16.18 mmol) and potassium carbonate (5.59 g, 40.4 mmol) and stirred at RT for 6 h. It was diluted with 250 mL of EtOAc, filtered through a fritted funnel, and rinsed with 2 Ã 15 mL of EtOAc. The filtrate was washed with satd NH<sub>4</sub>Cl (2 Ã 25 mL), followed by brine (15 mL). The organic solution was dried over sodium sulfate and concentrated. The residue was passed through a short column (35â75% EtOAc in hexanes) to remove the solvent front peaks and the baseline peaks. Fractions with <i>m</i>/<i>z</i> (ESI, +ve) 515.2 (M + H)<sup>+</sup> were collected and concentrated to give ethyl 4-((<i>tert</i>-butoxycarbonyl)amino)-2-(2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-2-oxoethyl)-3-oxopentanoate as a brown residue. To the brown residue in a glass tube in 25 mL of EtOH and 10 mL of HOAc was added ammonium acetate (8.46 g, 110 mmol). The tube was sealed and heated in an oil bath at 50 Â°C for 8 h. The mixture was concentrated to half of its volume, diluted with 250 mL of EtOAc, and washed sequentially with 15 mL of water, 15 mL of 1 N NaOH, and 5 mL of brine. The organic solution was concentrated, and the residue was purified on a silica gel column (eluted with a gradient of 35â65% EtOAc in hexanes) to give ethyl 2-(1-((<i>tert</i>-butoxycarbonyl)amino)ethyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylate (<b>9b</b>) (6.30 g, 79% yield) as a yellow amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.42 (1H, br), 7.76 (1H, dd, <i>J</i> = 7.4, 1.2 Hz), 7.63 (1H, dd, <i>J</i> = 8.0, 1.2 Hz), 7.38 (2H, m), 7.03 (1H, d, <i>J</i> = 7.8 Hz), 5.94 (1H, s), 5.44 (1H, m), 4.20 (2H, m), 2.56 (3H, s), 1.58 (9H, s), 1.40 (12H, m), 1.21 (3H, m). <i>m</i>/<i>z</i> (ESI, +ve) 496.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Step 2</h5><div class="NLM_p last">A mixture of ethyl 2-(1-((<i>tert</i>-butoxycarbonyl)amino)ethyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylate (<b>9b</b>) (6.30 g, 12.71 mmol) and lithium hydroxide monohydrate (2.67 g, 63.6 mmol) in dioxane (24 mL) and water (24 mL) was heated in an oil bath at 100 Â°C for 10 h. The reaction mixture was concentrated to half of its volume. The remaining mixture was lyophilized for 24 h to give a yellow solid. The yellow solid suspended in 15 mL of dioxane at 0 Â°C was treated with 35 mL of 4 N HCl in dioxane. The resulting orange mixture was stirred at RT for 2 h. The mixture was concentrated to half of its volume. The insoluble solid was filtered and rinsed with 2 Ã 10 mL of ether. The filtrate was discarded. The orange solid was dried in a vacuum oven at 40 Â°C for 1 h to give 2-(1-aminoethyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylic acid hydrochloride (<b>9c</b>), which was used as crude material and based on theoretical yield. <i>m</i>/<i>z</i> (ESI, +ve) 368.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Step 3</h5><div class="NLM_p">To a mixture of 2-(1-aminoethyl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylic acid hydrochloride (<b>9c</b>) (2/3 of the crude material from previous step, estimated to be 9.4 mmol) in 30 mL of DMF and 25 mL of DCM at 0 Â°C was added diisopropylethylamine (0.98 mL, 56.4 mmol) and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBop) (6.11 g, 11.75 mmol). The resulting homogeneous solution was stirred at RT for 8 h. It was diluted with 300 mL of DCM, washed sequentially with 15 mL of water, 2 Ã 10 mL of 1 N NaOH, and 10 mL of brine. The organic solution was concentrated, and the residue was purified on a silica gel column (eluted with a gradient of 1â5% MeOH in DCM) to provide a brown amorphous solid containing 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>9d</b>), <i>m</i>/<i>z</i> (ESI, +ve) 350.0 (M + H)<sup>+</sup>, and a significant amount of undesired side product, tri(pyrrolidin-1-yl)phosphine oxide, <i>m</i>/<i>z</i> (ESI, +ve) 258.0 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The individual enantiomers of <b>9d</b> (about 85% <i>ee</i>) were obtained by chiral SFC (Column, Chiralcel OJH (250 mm Ã 20 mm, 5 Î¼); mobile phase, 85:15 (A:B); A, liquid CO<sub>2</sub>; B, MeOH (20 mM ammonia); flow rate, 70 mL/min; oven temp, 40 Â°C; inlet pressure, 100 bar; wavelength, 278 nm) to give compound <b>9</b> (first eluting product) and compound <b>8</b> (second eluting product). Compound <b>9</b>: (6<i>R</i>)-2-(3-(<i>tert</i>-butylamino)-2-methyl-5-quinoxalinyl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (810 mg, 25% yield, >99% <i>ee</i>) as a yellow crystalline solid was obtained. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 12.00 (1H, br), 7.83 (1H, dd, <i>J</i> = 7.4, 1.2 Hz), 7.64 (2H, m), 7.37 (1H, t, <i>J</i> = 7.7 Hz), 6.85 (1H, d, <i>J</i> = 1.4 Hz), 6.02 (1H, s), 4.57 (1H, q, <i>J</i> = 6.6 Hz), 2.58 (3H, s), 1.56 (9H, s), 1.40 (3H, d, <i>J</i> = 6.7 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 350.0 (M + H)<sup>+</sup>. Compound <b>8</b>: (6<i>S</i>)-2-(3-(<i>tert</i>-butylamino)-2-methyl-5-quinoxalinyl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (85 mg, 2.6% yield, >99% <i>ee</i>) as a yellow crystalline solid was obtained. <i>m</i>/<i>z</i> (ESI, +ve) 350.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>R</i>)-6-(2-Aminoethyl)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>10</b>)</h4><div class="NLM_p">A solution of 6-(2-(benzyloxy)ethyl)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>10d</b>, 840 mg, 1.79 mmol) in DCM (20 mL) at 0 Â°C under nitrogen was treated with boron trichloride (1.0 M solution in DCM, 3.94 mL, 3.94 mmol) dropwise. The reaction mixture (rusty color) was stirred at 0 Â°C for 5 min then RT for 1 h. Additional 1.5 mL of BCl<sub>3</sub> (1.0 M in DCM) was added and the mixture stirred at RT for 20 min. It was treated with 10 mL of MeOH dropwise followed by sodium bicarbonate (1.50 g, 17.89 mmol). The solvents were removed under reduced pressure. The residue was purified by silica gel chromatography (5% MeOH in DCM followed by 5% 2 M NH<sub>3</sub> in MeOH in DCM) to provide two compounds. The first eluent was 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-6-(2-chloroethyl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (100 mg, 0.25 mmol, 14% yield) as an orange colored solid. <i>m</i>/<i>z</i> (ESI, +ve) 398.0 (M + H)<sup>+</sup>. The second  eluent was 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-6-(2-hydroxyethyl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (150 mg, 0.40 mmol, 22% yield) as an orange solid. <i>m</i>/<i>z</i> (ESI, +ve) 380.0 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a suspension of 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-6-(2-hydroxyethyl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (120 mg, 0.316 mmol) in 5 mL of DCM at 0 Â°C was added triethylamine (220 Î¼L, 1.58 mmol) followed by methanesulfonyl chloride (31 Î¼L, 0.39 mmol). It was stirred at 0 Â°C for 30 min and then diluted with 30 mL of DCM and washed sequentially with 5 mL of water, 5 mL of satd NaHCO<sub>3</sub>, and 5 mL of brine. The DCM solution was dried over sodium sulfate and concentrated. The brown residue was dissolved in 1 mL of DMF and treated with sodium azide (62 mg, 0.95 mmol). The mixture was heated in an oil bath at 55 Â°C for 2 h. It was cooled to RT and diluted with EtOAc (50 mL) and filtered. The filtrate was washed with 2 Ã 5 mL of water. The EtOAc solution was concentrated and the residue was purified on a silica gel column (2â8% MeOH in DCM) to give 6-(2-azidoethyl)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (97 mg, 0.24 mmol, 76% yield) as a brown solid. <i>m</i>/<i>z</i> (ESI, +ve) 405 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of 6-(2-azidoethyl)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (92 mg, 0.23 mmol) in 3 mL of THF and water (0.3 mL) at RT was added trimethylphosphine (0.34 mL of 1 M in THF, 0.34 mmol). It was stirred at RT for 45 min, then diluted with 50 mL of EtOAc and washed with 5 mL of water. The organic layer was concentrated to give an orange amorphous solid containing 6-(2-aminoethyl)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>10e</b>) (about 90% <i>ee</i>). <i>m</i>/<i>z</i> (ESI, +ve) 379.1 (M + H)<sup>+</sup>. The crude <b>10e</b> was subjected to chiral SFC [Column, Chiralpak ASH (250 mm Ã 30 mm, 5 Î¼); mobile phase, 80:20 (A:B); A, liquid CO<sub>2</sub>; B, MeOH containing 20 mM ammonia; flow rate, 70 mL/min; oven temp, 40 Â°C; inlet pressure, 100 bar; wavelength, 278 nm]. The first eluent was the minor enantiomer: <i>m</i>/<i>z</i> (ESI, +ve) 379.1 (M + H)<sup>+</sup>. The second eluent was the major enantiomer: (<i>R</i>)-6-(2-aminoethyl)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>10</b>) (38 mg, 0.10 mmol, 43% yield, 99% <i>ee</i>) as a yellow amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.81 (1H, dd, <i>J</i> = 7.4, 1.4 Hz), 7.71 (1H, s), 7.57â7.67 (1H, m), 7.35 (1H, t, <i>J</i> = 7.7 Hz), 6.84 (1H, s), 5.99 (1H, s), 4.57 (1H, dd, <i>J</i> = 8.4, 4.1 Hz), 3.41 (3H, br), 2.64â2.77 (2H, m), 2.56 (3H, s), 1.92 (1H, dd, <i>J</i> = 13.3, 4.3 Hz), 1.57â1.65 (1H, m), 1.55 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 379.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2â²-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-1â²<i>H</i>-spiro[cyclopropane-1,6â²-pyrrolo[3,4-<i>b</i>]pyrrol]-4â²(5â²<i>H</i>)-one (<b>11</b>)</h4><div class="NLM_p last">This compound was prepared according to the synthetic protocols described for compound <b>7</b>, starting from Î²-keto ester <b>11a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.64 (1H, br), 7.78 (1H, d, <i>J</i> = 6.5 Hz), 7.67 (1H, s), 7.60 (1H, m), 7.35 (1H, t, <i>J</i> = 7.8 Hz), 6.90 (1H, m), 6.00 (1H, s), 2.56 (3H, s), 1.52 (9H, s), 1.42 (2H, m), 1.33 (2H, m). <i>m</i>/<i>z</i> (ESI, +ve) 362.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2â²-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-2,3,5,6-tetrahydro-1â²<i>H</i>-spiro[pyran-4,6â²-pyrrolo[3,4-<i>b</i>]pyrrol]-4â²(5â²<i>H</i>)-one (<b>12</b>)</h4><div class="NLM_p last">2-(4-Aminotetrahydro-2<i>H</i>-pyran-4-yl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylic acid (<b>12c</b>) was prepared according to the synthetic protocols described for intermediate <b>7c</b>, starting from Î²-keto ester <b>12a</b>. A solution of 2-(4-aminotetrahydro-2<i>H</i>-pyran-4-yl)-5-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1<i>H</i>-pyrrole-3-carboxylic acid (<b>12c</b>, 54.7 mg, 0.13 mmol) and diisopropylethylamine (0.13 mL, 0.77 mmol) in DCM (0.65 mL)/DMF (0.65 mL) was stirred at 0 Â°C under nitrogen, and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (HATU) (81 mg, 0.15 mmol) was added. The reaction mixture was stirred at 0 Â°C for 45 min, then RT for 3 h. It was concentrated under reduced pressure and purified by reverse-phase preparative HPLC [using a Phenomenex Gemini column, 10 Î¼m, C18, 100 Ã, 150 mm Ã 30 mm, 0.1% TFA in CH<sub>3</sub>CN/H<sub>2</sub>O, gradient 10â95% over 8 min]. The product fractions were concentrated in a Genevac EZ-2 evaporator at 55 Â°C. They were reconstituted in MeOH and applied to a MeOH-washed SiliaPrep Si-carbonate cartridge to generate the free base. The yellow eluent was concentrated under reduced pressure to an orangeâyellow solid. LCMS did not give the product (ESI:electrospray positive). A significant yellow coloring remained on the basic column. It was flushed with 2 M NH<sub>3</sub>/MeOH to give a second yellow solution. The solution was concentrated under reduced pressure to give 2â²-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-1â²<i>H</i>-spiro[cyclopropane-1,6â²-pyrrolo[3,4-<i>b</i>]pyrrol]-4â²(5â²<i>H</i>)-one (<b>12</b>) (7.4 mg, 14% yield) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´: 12.02 (br, 1H), 7.96 (d, <i>J</i> = 6.3 Hz, 1H), 7.70 (d, <i>J</i> = 6.8 Hz, 1H), 7.39 (t, <i>J</i> = 7.8 Hz, 1H), 7.22 (d, <i>J</i> = 2.5 Hz, 1H), 5.96 (s, 1H), 4.88 (s, 1H), 4.36 (d, <i>J</i> = 2.5 Hz, 2H), 3.97 (t, <i>J</i> = 5.4 Hz, 2H), 2.63 (br, 2H), 2.57 (s, 3H), 1.62 (s, 9H), 1.26 (s, 2H). <i>m</i>/<i>z</i> (ESI, +ve) 407.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>R</i>)-2-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-3-chloro-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>13</b>)</h4><div class="NLM_p last">To a suspension of (<i>R</i>)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>9</b>) (524 mg, 1.50 mmol) in 15 mL of CHCl<sub>3</sub> at RT was added <i>N</i>-chlorosuccinimide (260 mg, 1.95 mmol) and the mixture was stirred at RT for 18 h, LCMS showed about 45% conversion. Additional <i>N</i>-chlorosuccinimide (52 mg, 0.38 mmol) was added, and the mixture was heated at 50 Â°C in an oil bath for 90 min. It was cooled to RT, treated with 15 mL of ice-cold 0.2 N NaOH, and extracted with 50 mL of DCM followed by 50 mL of EtOAc. The combined organic extracts were concentrated, and the residue was purified on a silica gel column (50% EtOAc in DCM followed by 5% MeOH in DCM) to give (<i>R</i>)-2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-3-chloro-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>13</b>) (400 mg, 1.04 mmol, 70% yield) as a yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.77 (1H, br), 7.78 (2H, m), 7.63 (1H, d, <i>J</i> = 7.2 Hz), 7.41 (1H, t, <i>J</i> = 7.7 Hz), 5.97 (1H, br), 4.46 (1H, d, <i>J</i> = 6.7 Hz), 2.55 (3H, s), 1.40 (12 H, m). <i>m</i>/<i>z</i> (ESI, +ve) 383.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14</b>)</h4><div id="sec5_2_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Step 1</h5><div class="NLM_p last">At 0 Â°C, to a solution of <i>N</i>-(<i>tert</i>-butyl)-2-formylthiophene-3-carboxamide (<b>14a</b>)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (2.37 g, 11.22 mmol) in 10 mL of MeOH and 10 mL of THF was added sodium borohydride (0.42 g, 11.22 mmol) in small portions. It was stirred at 0 Â°C for 15 min, then quenched with satd NH<sub>4</sub>Cl (20 mL), and extracted with EtOAc (2 Ã 50 mL). The combined organic solution was washed with 15 mL of brine and dried and concentrated to give <i>N</i>-(<i>tert</i>-butyl)-2-(hydroxymethyl)thiophene-3-carboxamide as a viscous colorless oil. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 7.13 (2H, q, <i>J</i> = 5.3 Hz), 6.05 (1H, br), 4.90 (1H, m), 4.78 (2H, d, <i>J</i> = 6.7 Hz), 1.47 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 214.1 (M + H)<sup>+</sup>. To the crude <i>N</i>-(<i>tert</i>-butyl)-3-(hydroxymethyl)thiophene-2-carboxamide in 50 mL of DCM at 0 Â°C was treated with diisopropylethylamine (3.90 mL, 22.43 mmol) followed by methanesulfonyl chloride (1.04 mL, 13.46 mmol) dropwise. It was stirred at 0 Â°C for 15 min then RT for 15 min. LC-MS indicated formation of predominantly the chloride (<i>m</i>/<i>z</i> (ESI, +ve) 232.1 (M + H)<sup>+</sup>). It was diluted with 100 mL of DCM, washed sequentially with 10 mL of ice-cold water, 10 mL satd NaHCO<sub>3</sub>, and 10 mL of brine. The DCM extracts were dried over sodium sulfate and concentrated, affording a viscous orange oil. At â78 Â°C, a solution of the obtained viscous orange oil in THF (40 mL) was treated with lithium bis(trimethylsilyl)amide (1 M solution in THF, 16.83 mL, 16.83 mmol). The resulting dark-brown solution was stirred at â78 Â°C for 10 min and then 0 Â°C for 10 min. It was quenched with water and extracted with EtOAc (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified on a silica gel column (20â50% EtOAc in hexanes), affording 5-(<i>tert</i>-butyl)-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14b</b>, 1.69 g, 8.65 mmol, 77% yield, in about 70% purity) as a yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 7.30 (1H, d, <i>J</i> = 4.9 Hz), 7.18 (1H, d, <i>J</i> = 4.9 Hz), 4.49 (2H, s), 1.54 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 196.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Step 2</h5><div class="NLM_p last">5-(<i>tert</i>-Butyl)-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14b</b>, 370 mg, 1.89 mmol) in DMF (5 mL) was treated with NBS (337 mg, 1.89 mmol) and allowed to stir at RT for 18 h. LC-MS indicated clean conversion to the desired product (<i>m</i>/<i>z</i> (ESI, +ve) 274.0/276.0 (M + H)<sup>+</sup>). The reaction mixture was treated with water (5 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine (3 Ã 5 mL) and dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was recrystallized from Et<sub>2</sub>O and hexanes, affording 2-bromo-5-(<i>tert</i>-butyl)-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14c</b>, 176 mg, 0.64 mmol, 34% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 7.18 (1H, s), 4.44 (2H, s), 1.53 (9H, s).</div></div><div id="sec5_2_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Step 3</h5><div class="NLM_p last">2-Bromo-5-(<i>tert</i>-butyl)-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14c</b>, 347 mg, 1.27 mmol) in dioxane (1 mL) and 20% sulfuric acid (1 mL) was heated in a microwave at 135 Â°C for 1.5 h. It was diluted with 50 mL of EtOAc and neutralized with 5 N NaOH. The organic layer was separated and washed with 5 mL of brine, dried, and concentrated. The residue was purified on a silica gel column (35â100% EtOAc in hexanes), affording 2-bromo-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14d</b>, 70.5 mg, 0.3 mmol, 25% yield) as an off-white crystalline solid. <sup>1</sup>H NMR (400 MHz, MeOH) Î´ ppm 7.29 (1H, s), 4.60 (1H, br), 4.51 (2H, m). <i>m</i>/<i>z</i> (ESI, +ve) 218.0/220.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step 4</h5><div class="NLM_p last">In a 5 mL glass microwave tube, 2-bromo-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one (<b>14d</b>, 35 mg, 0.16 mmol), dicyclohexyl(2â²,4â²,6â²-triisopropyl-[1,1â²-biphenyl]-2-yl)phosphine (4.59 mg, 9.63 Î¼mol), Pd<sub>2</sub>(dba)<sub>3</sub> (4.41 mg, 4.81 Î¼mol), potassium phosphate (102 mg, 0.48 mmol), and <i>N</i>-(<i>tert</i>-butyl)-3-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-amine (<b>AQ2</b>, 65.70 mg, 0.19 mmol) were purged with argon and treated with dioxane (2.0 mL) and water (0.6 mL) and heated in a microwave at 140 Â°C for 20 min. The reaction mixture was treated with water, extracted with EtOAc, washed with brine, and concentrated. Purification on a Gilson reverse phase HPLC (20â95% 0.1%TFA/CH<sub>3</sub>CN in 0.1%TFA/water)) afforded 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-5,6-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-4-one 2,2,2-trifluoroacetate (<b>14</b>) (20 mg, 0.04 mmol, 26% yield) as a bright-yellow amorphous powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.31 (1H, s), 7.86 (1H, dd, <i>J</i> = 7.4, 1.2 Hz), 7.71 (1H, m), 7.69 (1H, s), 7.37 (1 H, t, <i>J</i> = 7.8 Hz), 5.99 (1H, s), 4.52 (2H, s), 2.55 (3 H, m), 1.54 (9H, s). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â74.50 (s). <i>m</i>/<i>z</i> (ESI, +ve) 353.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-(3-(<i>tert</i>-Butylamino)-2-methylquinoxalin-5-yl)-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15</b>)</h4><div id="sec5_2_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Step 1</h5><div class="NLM_p last">At 0 Â°C, to a solution of <i>N</i>-(<i>tert</i>-butyl)-3-formylthiophene-2-carboxamide (<b>15a</b>)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (2.79 g, 13.21 mmol) in 10 mL of MeOH and 10 mL of THF was added sodium borohydride (0.50 g, 13.21 mmol) in small portions. After the reaction was stirred at 0 Â°C for 15 min, it was quenched with 15 mL of satd NH<sub>4</sub>Cl and extracted with 2 Ã 75 mL of EtOAc. The combined organic solution was washed with 15 mL of brine and dried, concentrated to give a sticky oil containing <i>N</i>-(<i>tert</i>-butyl)-3-(hydroxymethyl)thiophene-2-carboxamide that was used as crude. <i>m</i>/<i>z</i> (ESI, +ve) 214.1 (M + H)<sup>+</sup>. The crude <i>N</i>-(<i>tert</i>-butyl)-3-(hydroxymethyl)thiophene-2-carboxamide in 50 mL of DCM at 0 Â°C was treated with diisopropylethylamine (4.59 mL, 26.4 mmol) followed by methanesulfonyl chloride (1.23 mL, 15.85 mmol) dropwise. It was stirred at 0 Â°C for 15 min and then RT for 10 min. It was diluted with 100 mL of DCM and washed sequentially with 10 mL of ice-cold water, 10 mL satd NaHCO<sub>3</sub>, and 10 mL of brine. The DCM extracts were dried over sodium sulfate and concentrated to give a brown amorphous solid (<i>m</i>/<i>z</i> (ESI, +ve) 232 (M + H)<sup>+</sup>). The brown solid was dissolved in 15 mL of THF and cooled to â78 Â°C. Lithium bis(trimethylsilyl)amide (19.8 mL of 1 M solution in THF, 19.8 mmol) was added in dropwise, and the resulting dark-brown solution was stirred at â78 Â°C for 10 min and then 0 Â°C for 10 min. It was quenched with 15 mL of satd NH<sub>4</sub>Cl and extracted with 2 Ã 75 mL of EtOAc. The combined organic solution was concentrated. The residue was purified on a silica gel column (25â45% EtOAc in hexanes) to give 5-(<i>tert</i>-butyl)-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15b</b>, 1.55 g, 7.94 mmol, 60% yield) as a yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.89 (1 H, d, <i>J</i> = 4.7 Hz), 7.17 (1 H, d, <i>J</i> = 4.7 Hz), 4.49 (2 H, s), 1.46 (9 H, s). <i>m</i>/<i>z</i> (ESI, +ve) 196.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Step 2</h5><div class="NLM_p last">At 0 Â°C, to a suspension of 5-(<i>tert</i>-butyl)-4H-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15b</b>, 235 mg, 1.20 mmol) in 0.6 mL of HOAc and 1.2 mL of water was added a solution of bromine (0.06 mL, 1.26 mmol) in 0.6 mL of HOAc. After 30 min at 0 Â°C, LCMS indicated only 25% conversion. Additional bromine (0.04 mL) was added, and the resulting heterogeneous mixture was stirred at RT for 15 min. LCMS indicated 50% conversion. Additional bromine (0.13 mL) in 0.4 mL of HOAc was added, and the resulting heterogeneous mixture was stirred at RT for 1 h, then 45 Â°C for 15 min. LCMS indicated about 80% conversion. It was cooled to RT, diluted with 50 mL of EtOAc, and neutralized with 10 N NaOH to pH of 7. The aqueous layer was discarded; the organic layer was concentrated to give 2-bromo-5-(<i>tert</i>-butyl)-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15c</b>, <i>m</i>/<i>z</i> (ESI, +ve) 274/276 (M + H)<sup>+</sup>), which was used in the next step without purification.</div></div><div id="sec5_2_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Step 3</h5><div class="NLM_p last">Crude <b>15c</b> in 1 mL of dioxane and 1 mL of 15% sulfuric acid was heated in an oil bath at 100 Â°C for 30 min. LCMS indicated no removal of <i>tert</i>-butyl at all. It was heated in a microwave at 130 Â°C for 80 min. It was diluted with 50 mL of EtOAc and neutralized to pH of 7 with 5 N NaOH. The organic layer was separated and washed with 5 mL of brine, dried, and concentrated. The residue was purified on a silica gel column (35â85% EtOAc in hexanes) to provide 2-bromo-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15d</b>, 179 mg, 0.82 mmol, 68% yield, in about 85% pure) as an off white crystalline solid. <i>m</i>/<i>z</i> (ESI, +ve) 218/220 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Step 4</h5><div class="NLM_p last">In a 5 mL glass microwave tube, a mixture of <i>N</i>-(<i>tert</i>-butyl)-3-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-amine (<b>AQ2</b>, 139 mg, 0.41 mmol), dicyclohexyl(2â²,4â²,6â²-triisopropyl-[1,1â²-biphenyl]-2-yl)phosphine (10.62 mg, 0.02 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (10.20 mg, 0.01 mmol), 2-bromo-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15d</b>, 81 mg, 0.37 mmol), and potassium phosphate (237 mg, 1.11 mmol) was purged with argon and treated with dioxane (1.5 mL) and water (0.5 mL) and heated in a microwave at 125 Â°C for 20 min. The reaction mixture was treated with 2 mL of 1 N NaOH and extracted with EtOAc (2 Ã 5 mL). The organic extracts were concentrated. Purification of the brown residue on a silica gel column (eluted with 100% EtOAc)) afforded 2-(3-(<i>tert</i>-butylamino)-2-methylquinoxalin-5-yl)-4<i>H</i>-thieno[2,3-<i>c</i>]pyrrol-6(5<i>H</i>)-one (<b>15</b>) (69 mg, 0.2 mmol, 53% yield) as a yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.37 (1H, s), 7.92 (1H, dd, <i>J</i> = 7.5, 1.3 Hz), 7.74 (1H, m), 7.70 (1H, s), 7.40 (1H, t, <i>J</i> = 7.8 Hz), 6.04 (1H, s), 4.37 (2H, s), 2.58 (3H, s), 1.56 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 353.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>R</i>)-2-(<i>tert</i>-Butylamino)-3-methyl-9-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>16</b>)</h4><div id="sec5_2_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Step 1</h5><div class="NLM_p last">2-Amino-3-bromopyridine (3.30 g, 19.07 mmol) and diethyl methylmalonate (7.95 mL, 46.7 mmol) in a 100 mL round-bottomed flask was fitted with a water-cooled reflux condenser open to air and placed in a 170 Â°C oil bath. After 2 h, LCMS detected <i>m</i>/<i>z</i> (ESI, +ve ion) 301/303 (M + H)<sup>+</sup>. The reaction was heated to reflux at 220 Â°C in a heating block for 18 h. The reaction was cooled to RT and purified by silica gel chromatography (eluted with 0â100% EtOAc/DCM) to afford 9-bromo-2-hydroxy-3-methyl-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>16a</b>, 0.61 g, 2.38 mmol, 13% yield) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.76 (1H, s), 8.88 (1H, dd, <i>J</i> = 7.0, 1.4 Hz), 8.27 (1H, dd, <i>J</i> = 7.2, 1.4 Hz), 7.09 (1H, t, <i>J</i> = 7.2 Hz), 1.98 (3H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 254.9/257.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Step 2</h5><div class="NLM_p last">9-Bromo-2-hydroxy-3-methyl-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>16a</b>, 0.42 g, 1.65 mmol) was treated with 3 mL of DMF and 1,8-diazabicyclo-[5.4.0]undec-7-ene (0.49 mL, 3.29 mmol) and <i>tert</i>-butylamine (0.86 mL, 8.23 mmol) was added, followed by (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (1.09 g, 2.47 mmol). The reaction was sealed and placed in a 70 Â°C oil bath for 16 h. The reaction was partitioned between satd NaHCO<sub>3</sub> and EtOAc. The organic layer was washed with satd NaHCO<sub>3</sub> twice and brine once, and the organics were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The material was purified by silica gel chromatography (40 g column, using 0â50% EtOAc/hexanes). The product-containing fractions were concentrated to afford a yellow foam (0.11 g, 0.35 mmol, 21% yield), as a mixture of two compounds: 75% of 9-bromo-2-(<i>tert</i>-butylamino)-3-methyl-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one [<b>16b</b>, <i>m</i>/<i>z</i> (ESI, +ve ion) 310/312 (M + H)<sup>+</sup>], and 25% of 9-bromo-2-(dimethylamino)-3-methyl-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one [<i>m</i>/<i>z</i> (ESI, +ve ion) 282/284 (M + H)<sup>+</sup>]. The mixture was used without further purification in step 3.</div></div><div id="sec5_2_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Step 3</h5><div class="NLM_p last">Argon was bubbled into a mixture of potassium phosphate tribasic (0.30 g, 1.41 mmol), XPhos Pd G2 (14 mg, 18 Î¼mol), (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 0.19 g, 0.71 mmol), and 9-bromo-2-(<i>tert</i>-butylamino)-3-methyl-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>16b</b>, 0.11 g, 0.35 mmol) in 3 mL of dioxane and 0.5 mL of water for 1 min. The reaction was placed in a 60 Â°C oil bath for 30 min. The reaction was cooled, and 1.5 g of silica gel was added. It was concentrated in vacuo. The residue was purified by silica gel chromatography (eluted with 0â100% of 90/10 DCM/MeOH in DCM). The product-containing fractions were concentrated, and the residue was washed with (2 Ã 3 mL) of MeOH. The solid was collected and dried in vacuo to give (<i>R</i>)-2-(<i>tert</i>-butylamino)-3-methyl-9-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>16</b>) (52 mg, 0.14 mmol, 40% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.77 (1H, s), 8.83 (1H, dd, <i>J</i> = 7.0, 1.6 Hz), 7.93 (1H, dd, <i>J</i> = 7.0, 1.6 Hz), 7.66 (1H, s), 7.12 (1H, t, <i>J</i> = 7.1 Hz), 6.76 (1H, s), 5.43 (1H, s), 4.52 (1H, q, <i>J</i> = 6.6 Hz), 2.00 (3H, s), 1.44 (9H, s), 1.36 (3H, d, <i>J</i> = 6.7 Hz). <i>m</i>/<i>z</i> (ESI, +ve ion) 366.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>R</i>)-2-(<i>tert</i>-Butylamino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>17</b>)</h4><div id="sec5_2_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Step 1</h5><div class="NLM_p last">A solution of 2-amino-3-bromobenzoic acid (<b>17a</b>, 3.00 g, 13.9 mmol) and methylamine (2.0 M solution in THF, 27.8 mL, 55.5 mmol) in EtOAc (18 mL) at RT was treated with propylphosphonic anhydride (T3P) (50% wt in EtOAc, 13.2 mL, 20.8 mmol) and stirred at RT for 18 h. It was then quenched with satd NaHCO<sub>3</sub> (20 mL) and extracted with 2 Ã 30 mL of EtOAc. The organic layers were combined and washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 2-amino-3-bromo-<i>N</i>-methylbenzamide (<b>17b</b>, 2.9 g, 12.8, 92% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.36 (br s, 1H), 7.50 (t, <i>J</i> = 8.5 Hz, 2H), 6.52 (t, <i>J</i> = 7.8 Hz, 1H), 6.47 (br s, 2H), 2.74 (d, <i>J</i> = 1.8 Hz, 3H). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 229/231 (M + 1).</div></div><div id="sec5_2_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Step 2</h5><div class="NLM_p last">A solution of 2-amino-3-bromo-<i>N</i>-methylbenzamide (<b>17b</b>, 1.09 g, 4.76 mmol), DIPEA (0.83 mL, 4.76 mmol), and triphosgene (0.49 g, 1.66 mmol) in DCM (48 mL) was stirred at reflux for 18 h when LCMS showed that starting material was still present. More triphosgene (0.21 g, 0.71 mmol) was added, and the reaction mixture was refluxed for 1 h. It was concentrated under reduced pressure, and the residue was purified via silica gel flash chromatography (0â100% EtOAc in hexanes) to give 8-bromo-3-methylquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>17c</b>, 1.19 g, 4.67 mmol, 98% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 3.46 (s, 3H), 7.13 (t, <i>J</i> = 7.92 Hz, 1H), 7.81 (dd, <i>J</i> = 7.92, 1.27 Hz, 1H), 8.12 (dd, <i>J</i> = 8.02, 0.59 Hz, 1H), 8.20 (br, 1H). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 254.9/257 (M + 1).</div></div><div id="sec5_2_13_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Step 3</h5><div class="NLM_p last">A slurry of 8-bromo-3-methylquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>17c</b>, 1.14 g, 4.47 mmol), phosphoryl trichloride (4.09 mL, 44.70 mmol), and DIPEA (3.11 mL, 17.88 mmol) was stirred at 100 Â°C for in an oil bath for 19 h. The reaction mixture was concentrated, diluted with ice, and basified with 10 N NaOH to â¼pH 10. The mixture was filtered and washed with water to give a brown solid. The solid was transferred to an Erlenmeyer flask and dissolved in DCM when a small aqueous layer formed; this was partitioned in a separatory funnel. The organic layer was partially concentrated, loaded onto a silica gel column, and eluted with 0â40% EtOAc in hexanes to give 8-bromo-2-chloro-3-methylquinazolin-4(3<i>H</i>)-one (<b>17d</b>, 1.03 g, 3.77 mmol, 84% yield) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 3.77 (s, 3H), 7.35 (t, <i>J</i> = 7.92 Hz, 1H), 8.02 (dd, <i>J</i> = 7.82, 1.37 Hz, 1H), 8.21 (dd, <i>J</i> = 8.02, 1.37 Hz, 1H). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 273.9/275.9 (M + 1).</div></div><div id="sec5_2_13_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step 4</h5><div class="NLM_p last">A mixture of 8-bromo-2-chloro-3-methylquinazolin-4(3<i>H</i>)-one (<b>17d</b>, 0.66 g, 2.41 mmol) and <i>tert</i>-butylamine (3.80 mL, 36.20 mmol) in a sealed tube was heated at 80 Â°C in an oil bath overnight. The mixture was allowed to cool to RT, and water was added. The mixture was extracted with EtOAc (3Ã). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give 8-bromo-2-(<i>tert</i>-butylamino)-3-methylquinazolin-4(3<i>H</i>)-one (<b>17e</b>, 0.71 g, 2.30 mmol, 96% yield) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.90 (m, 2H), 7.03 (t, <i>J</i> = 7.73 Hz, 1H), 6.07 (s, 1H), 3.43 (s, 3H), 1.57 (s, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) 310.0/312.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_13_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step 5</h5><div class="NLM_p last">A mixture of (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 263 mg, 0.90 mmol), 8-bromo-2-(<i>tert</i>-butylamino)-3-methylquinazolin-4(3<i>H</i>)-one (<b>17e</b>, 200 mg, 0.64 mmol), potassium phosphate tribasic (411 mg, 1.93 mmol), and XPhos Pd G2 (12 mg, 0.016 mmol) in 3 mL of 1,4-dioxane/water (3/1) was heated in an oil bath at 45 Â°C for 30 min. The reaction mixture was allowed to cool to RT, treated with 3 mL of water, and stirred for 30 min. The resulting precipitate was collected by filtration, washed with water (2 Ã 3 mL) ,and dried to give a light-brown solid. The light-brown solid was stirred in 3 mL of MeOH for 5 min at RT. The resulting solid was collected by filtration, washed with MeOH (3 mL), and dried to give (<i>R</i>)-2-(<i>tert</i>-butylamino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>17</b>) (211 mg, 0.58 mmol, 90% yield) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.94 (s, 1H), 7.85â7.94 (m, 2H), 7.61 (s, 1H), 7.18 (t, <i>J</i> = 7.7 Hz, 1H), 6.73 (d, <i>J</i> = 1.0 Hz, 1H), 5.95 (s, 1H), 4.53 (q, <i>J</i> = 6.5 Hz, 1H), 3.48 (s, 3H), 1.51 (s, 9H), 1.37 (d, <i>J</i> = 6.7 Hz, 3H). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 366 (M + 1).</div></div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>R</i>)-2-(<i>tert</i>-Butylamino)-7-fluoro-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>18</b>)</h4><div class="NLM_p">8-Bromo-2-chloro-7-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (<b>18d</b>) was prepared according to the procedures described for intermediate <b>17d</b>, starting from <b>18a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.22 (1H, m), 7.27 (1H, m), 3.77 (3H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 290.9/292.9 (M + H)<sup>+</sup>.</div><div class="NLM_p">A slurry of 8-bromo-2-chloro-7-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (<b>18d</b>, 0.45 g, 1.54 mmol) in <i>tert</i>-butylamine (2.43 mL, 23.16 mmol) was sealed and placed in an 80 Â°C oil bath. The reaction became a solid mass after 15â30 min. After 1 h, the mass was analyzed by LC/MS and judged complete. The reaction was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (eluted with 0â50% EtOAc/hexanes) to afford 8-bromo-2-(<i>tert</i>-butylamino)-7-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (<b>18e</b>, 0.47 g, 1.44 mmol, 94% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.06 (1H, m), 6.90 (1H, m), 4.55 (1H, br), 3.46 (3H, s), 1.63 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 328/330 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Argon was bubbled into a mixture of tris(dibenzylideneacetone)dipalladium (0) (14 mg, 15 Î¼mol), 2-(dicyclohexylphosphino)-2â²,4â²,6â²,-tri-isopropyl-1,1â²-biphenyl (15 mg, 30 Î¼mol), (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 0.16 g, 0.61 mmol), 8-bromo-2-(<i>tert</i>-butylamino)-7-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (<b>18e</b>, 0.10 g, 0.30 mmol), and potassium phosphate (0.19 g, 0.91 mmol) in 2 mL of dioxane and 0.4 mL water for 1 min. The reaction was sealed and heated to 80 Â°C for 2 h. The reaction was cooled and transferred to a round-bottomed flask with some MeOH and adsorbed onto 1.5 g of silica gel and dried in vacuo. The material was purified by silica gel chromatography (eluted with 0â100% of 90/10 DCM/MeOH in DCM) to afford (<i>R</i>)-2-(<i>tert</i>-butylamino)-7-fluoro-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>18</b>) (0.06 g, 0.15 mmol, 51% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.76 (1H, s), 7.96 (1H, dd, <i>J</i> = 8.8, 6.3 Hz), 7.58 (1H, s), 7.07 (1H, dd, <i>J</i> = 10.0, 8.8 Hz), 6.35 (1H, t, <i>J</i> = 1.8 Hz), 6.01 (1H, s), 4.50 (1H, q, <i>J</i> = 6.7 Hz), 3.45 (3H, s), 1.38 (9H, s), 1.35 (3H, d, <i>J</i> = 6.7 Hz). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â105.07 (s). <i>m</i>/<i>z</i> (ESI, +ve ion) 384.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (<i>R</i>)-2-(<i>tert</i>-Butylamino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)pyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (<b>19</b>)</h4><div id="sec5_2_15_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step 1</h5><div class="NLM_p last">A solution of 3-amino-2-chloroisonicotinic acid (600 mg, 3.48 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.60 mL, 3.48 mmol) in 1,4-dioxane (5 mL) in a glass tube was treated with triphosgene (0.51 mL, 3.48 mmol). The tube was sealed and heated in a microwave reactor (Personal Chemistry) at 80 Â°C for 20 min. It was cooled with an ice bath and treated with methylamine (33% wt solution in absolute ethanol, 4.67 mL, 34.8 mmol) dropwise (exothermic) and stirred for 20 min. Additional triphosgene (0.25 mL) was added, and the reaction was heated at 50 Â°C in an oil bath for 15 h. The mixture was cooled to RT and quenched with water. The suspension was filtered, and the solid was dried to give 8-chloro-3-methylpyrido[3,4-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19a</b>, 324 mg, 1.53 mmol, 44% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.32 (1 H, s), 8.21 (1H, d, <i>J</i> = 5.1 Hz), 7.84 (1H, d, <i>J</i> = 5.1 Hz), 3.27 (3 H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 212.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_15_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step 2</h5><div class="NLM_p last">To a 50 mL round-bottomed flask was added 8-chloro-3-methylpyrido[3,4-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19a</b>, 320 mg, 1.51 mmol) and (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (803 mg, 1.81 mmol) in DMF (5 mL) followed by <i>t</i>-butylamine (2.38 mL, 22.68 mmol). The suspension turned clear and was heated at 40 Â°C for 8 h. It was quenched with water (30 mL), and the suspension was filtered and the solid was dried to give 2-(<i>tert</i>-butylamino)-8-chloro-3-methylpyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (<b>19b</b>, 255 mg, 0.95 mmol, 63% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.09 (1H, d, <i>J</i> = 5.1 Hz), 7.82 (1H, d, <i>J</i> = 5.1 Hz), 4.62 (1H, br s), 3.49 (3H, s), 1.62 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 267.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_15_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step 3</h5><div class="NLM_p last">To a 50 mL round-bottomed flask was added 2-(<i>tert</i>-butylamino)-8-chloro-3-methylpyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (<b>19b</b>, 250 mg, 0.93 mmol) and (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 295 mg, 1.12 mmol) in 1,4-dioxane (4 mL) and water (1 mL) followed by potassium phosphate (0.233 mL, 2.81 mmol) and XPhos Pd G2 (36.9 mg, 0.047 mmol). The reaction mixture was stirred at 40 Â°C for 3 h and then diluted with water (30 mL). The mixture was extracted with CHCl<sub>3</sub>/iPrOH (4:1, 3 Ã 30 mL), and the combined organic layers were dried, filtered, and concentrated. The residue was triturated with DCM, and the suspension was filtered. The filtrate was concentrated and purified with RP-HPLC (10â70% MeCN in water with 0.1% TFA in 30 min) to give (<i>R</i>)-2-(<i>tert</i>-butylamino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)pyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (<b>19</b>) (72 mg, 0.20 mmol, 21% yield) as an orange solid as a TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 12.01 (1H, s), 8.27 (1H, d, <i>J</i> = 5.1 Hz), 7.51â7.72 (3H, m), 6.10 (1H, s), 4.49 (1H, q, <i>J</i> = 6.6 Hz), 3.50 (3H, s), 1.61 (9H, s), 1.39 (3H, d, <i>J</i> = 6.7 Hz). <i>m</i>/<i>z</i> (ESI, +ve ion) 367.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>R</i>)-3-Methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)-2-neopentylquinazolin-4(3<i>H</i>)-one (<b>20</b>)</h4><div id="sec5_2_16_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Step 1</h5><div class="NLM_p last">To a solution of 2-amino-3-bromobenzoic acid (2.00 g, 9.26 mmol) and methylamine (2.0 M solution in THF, 18.52 mL, 37.04 mmol) in 10 mL of EtOAc at 0 Â°C was added T3P (6.48 mL, 10.18 mmol). The reaction was sealed and stirred at RT for 18 h. The reaction was partitioned between satd NaHCO<sub>3</sub> and EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 2-amino-3-bromo-<i>N</i>-methylbenzamide (<b>20a</b>, 1.32 g, 5.76 mmol, 62% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.36 (1H, d, <i>J</i> = 3.5 Hz), 7.41â7.57 (2H, m), 6.40â6.57 (3H, m), 2.74 (3H, d, <i>J</i> = 4.5 Hz). <i>m</i>/<i>z</i> (ESI, +ve ion) 228.9/230.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_16_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Step 2</h5><div class="NLM_p last">To a solution of 2-amino-3-bromo-<i>N</i>-methylbenzamide (<b>20a</b>, 0.20 g, 0.87 mmol) in 2 mL of dioxane at RT was added <i>t</i>-butylacetyl chloride (0.13 mL, 0.96 mmol). The reaction became cloudy over 5 min. After 1 h, additional <i>t</i>-butylacetyl chloride (0.13 mL) was added. After 1 h, the reaction was sealed and placed in a 100 Â°C oil bath. After 30 min, the reaction was homogeneous. The reaction was heated an additional 1.5 h, cooled, and allowed to stir overnight. The reaction was partitioned between satd aqueous sodium bicarbonate and EtOAc. The organic layer was washed with satd aqueous sodium bicarbonate once, brine once, and the organics were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 8-bromo-3-methyl-2-neopentylquinazolin-4(3<i>H</i>)-one (<b>20b</b>, 0.28 g, 0.90 mmol, 100% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.23 (1H, dd, <i>J</i> = 7.9, 1.5 Hz) 8.00 (1H, dd, <i>J</i> = 7.6, 1.4 Hz) 7.27â7.31 (1H, m) 3.65 (3H, s) 2.81 (2H, s) 1.19 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 309.0/311.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_16_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> Step 3</h5><div class="NLM_p last">Argon was bubbled into a mixture of X-Phos Pd G2 (0.014 g, 0.018 mmol), potassium phosphate (0.23 g, 1.07 mmol), (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 0.14 g, 0.53 mmol), and 8-bromo-3-methyl-2-neopentylquinazolin-4(3<i>H</i>)-one (<b>20b</b>, 0.11 g, 0.36 mmol) in 2 mL of dioxane and 0.4 mL of water for 1 min. The reaction was placed in a 45 Â°C oil bath. After 1 h, the reaction was cooled and adsorbed onto 1 g of silica gel. The material was purified by silica gel chromatography (24 g column using 0â10% MeOH in DCM) to afford (<i>R</i>)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)-2-neopentylquinazolin-4(3<i>H</i>)-one (<b>20</b>) (0.08 g, 0.22 mmol, 62% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 12.21 (1H, s), 8.19 (1H, dd, <i>J</i> = 7.6, 1.4 Hz), 7.97 (1H, dd, <i>J</i> = 7.9, 1.3 Hz), 7.65 (1H, s), 7.48 (1H, t, <i>J</i> = 7.8 Hz), 6.97 (1H, d, <i>J</i> = 1.4 Hz), 4.56 (1H, q, <i>J</i> = 6.7 Hz), 3.63 (3H, s), 3.04 (2H, s), 1.38 (3H, d, <i>J</i> = 6.7 Hz), 1.09 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 365.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (<i>R</i>)-2-(3-(<i>tert</i>-Butylamino)-2-methyl-1,1-dioxido-2<i>H</i>-benzo[<i>e</i>][1,2,4]thiadiazin-5-yl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>21</b>)</h4><div id="sec5_2_17_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Step 1</h5><div class="NLM_p last">3-Bromo-2-nitro aniline (Combi-Blocks, 4.32 g, 19.91 mmol) was stirred in concentrated HCl (20 mL, 237 mmol) at 0 Â°C and treated with sodium nitrite (1.44 g, 20.87 mmol) in water (3 mL) dropwise and allowed to stir at ca. 5â10 Â°C for 30 min. The suspension was filtered, and the diazonium solution was simultaneously added with sodium sulfite (2.51 g, 19.91 mmol) in water (10 mL) to a solution of concentrated HCl (45 mL), anhydrous copper(II) sulfate (0.32 g, 1.99 mmol), sodium sulfite (2.51 g, 19.91 mmol), and water (10 mL). The addition was done in ca. 10â15 min. The reaction mixture was stirred for another 30 min at 0 Â°C and then filtered through a sintered glass frit washing with cold water. The resulting light-yellow solid was collected and dried under high vacuum overnight to give 3-bromo-2-nitrobenzene-1-sulfonyl chloride (<b>21a</b>), which was used as crude.</div></div><div id="sec5_2_17_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> Step 2</h5><div class="NLM_p last">The crude <b>21a</b> in 5 mL of THF was treated with methanamine (2.0 M in THF) (12.98 mL, 25.96 mmol) at 0 Â°C and stirred at RT for 48 h. LC-MS indicated a small amount of the desired product [<i>m</i>/<i>z</i> (ESI, +ve) 316.8/318.8 (M + H)<sup>+</sup>] was formed. The reaction mixture was treated with Hunigâs base (1.28 mL, 7.32 mmol) and heated to 50 Â°C for 18 h. The reaction mixture was concentrated, and the crude residue was purified on the ISCO Combiflash RF (40 g Thomson SingleStep column, using a gradient of 20â100% EtOAc in hexanes), affording 3-bromo-<i>N</i>-methyl-2-nitrobenzenesulfonamide (<b>21b</b>, 556 mg, 1.88 mmol, 26% yield) as a light-yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.00 (1H, dd, <i>J</i> = 8.0, 1.2 Hz), 7.92 (1H, dd, <i>J</i> = 8.1, 1.1 Hz), 7.53 (1H, t, <i>J</i> = 8.0 Hz), 4.63â4.79 (1H, m), 2.75 (3H, d, <i>J</i> = 5.1 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 316.8/318.8 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_17_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> Step 3</h5><div class="NLM_p last">3-Bromo-<i>N</i>-methyl-2-nitrobenzenesulfonamide (<b>21b</b>, 556 mg, 1.88 mmol) was treated with platinum (10% wt on activated carbon, 184 mg, 0.09 mmol) and MeOH (20 mL) and fitted with a balloon filled with hydrogen. The flask was purged (5Ã) with vacuum/hydrogen backfill cycles and allowed to stir overnight at RT. The reaction mixture was filtered through a 0.45 Î¼m acrodisc to remove the Pt/C washing with MeOH and concentrated to dryness under high vacuum, affording 2-amino-3-bromo-<i>N</i>-methylbenzenesulfonamide (<b>21c</b>, 477 mg, 1.80 mmol, 95% yield) as a yellow crystalline solid. This material was used as crude. <i>m</i>/<i>z</i> (ESI, +ve) 266.1/268.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_17_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Step 4</h5><div class="NLM_p last">To a suspension of crude 2-amino-3-bromo-<i>N</i>-methylbenzenesulfonamide (<b>21c</b>, 477 mg, 1.799 mmol) in MeCN (6.60 mL) at 0 Â°C was added <i>tert</i>-butyl nitrite (90% pure grade, 0.35 mL, 2.70 mmol) followed by azidotrimethylsilane (0.28 mL, 2.16 mmol) dropwise. Gas evolution was observed. The solution was allowed to warm up to RT and stirred for 1 h. The reaction mixture was treated with <i>tert</i>-butyl nitrite (0.35 mL) and azidotrimethylsilane (0.28 mL) again and allowed to stir for 3 h. The reaction mixture was concentrated. The orange residue was purified by chromatography on an ISCO Combiflash RF (25 g Thomson SingleStep column, using a gradient of 20â80% EtOAc in hexanes), affording 2-azido-3-bromo-<i>N</i>-methylbenzenesulfonamide (<b>21d</b>, 106 mg, 0.37 mmol, 20% yield) as a light-yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 7.97 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.80 (1H, m), 7.25 (1H, m), 5.02 (1 H, d, <i>J</i> = 4.9 Hz), 2.64 (3 H, m). <i>m</i>/<i>z</i> (ESI, +ve) 291.1/293.1 (M + H)<sup>+</sup>. <i>Note</i>: A byproduct was isolated whose mass was consistent with 5-bromo-2-methyl-2<i>H</i>-benzo[<i>e</i>][1,2,3,4]thiatriazine-1,1-dioxide (70 mg, 0.25 mmol, 14% yield) as a light-yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.08â8.15 (1H, m), 7.94â8.01 (1H, m), 7.62 (1H, t, <i>J</i> = 7.9 Hz), 3.93 (3H, s). <i>m</i>/<i>z</i> (ESI, +ve) 275.9/277.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_17_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Step 5</h5><div class="NLM_p last">2-Azido-3-bromo-<i>N</i>-methylbenzenesulfonamide (<b>21d</b>, 106 mg, 0.364 mmol) in DCM (4.0 mL) was treated with triphenylphosphine (115 mg, 0.437 mmol), resulting in a bright-yellow solution, and the mixture was allowed to stir at RT for 3 h. The DCM was removed under reduced pressure, and the crude reaction mixture was treated with THF (4 mL) and 2-isocyanato-2-methylpropane (0.051 mL, 0.437 mmol) and heated to 80 Â°C in a heating block for 2 h. The reaction mixture was treated with DBU (0.066 mL, 0.437 mmol) and stirred overnight at 80 Â°C. It was heated to 120 Â°C for 4 h. LC-MS indicated ca. 35% conversion to the desired product [<i>m</i>/<i>z</i> (ESI, +ve) 345.9/347.9 (M + H)<sup>+</sup>]. The reaction mixture was concentrated, and the crude residue was purified on a reverse phase HPLC (Gemini Phenomenex; 30 mm Ã 150 mm, 5 Î¼, 30â95% 0.1%TFA/CH<sub>3</sub>CN in 0.1% TFA/water) to give 5-bromo-3-(<i>tert</i>-butylamino)-2-methyl-2<i>H</i>-benzo[<i>e</i>][1,2,4]thiadiazine-1,1-dioxide (<b>21e</b>, 56 mg, 0.16 mmol, 45% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.92 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.70 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.11 (1H, t, <i>J</i> = 7.8 Hz), 7.07 (1H, s), 3.31 (3H, s), 1.52 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 345.8/347.8 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_17_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Step 6</h5><div class="NLM_p last">A 100 mL round-bottomed flask was charged with (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 70 mg, 0.26 mmol), XPhos Pd G2 (6.25 mg, 7.94 Î¼mol), potassium phosphate (101 mg, 0.47 mmol), and 5-bromo-3-(<i>tert</i>-butylamino)-2-methyl-2<i>H</i>-benzo[<i>e</i>][1,2,4]thiadiazine-1,1-dioxide (<b>21e</b>, 55 mg, 0.16 mmol) in 1,4-dioxane (4 mL)/water (0.67 mL) followed by purging the flask with argon. The mixture was stirred at 40 Â°C for 1.5 h. The mixture was diluted with EtOAc (50 mL) and water (10 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (3 Ã 50 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and filtered. The crude residue was purified on a silica gel column (0â10% MeOH in DCM), affording a viscous light-yellow oil. It was suspended in ether and filtered to give (<i>R</i>)-2-(3-(<i>tert</i>-butylamino)-2-methyl-1,1-dioxido-2<i>H</i>-benzo[<i>e</i>][1,2,4]thiadiazin-5-yl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>21</b>) (45 mg, 0.11 mmol, 71% yield) as a white amorphous powder after drying in the vacuum oven overnight. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.67 (1H, s), 7.77 (1H, dd, <i>J</i> = 7.6, 1.6 Hz), 7.63 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.59 (1H, s), 7.25 (1H, t, <i>J</i> = 7.8 Hz), 6.97 (1H, s), 6.51 (1H, d, <i>J</i> = 1.6 Hz), 4.48 (1H, q, <i>J</i> = 6.7 Hz), 3.24 (3H, s), 1.37 (3H, br), 1.35 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve) 402.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (<i>R</i>)-3-Methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3<i>H</i>)-one (<b>22</b>)</h4><div id="sec5_2_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> Step 1</h5><div class="NLM_p last">A sealable flask was charged with 2-amino-3-iodobenzoic acid (<b>22a</b>, Bosche Scientific, catalogue no. A12065; 10.0 g, 38.0 mmol) and methyl isothiocyanate (5.6 g, 76 mmol) in EtOH (120 mL) followed by triethylamine (7.9 mL, 57.0 mmol). The flask was sealed and heated in an oil bath at 100 Â°C for 4 h behind a blast shield. The mixture was cooled to RT, and the solvents were removed in vacuo. The residue was triturated with ether (40 mL), filtered, and dried to give 8-iodo-3-methyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one (11.2 g, 35.3 mmol, 93% yield) as an off-white solid. The material was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 9.97 (1H, br), 8.23 (1H, d, <i>J</i> = 8.4 Hz), 8.00 (1H, d, <i>J</i> = 8.0 Hz), 7.15 (1H, t, <i>J</i> = 7.5 Hz), 3.65 (3H, s). <i>m</i>/<i>z</i> (ES, +ve) 318.8 (M + H)<sup>+</sup>. To a mixture of 8-iodo-3-methyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one (11.2 g, 35.3 mmol) and potassium carbonate (9.7 g, 70.6 mmol) in THF (100 mL) was added iodomethane (6.6 mL, 106.0 mmol). The reaction mixture was heated to reflux for 6 h and then cooled to RT. The mixture was poured into ice/water (300 mL) and stirred for 10 min. The suspension was filtered, and the solid was washed with cold water (20 mL) followed by cold ether (20 mL). The solid was dried to give 8-iodo-3-methyl-2-(methylthio)quinazolin-4(3<i>H</i>)-one (<b>22b</b>, 11.4 g, 97% yield) as an off-white solid. The crude material was used in the next step. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.31 (1H, dd, <i>J</i> = 7.6, 1.4 Hz), 8.08 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.19 (1H, t, <i>J</i> = 7.7 Hz), 3.51 (3H, s), 2.73 (3H, s). <i>m</i>/<i>z</i> (ES, +ve) 332.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Step 2</h5><div class="NLM_p last">To a stirred suspension of 8-iodo-3-methyl-2-(methylthio)quinazolin-4(3<i>H</i>)-one (<b>22b</b>, 15.00 g, 45.20 mmol) in 400 mL of dichloromethane at 0 Â°C was added 3-chlorobenzoperoxoic acid (15.59 g of 77% max, Aldrich, 70 mmol) portionwise over 10 min. The ice bath was removed, and the reaction mixture was allowed to stir at RT for 30 min. It was diluted with 200 mL of DCM, washed sequentially with ice-cold 2 Ã 50 mL of satd Na<sub>2</sub>CO<sub>3</sub>, 2 Ã 50 mL of satd Na<sub>2</sub>SO<sub>3</sub> solution, and 15 mL of brine. The organic solution was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a yellow crystalline solid containing a mixture of 8-iodo-3-methyl-2-(methylsulfinyl)quinazolin-4(3<i>H</i>)-one and 8-iodo-3-methyl-2-(methylsulfonyl)quinazolin-4(3<i>H</i>)-one. The crude material in 40 mL of THF and 40 mL of water at RT was treated with LiOHâH<sub>2</sub>O (6.60 g, 275.00 mmol). The reaction mixture was stirred in an oil bath at 75 Â°C for 2.5 h. It was concentrated to half of its volume under reduced pressure. The precipitated solid was filtered and rinsed with 2 Ã 5 mL of water followed by 2 Ã 5 mL of ether. The off-white crystalline solid was dried in a vacuum oven at 45 Â°C for 48 h to give 2-hydroxy-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>22c</b>, 12.79 g, 42.30 mmol, 94% yield). The crude material was used in the next step. <i>m</i>/<i>z</i> (ES, +ve) 302.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_18_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> Step 3</h5><div class="NLM_p last">At RT, 2-hydroxy-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>22c</b>, 12.8 g, 42.3 mmol) was mixed with phosphorus oxychloride (46.5 mL, 508.0 mmol). The resulting white suspension was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (14.7 mL, 85.0 mmol) dropwise. The heterogeneous mixture was heated in an oil bath at 105 Â°C for 26 h. LCMS indicated the reaction was about 60% conversion. It was cooled to RT and treated with additional phosphorus oxychloride (12 mL) and <i>N</i>,<i>N</i>-diisopropylethylamine (15 mL). The resulting dark homogeneous solution was heated at 110 Â°C in an oil bath for 24 h. LCMS indicated the reaction was about >95% conversion. It was concentrated under reduced pressure. The brown sticky solution was treated with 50 mL of toluene and concentrated under reduced pressure again. The brown residue was cooled with an ice bath, and ice was added to the flask, followed by 5 N NaOH solution until pH > 9. It was extracted with 3 Ã 250 mL of EtOAc. The combined organic solution was washed with 2 Ã 25 mL of brine, dried over sodium sulfate, filtered, and concentrated. The brown residue was purified via silica gel chromatography (25â50% EtOAc in hexanes) to afford 2-chloro-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>22d</b>, 10.5 g, 32.8 mmol, 77% yield) as an off-white crystalline solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.27 (m, 2 H), 7.22 (t, <i>J</i> = 7.82 Hz, 1 H), 3.77 (s, 3 H). <i>m</i>/<i>z</i> (ES, +ve) 328.8 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_18_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Step 4</h5><div class="NLM_p last">A heterogeneous mixture of 1-methylcyclopropanamine hydrochloride (0.47 g, 4.38 mmol), 2-chloro-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>22d</b>, 0.80 g, 2.50 mmol), and triethylamine (2.10 mL, 15.10 mmol) in 2 mL of THF in a sealed glass tube was heated in an oil bath at 80 Â°C for 5 h. It was diluted with EtOAc and washed water followed by brine. The organic extract was concentrated, and the residue was purified on a silica gel column (25â55% EtOAc in hexanes) to afford 8-iodo-3-methyl-2-((1-methylcyclopropyl)amino)quinazolin-4(3<i>H</i>)-one (<b>22e</b>, 0.71 g, 2.00 mmol, 80% yield) as a yellow crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.14 (1H, dd, <i>J</i> = 7.5, 1.3 Hz), 7.93 (1H, dd, <i>J</i> = 7.9, 1.3 Hz), 7.49 (1H, s), 6.89 (1H, t, <i>J</i> = 7.7 Hz), 3.32 (3H, m), 1.58 (3H, s), 0.84 (2H, m), 0.74 (2H, m). <i>m</i>/<i>z</i> (ES, +ve) 355.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_18_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Step 5</h5><div class="NLM_p last">A mixture of 2-(dicyclohexylphosphino)-2â²,4â²,6â²-tri-isopropyl1,1â²-biphenyl (17 mg, 0.036 mmol), tris(dibenzylideneacetone)dipalladium (0) (16 mg, 0.018 mmol), potassium phosphate tribasic monohydrate (311 mg, 1.35 mmol), (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 130 mg, 0.49 mmol), and 8-iodo-3-methyl-2-((1-methylcyclopropyl)amino)quinazolin-4(3<i>H</i>)-one (<b>22e</b>, 160 mg, 0.45 mmol) in dioxane (2.5 mL) and water (0.6 mL) in a sealed glass tube was heated in an Initiator microwave reactor (Personal Chemistry, Biotage AB, Inc., Upssala, Sweden) at 105 Â°C for 35 min. It was partitioned between 25 mL of EtOAc and 2 mL of 0.5 N of NaOH. The organic layer was separated and concentrated under reduced pressure. The crude material was purified by silica gel (eluted with a gradient of 1â5% MeOH in DCM) to afford (<i>R</i>)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3<i>H</i>)-one (<b>22</b>) (85 mg, 0.23 mmol, 52% yield) as a brown crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 13.02 (1H, br), 8.13 (1H, dd, <i>J</i> = 7.6, 1.4 Hz), 7.83 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.69 (2H, d, <i>J</i> = 3.1 Hz), 7.18 (1H, t, <i>J</i> = 7.7 Hz), 6.96 (1H, s), 4.64 (1H, q, <i>J</i> = 6.6 Hz), 3.40 (3H, s), 1.56 (3H, s), 1.37 (3H, d, <i>J</i> = 6.7 Hz), 1.01 (2H, m), 0.86 (2H, m). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 364.0 (M + 1).</div></div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (<i>R</i>)-2-((1-Hydroxy-2-methylpropan-2-yl)amino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>23</b>)</h4><div id="sec5_2_19_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> Step 1</h5><div class="NLM_p last">A glass microwave reaction vessel was charged with 2-chloro-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>22d</b>, 160 mg, 0.50 mmol) and 2-amino-2-methyl-1-propanol (0.24 mL, 2.50 mmol) in DMSO (1.0 mL). The reaction mixture was stirred and heated at 80 Â°C for 22 h. It was cooled to RT, treated with water (10 mL), and extracted with EtOAc (3 Ã 10 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by silica gel chromatography (50â100% EtOAc in hexanes) to provide 2-((1-hydroxy-2-methylpropan-2-yl)amino)-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>23e</b>, 110 mg, 0.30 mmol, 59% yield) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.11 (ddd, <i>J</i> = 7.58, 5.92, 1.37 Hz, 2H), 6.90 (t, <i>J</i> = 7.82 Hz, 1H), 4.81 (s, 1H), 3.89 (d, <i>J</i> = 5.87 Hz, 2H), 3.62â3.69 (m, 1H), 3.50 (s, 3H), 1.62 (s, 6H). <i>m</i>/<i>z</i> (ESI, +ve) 374.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_19_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> Step 2</h5><div class="NLM_p last">A glass microwave reaction vessel was charged with 2-((1-hydroxy-2-methylpropan-2-yl)amino)-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>23e</b>, 105 mg, 0.28 mmol), (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 221 mg, 0.84 mmol), XPhos Pd G2 (11 mg, 14 Î¼mol), and potassium phosphate (179 mg, 0.84 mmol) in dioxane (2.5 mL) and water (0.6 mL). The reaction mixture was stirred and heated in an oil bath at 45 Â°C for 90 min. Water (5 mL) and EtOAc (5 mL) were added, and the layers were separated. The aqueous layer was extracted with EtOAc (2 Ã 5 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by silica gel chromatography (0â10% MeOH in DCM) to provide (<i>R</i>)-2-((1-hydroxy-2-methylpropan-2-yl)amino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>23</b>) (55 mg, 0.14 mmol, 51% yield) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 12.03 (s, 1 H), 7.90 (ddd, <i>J</i> = 10.32, 7.78, 1.47 Hz, 2 H), 7.61 (s, 1 H), 7.18 (t, <i>J</i> = 7.73 Hz, 1 H), 6.71 (d, <i>J</i> = 1.37 Hz, 1 H), 5.79 (s, 1 H), 5.17 (t, <i>J</i> = 5.67 Hz, 1 H), 4.53 (q, <i>J</i> = 6.59 Hz, 1 H), 3.59 (m, 2 H), 3.48 (s, 3 H), 1.46 (d, <i>J</i> = 9.78 Hz, 6 H), 1.38 (d, <i>J</i> = 6.65 Hz, 3 H). <i>m</i>/<i>z</i> (ESI, +ve) 382.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (<i>R</i>)-2-(<i>tert</i>-Butyl(methyl)amino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>24</b>)</h4><div id="sec5_2_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> Step 1</h5><div class="NLM_p last">A mixture of 2-chloro-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>22d</b>, 2.44 g, 7.61 mmol) and <i>t</i>-butylamine (16.00 mL, 152 mmol) was heated at 80 Â°C in a sealed tube for 6 h. The reaction mixture was transferred to a round-bottomed flask and concentrated to remove excess of <i>t</i>-butylamine. The residue was then treated with water and extracted with EtOAc/Et<sub>2</sub>O 1:1 (2 Ã 75 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated, affording 2-(<i>tert</i>-butylamino)-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>24e</b>, 2.68 g, 7.50 mmol, 99% yield) as a yellow amorphous solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 8.10 (2H, m), 6.87 (1H, t, <i>J</i> = 7.7 Hz), 4.45 (1H, br), 3.46 (3H, s), 1.65 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 358.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Step 2</h5><div class="NLM_p last">To a solution of 2-(<i>tert</i>-butylamino)-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>24e</b>, 400 mg, 1.12 mmol) in 3 mL of DMF at 0 Â°C was added sodium hydride (60% wt in mineral oil) (81 mg, 2.02 mmol). The resulting yellow suspension was stirred at RT for 15 min and then cooled at 0 Â°C and treated with iodomethane (70 Î¼L, 1.12 mmol). It was stirred at RT for 90 min and then treated with 5 mL of satd NH<sub>4</sub>Cl. The precipitated white solid was filtered, rinsed with 2 Ã 3 mL of water, followed by 2 Ã 2 mL of ether. The filtrate was discarded. The white solid was dried in a vacuum oven at 40 Â°C for 2 h to afford 2-(<i>tert</i>-butyl(methyl)amino)-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>24f</b>, 355 mg, 0.95 mmol, 85% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.23 (1H, dd, <i>J</i> = 7.6, 1.4 Hz), 8.02 (1H, dd, <i>J</i> = 7.8, 1.4 Hz), 7.09 (1H, t, <i>J</i> = 7.6 Hz), 3.48 (3 H, s), 2.74 (3 H, s), 1.49 (9 H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 372.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_20_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> Step 3</h5><div class="NLM_p last">A mixture of (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 275 mg, 1.05 mmol), 2-(<i>tert</i>-butyl(methyl)amino)-8-iodo-3-methylquinazolin-4(3<i>H</i>)-one (<b>24f</b>, 300 mg, 0.81 mmol), potassium phosphate tribasic (515 mg, 2.42 mmol), and XPhos Pd G2 (31 mg, 0.04 mmol) in 1,4-dioxane (4 mL)/water (1.2 mL) was heated in an oil bath at 50 Â°C for 1 h. Additional XPhos Pd G2 (15 mg, 0.02 mmol) and <b>BE1</b> (50 mg, 0.19 mmol) were added to the reaction mixture, and heating was continued at 50 Â°C for 35 min. It was cooled to RT, treated with 5 mL of water, and extracted with 50 mL of EtOAc. The EtOAc layer was washed with 5 mL of brine, concentrated, and the residue purified on a silica gel column (eluted with 1â5% MeOH in EtOAc) to give (<i>R</i>)-2-(<i>tert</i>-butyl(methyl)amino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>24</b>) (160 mg, 0.42 mmol, 52% yield) as a brown crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.85 (1H, br), 8.00 (2H, m), 7.64 (1H, s), 7.42 (1H, t, <i>J</i> = 7.7 Hz), 6.83 (1H, s), 4.54 (1H, d, <i>J</i> = 6.5 Hz), 3.56 (3H, s), 2.75 (3H, s), 1.37 (3H, d, <i>J</i> = 6.7 Hz), 1.33 (9H, s). <i>m</i>/<i>z</i> (ESI, +ve ion) 380.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (<i>R</i>)-2-(2,2-Dimethylpyrrolidin-1-yl)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>25</b>)</h4><div class="NLM_p">A mixture of 2,2-dimethylpyrrolidine hydrochloride (280 mg, 2.062 mmol, Enamine Ltd., cataloue no. EN300-62047), 8-bromo-2-chloro-3-methylquinazolin-4(3<i>H</i>)-one (<b>17d</b>, 470 mg, 1.72 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.20 mL, 6.87 mmol) in 2 mL of DMSO was heated in a microwave at 140 Â°C for 35 min. It was partitioned between 10 mL of water and 50 mL of EtOAc. The organic layer was separated and concentrated. The residue was purified on a silica gel column (35â55% EtOAc in hexanes) to give 8-bromo-2-(2,2-dimethylpyrrolidin-1-yl)-3-methylquinazolin-4(3<i>H</i>)-one (<b>25e</b>, 497 mg, 1.48 mmol, 86% yield) as a brown amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.93 (2H, d, <i>J</i> = 8.0 Hz), 7.06 (1H, t, <i>J</i> = 7.8 Hz), 3.57 (2H, t, <i>J</i> = 7.0 Hz), 3.48 (3H, s), 1.941 (2H, m), 1.80 (2H, m), 167 (6H, s). <i>m</i>/<i>z</i> (ESI, +ve) 336/338 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A mixture of 8-bromo-2-(2,2-dimethylpyrrolidin-1-yl)-3-methylquinazolin-4(3<i>H</i>)-one (<b>25e</b>, 320 mg, 0.95 mmol), (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 324 mg, 1.23 mmol), potassium phosphate (606 mg, 2.86 mmol), and XPhos Pd G2 (37.4 mg, 0.048 mmol) in 1,4-dioxane (4 mL)/water (1.2 mL) was heated in an oil bath at 50 Â°C for 1 h. It was cooled to room temperature. The mixture was partitioned between 5 mL of water and 50 mL of EtOAc. The EtOAc layer was washed with 5 mL of brine, concentrated, and the residue purified on a silica gel column (1â5% MeOH in EtOAc) to give (<i>R</i>)-2-(2,2-dimethylpyrrolidin-1-yl)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-<i>b</i>]pyrrol-2-yl)quinazolin-4(3<i>H</i>)-one (<b>25</b>) (289 mg, 0.73 mmol, 78% yield) as a brown crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.67 (1H, br), 7.93 (1H, m), 7.85 (1H, m), 7.59 (1H, s), 7.26 (1H, t, <i>J</i> = 7.7 Hz), 6.61 (1H, s), 4.51 (1H, d, <i>J</i> = 6.7 Hz), 3.56 (2H, m), 3.44 (3H, s), 1.97 (2H, m), 1.77 (2H, m), 1.47 (3H, s), 1.43 (3H, s), 1.36 (3H, d, <i>J</i> = 6.7 Hz). <i>m</i>/<i>z</i> (ESI, +ve) 392.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (<i>R</i>)-2-(3-(<i>tert</i>-Butylamino)-6-fluoro-2-methylquinoxalin-5-yl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>26</b>)</h4><div id="sec5_2_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> Step 1</h5><div class="NLM_p last">2-Bromo-1,3-difluoro-4-nitrobenzene (<b>26a</b>), Combi-Blocks, 27.15 g, 114 mmol) was treated with ammonium carbonate (10.96 g, 114 mmol) and DMF (200 mL) followed by Et<sub>3</sub>N (47.7 mL, 342 mmol) and stirred at RT for 48 h. The mixture was treated with water and extracted with DCM (300 mL). The DCM layer was washed with water (3 Ã 200 mL) and brine (3 Ã 200 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated, affording crude 2-bromo-3-fluoro-6-nitroaniline (<b>26b</b>, 26 g, 111 mmol, 97% yield) as a bright-yellow amorphous solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.22 (1H, dd, <i>J</i> = 9.6, 5.9 Hz), 6.81 (2H, br), 6.56 (2H, dd, <i>J</i> = 9.6, 7.2 Hz). <sup>19</sup>F NMR (376 MHz, CCDCl<sub>3</sub>) Î´ ppm â90.92 (s). <i>m</i>/<i>z</i> (ESI, +ve ion) 234.9/236.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> Step 2</h5><div class="NLM_p last">A 500 mL round-bottomed flask containing Pt/C (5% wt, 6.00 g, 1.54 mmol) and 2-bromo-3-fluoro-6-nitroaniline (<b>26b</b>) (20.85 g, 89 mmol) was treated with EtOH (250 mL) and stirred under an atmosphere of H<sub>2</sub> (balloon) for 22 h. LC-MS indicated ca. 35% conversion to the desired material (<i>m</i>/<i>z</i> (ESI, +ve ion) 204.9/206.9 (M + H)<sup>+</sup>). Another balloon of H<sub>2</sub> was added, and it was stirred for another 16 h, resulting in >90% conversion to the desired product. The suspension was filtered through a plug of Celite washing with EtOH and concentrated, affording crude 3-bromo-4-fluorobenzene-1,2-diamine (18 g, 88 mmol, 99% yield) as a black/purple viscous oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 6.60 (1H, dd, <i>J</i> = 8.5, 5.2 Hz), 6.47 (1H, m). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) Î´ ppm â116.48 (s). <i>m</i>/<i>z</i> (ESI, +ve ion) 204.9/206.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_22_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> Step 3</h5><div class="NLM_p last">A 500 mL found-bottom flask charged with 3-bromo-4-fluorobenzene-1,2-diamine (<b>26c</b>) (18.00 g, 88.00 mmol), DMF (100 mL), ethyl 2-bromopropionate (11.54 mL, 89.00 mmol), and NaHCO<sub>3</sub> (7.60 g, 90.00 mmol) was heated to 90 Â°C with a reflux condenser for 30 min and then at 120 Â°C for 15 h. The reaction mixture was cooled to RT, treated with brine, and extracted with EtOAc (2 Ã 200 mL), washed with brine (3Ã), and dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated, affording crude 8-bromo-7-fluoro-3-methyl-3,4-dihydroquinoxalin-2(1<i>H</i>)-one (<b>26d</b>, 21.75 g, 84.00 mmol, 96% yield) as an orangeâbrown viscous oil. The material was used in the subsequent step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 9.67 (s, 1H) 6.80 (m, 1H) 6.60 (m, 1H) 6.27 (m, 1H) 1.25 (d, <i>J</i> = 6.46 Hz, 3H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â120.49 (s). <i>m</i>/<i>z</i> (ESI, +ve ion) 259.0/261.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_22_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> Step 4</h5><div class="NLM_p last">A mixture of water (14 mL) and 30% H<sub>2</sub>O<sub>2</sub> (30.0 mL, 294 mmol) was added slowly dropwise to a solution of 8-bromo-7-fluoro-3-methyl-3,4-dihydroquinoxalin-2(1<i>H</i>)-one (<b>26d</b>) (21.7 g, 84.0 mmol) in 1 N NaOH (168 mL) and MeOH (140 mL). The flask was fitted with a reflux condenser and heated at 85 Â°C for 3 h. LC-MS indicated ca. 87% conversion to the desired product (<i>m</i>/<i>z</i> (ESI, +ve ion) 257.0/259.0 (M + H)<sup>+</sup>). The reaction mixture was cooled to RT and acidified with 2 N HCl to ca. pH 6 and was diluted with CHCl<sub>3</sub>/IPA (4:1) (100 mL), added to a separatory funnel. The resulting suspension was filtered through a sintered glass frit, washed with water, and dried, affording 8-bromo-7-fluoro-3-methylquinoxalin-2(1<i>H</i>)-one (5.8 g, 22.0 mmol, 22% yield) as a light-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.83 (1H, br), 7.78 (1H, m), 7.34 (1H, t, <i>J</i> = 8.4 Hz), 2.43 (3H, s). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â104.13 (s). <i>m</i>/<i>z</i> (ESI, +ve ion) 257.0/259.0 (M + H)<sup>+</sup>. The aqueous solution was extracted with CHCl<sub>3</sub>:<i>i</i>-PrOH = 9:1 (6 Ã 100 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated, affording additional 8-bromo-7-fluoro-3-methylquinoxalin-2(1<i>H</i>)-one (<b>26e</b>, 12.5 g, 49.0 mmol, 58% yield) as a dark-brown amorphous solid (ca. 80% purity). The material was used in the subsequent step without further purification.</div></div><div id="sec5_2_22_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> Step 5</h5><div class="NLM_p last">In a 500 mL round-bottomed flask, a mixture of 8-bromo-7-fluoro-3-methylquinoxalin-2(1<i>H</i>)-one (<b>26e</b>, 3.57 g, 13.89 mmol) and POCl<sub>3</sub> (20.0 mL) was heated at 90 Â°C for 1.5 h with a reflux condenser. The reaction mixture was cooled to RT, and most of the excess POCl<sub>3</sub> was removed under reduced pressure. The mixture was treated with EtOAc (100 mL), cooled in an ice bath, and treated with ice chips and 1 N NaOH slowly. After phase separation, the organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated to afford the crude product as a brown solid. The crude residue was purified by silica gel chromatography (10â100% DCM in hexanes), affording 5-bromo-3-chloro-6-fluoro-2-methylquinoxaline (<b>26f</b>, 1.88 g, 6.82 mmol, 49% yield) as a light-orange crystalline solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.01 (1H, dd, <i>J</i> = 9.3, 5.4 Hz), 7.58 (1H, dd, <i>J</i> = 9.1, 8.1 Hz), 2.86 (3H, s). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) Î´ ppm â99.07 (s). <i>m</i>/<i>z</i> (ESI, +ve ion) 275.0/277.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_22_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> Step 6</h5><div class="NLM_p last">A mixture of 5-bromo-3-chloro-6-fluoro-2-methylquinoxaline (<b>26f</b>, 5.00 g, 18.15 mmol) and <i>t</i>-butylamine (9.62 mL, 91.00 mmol) in DMSO (50 mL) in a sealed tube was heated at 100 Â°C for 2 h. After cooling to RT, the mixture was diluted with EtOAc and satd NaHCO<sub>3</sub> (aq). The layers were separated, and the aqueous layer was extracted with EtOAc (3Ã). The combined organic layers were washed with water and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was absorbed onto a plug of silica gel and purified by silica gel chromatography (0â20% EtOAc in hexanes) to provide 8-bromo-<i>N</i>-(<i>tert</i>-butyl)-7-fluoro-3-methylquinoxalin-2-amine (<b>26g</b>) (4.70 g, 15.06 mmol, 83% yield) as an orange solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ ppm 7.71 (1H, dd, <i>J</i> = 9.0, 5.7 Hz), 7.14 (1H, t, <i>J</i> = 8.6 Hz), 4.82 (1H, br), 2.51 (3H, s), 1.64 (9H, s). <sup>19</sup>F NMR (376 MHz, chloroform-<i>d</i>) Î´ ppm â103.85 (s). <i>m</i>/<i>z</i> (ESI, +ve) 312.0, 314.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_22_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> Step 7</h5><div class="NLM_p last">To a 250 mL round-bottomed flask was added (<i>R</i>)-6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>BE1</b>, 5.52 g, 19.40 mmol) and 8-bromo-<i>N</i>-(<i>tert</i>-butyl)-7-fluoro-3-methylquinoxalin-2-amine (<b>26g</b>, 6.06 g, 19.40 mmol) in 1,4-dioxane (40 mL)/water (12 mL), followed by potassium phosphate (12.35 g, 58.20 mmol) and XPhos Pd G2 (0.763 g, 0.97 mmol). The reaction mixture was heated in an oil bath at 45 Â°C for 1 h. The mixture was added 10 mL of iceâwater. The resulting precipitate was collected by filtration, washed with water, and dried under vacuo to give some brown solid that contained the desired product. The filtrate was extracted with EtOAc (3 Ã 100 mL). The organic extracts were combined and dried with (MgSO<sub>4</sub>), filtered, and concentrated. The residue was combined with the brown solid that contained the desired product, loaded on a silica gel column, and eluted with 1â10% MeOH in DCM to give (<i>R</i>)-2-(3-(<i>tert</i>-butylamino)-6-fluoro-2-methylquinoxalin-5-yl)-6-methyl-5,6-dihydropyrrolo[3,4-<i>b</i>]pyrrol-4(1<i>H</i>)-one (<b>26</b>) (3.86 g, 10.51 mmol, 54% yield) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.88 (s, 1H), 7.70 (dd, <i>J</i> = 8.9, 6.0 Hz, 1H), 7.61 (s, 1H), 7.29 (dd, <i>J</i> = 10.4, 9.0 Hz, 1H), 6.46 (t, <i>J</i> = 1.8 Hz, 1H), 6.08 (s, 1H), 4.52 (q, <i>J</i> = 6.7 Hz, 1H), 2.53 (s, 3H), 1.44 (s, 9H), 1.37 (d, <i>J</i> = 6.7 Hz, 3H). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 368 (M + 1).</div></div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Solubility Assays in PBS and FaSIF</h3><div class="NLM_p last">Compounds as 10 mM DMSO stock solutions were dispensed into 96-deep-well plates at a volume of 10 Î¼L per well. Four copies of identical plates were created. The DMSO was removed in a Genevac evaporator for 2.5 h, at 40 Â°C, under full vacuum. After dry down was complete, a Tecan Evo liquid handler was used to transfer 200 Î¼L of each of the buffers/solvent to the corresponding plate copy. The buffers used were 1Ã PBS (pH 7.4), and fasted state simulated intestinal fluid (FaSIF, pH 6.8) and the solvent DMSO was used to create the standard plate for comparison. The plates were sealed and centrifuged at 1000 rpm for 1 min to push all liquid from walls to the bottom of the wells. The plates were shaken at 1500 rpm on a 3 mm radius orbital shaker for 1 h. The samples were equilibrated at RT for 72 h. The plates were centrifuged at 4000 rpm for 30 min. The supernatant was analyzed by LC/MS (at 215 nm, 2 Î¼L injection volume). Peak area in PBS and fasted state simulated intestinal fluid were compared to DMSO standard to determine solubility, accurate within the range of 5â500 Î¼M.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i113"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00610">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00610" class="ext-link">10.1021/acs.jmedchem.6b00610</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Statistical analysis of data presented in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Atomic coordinates and experimental data of <b>17</b>/Pim-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ">5IPJ</a>). Mouse body weight for the KMS-12 BM xenograft study presented in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. KINOMEscan data of <b>17</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_002.csv">jm6b00610_si_002.csv (1.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_003.pdf">jm6b00610_si_003.pdf (315.26 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00610" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48634" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48634" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liping H. Pettus</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9ef2eefbeaeaebeddefff3f9fbf0b0fdf1f3"><span class="__cf_email__" data-cfemail="167a66736262636556777b7173783875797b">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristin L. Andrews</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shon K. Booker</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Chen</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor J. Cee</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Chavez</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuping Chen</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heather Eastwood</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadia Guerrero</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bradley Herberich</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean Hickman</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian A. Lanman</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jimmy Laszlo</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Lee</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Russell Lipford</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bethany Mattson</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Mohr</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yen Nguyen</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark H. Norman</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Powers</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony B. Reed</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Rex</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Sastri</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nuria Tamayo</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Wang</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey T. Winston</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Wu</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tian Wu</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan P. Wurz</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Xu</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihong Zhou</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew S. Tasker</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Ling Wang</span> - <span class="hlFld-Affiliation affiliation">â Department of Therapeutic DiscoveryâMedicinal
Chemistry, â¡Molecular Structure, Â§Pharmacokinetics and Drug Metabolism, â¥Oncology Research, â¥Pharmaceutics, #Discovery Technologies, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d3161e7838-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i115">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Wes Barnhart, Kyung Gahm, and Sam Thomas for chiral SFC separation of intermediates and final compounds; Chris Wilde for NMR studies.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i116" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i116"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i117" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i117"> Abbreviations Used</h2><tr><td class="NLM_term">BAD</td><td class="NLM_def"><p class="first last">Bcl-2-associated death promoter</p></td></tr><tr><td class="NLM_term">BM</td><td class="NLM_def"><p class="first last">bone marrow</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CPK</td><td class="NLM_def"><p class="first last">CoreyâPaulingâKoltun</p></td></tr><tr><td class="NLM_term">DMAC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">Pim</td><td class="NLM_def"><p class="first last">proviral insertion site of moloney murine leukemia</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">percent of control</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once a day</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i118">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Brault, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span> </span><span class="NLM_article-title">PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">â</span> <span class="NLM_lpage">1015</span><span class="refDoi">Â DOI: 10.3324/haematol.2009.017079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.3324%2Fhaematol.2009.017079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=20145274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlShu7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=1004-1015&author=L.+Braultauthor=C.+Gasserauthor=F.+Bracherauthor=K.+Huberauthor=S.+Knappauthor=J.+Schwaller&title=PIM+serine%2Fthreonine+kinases+in+the+pathogenesis+and+therapy+of+hematologic+malignancies+and+solid+cancers&doi=10.3324%2Fhaematol.2009.017079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers</span></div><div class="casAuthors">Brault, Laurent; Gasser, Christelle; Bracher, Franz; Huber, Kilian; Knapp, Stefan; Schwaller, Jurg</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1004-1015</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">A review.  The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biol.  Whereas elevated levels of PIM1 and PIM2 were mostly found in hematol. malignancies and prostate cancer, increased PIM3 expression was obsd. in different solid tumors.  PIM kinases are constitutively active and their activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing no. of common as well as isoform-specific substrates including several cell cycle regulators and apoptosis mediators.  PIM1 but not PIM2 seems also to mediate homing and migration of normal and malignant hematopoietic cells by regulating chemokine receptor surface expression.  Knockdown expts. by RNA interference or dominant-neg. acting mutants suggested that PIM kinases are important for maintenance of a transformed phenotype and therefore potential therapeutic targets.  Detn. of the protein structure facilitated identification of an increasing no. of potent small mol. PIM kinase inhibitors with in vitro and in vivo anticancer activity.  Ongoing efforts aim to identify isoform-specific PIM inhibitors that would not only help to dissect the kinase function but hopefully also provide targeted therapeutics.  Here, we summarize the current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematol. malignancies and solid cancers, and we highlight structural principles and recent progress on small mol. PIM kinase inhibitors that are on their way into first clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM0F0X8PArhLVg90H21EOLACvtfcHk0liJ6UkNTsQ63w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlShu7%252FO&md5=241c17f65ee9203be2a6ee138a914781</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2009.017079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2009.017079%26sid%3Dliteratum%253Aachs%26aulast%3DBrault%26aufirst%3DL.%26aulast%3DGasser%26aufirst%3DC.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSchwaller%26aufirst%3DJ.%26atitle%3DPIM%2520serine%252Fthreonine%2520kinases%2520in%2520the%2520pathogenesis%2520and%2520therapy%2520of%2520hematologic%2520malignancies%2520and%2520solid%2520cancers%26jtitle%3DHaematologica%26date%3D2010%26volume%3D95%26spage%3D1004%26epage%3D1015%26doi%3D10.3324%2Fhaematol.2009.017079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Nawijn, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alendar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berns, A.</span><span> </span><span class="NLM_article-title">For better or for worse: the role of Pim oncogenes in tumorigenesis</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span><span class="refDoi">Â DOI: 10.1038/nrc2986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1038%2Fnrc2986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=21150935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCjsrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=23-34&author=M.+C.+Nawijnauthor=A.+Alendarauthor=A.+Berns&title=For+better+or+for+worse%3A+the+role+of+Pim+oncogenes+in+tumorigenesis&doi=10.1038%2Fnrc2986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">For better or for worse: the role of Pim oncogenes in tumorigenesis</span></div><div class="casAuthors">Nawijn, Martijn C.; Alendar, Andrej; Berns, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Pim oncogenes are overexpressed in a wide range of tumors from a hematol. and epithelial origin.  Pim genes encode serine/threonine kinases that have been shown to counteract the increased sensitivity to apoptosis induction that is assocd. with MYC-driven tumorigenesis.  Recently, considerable progress has been made in characterizing the pathways of PIM-mediated survival signalling.  Given the unique structure of their active site and the minimal phenotype of mice mutant for all Pim family members, these oncogenes might be promising targets for highly specific and selective drugs with favorable toxicity profiles.  In this Review, we discuss the physiol. functions and oncogenic activities of Pim kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu23UDfObMZrVg90H21EOLACvtfcHk0liJ6UkNTsQ63w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCjsrjE&md5=fe08e70454ca8c4d808715db87d195e1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2986%26sid%3Dliteratum%253Aachs%26aulast%3DNawijn%26aufirst%3DM.%2BC.%26aulast%3DAlendar%26aufirst%3DA.%26aulast%3DBerns%26aufirst%3DA.%26atitle%3DFor%2520better%2520or%2520for%2520worse%253A%2520the%2520role%2520of%2520Pim%2520oncogenes%2520in%2520tumorigenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D23%26epage%3D34%26doi%3D10.1038%2Fnrc2986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Yan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemskova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskinen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilly, M.</span><span> </span><span class="NLM_article-title">The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">45358</span><span class="NLM_x">â</span> <span class="NLM_lpage">45367</span><span class="refDoi">Â DOI: 10.1074/jbc.M307933200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1074%2Fjbc.M307933200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=45358-45367&author=B.+Yanauthor=M.+Zemskovaauthor=S.+Holderauthor=V.+Chinauthor=A.+Kraftauthor=P.+J.+Koskinenauthor=M.+Lilly&title=The+PIM-2+kinase+phosphorylates+BAD+on+serine+112+and+reverses+BAD-induced+cell+death&doi=10.1074%2Fjbc.M307933200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307933200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307933200%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DB.%26aulast%3DZemskova%26aufirst%3DM.%26aulast%3DHolder%26aufirst%3DS.%26aulast%3DChin%26aufirst%3DV.%26aulast%3DKraft%26aufirst%3DA.%26aulast%3DKoskinen%26aufirst%3DP.%2BJ.%26aulast%3DLilly%26aufirst%3DM.%26atitle%3DThe%2520PIM-2%2520kinase%2520phosphorylates%2520BAD%2520on%2520serine%2520112%2520and%2520reverses%2520BAD-induced%2520cell%2520death%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D45358%26epage%3D45367%26doi%3D10.1074%2Fjbc.M307933200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Fox, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammerman, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinalli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Master, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodosh, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">â</span> <span class="NLM_lpage">1854</span><span class="refDoi">Â DOI: 10.1101/gad.1105003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1101%2Fgad.1105003" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=1841-1854&author=C.+J.+Foxauthor=P.+S.+Hammermanauthor=R.+M.+Cinalliauthor=S.+R.+Masterauthor=L.+A.+Chodoshauthor=C.+B.+Thompson&title=The+serine%2Fthreonine+kinase+Pim-2+is+a+transcriptionally+regulated+apoptotic+inhibitor&doi=10.1101%2Fgad.1105003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fgad.1105003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1105003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DC.%2BJ.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DCinalli%26aufirst%3DR.%2BM.%26aulast%3DMaster%26aufirst%3DS.%2BR.%26aulast%3DChodosh%26aufirst%3DL.%2BA.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520serine%252Fthreonine%2520kinase%2520Pim-2%2520is%2520a%2520transcriptionally%2520regulated%2520apoptotic%2520inhibitor%26jtitle%3DGenes%2520Dev.%26date%3D2003%26volume%3D17%26spage%3D1841%26epage%3D1854%26doi%3D10.1101%2Fgad.1105003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">An, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.</span><span> </span><span class="NLM_article-title">Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="refDoi">Â DOI: 10.1186/1756-8722-6-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1186%2F1756-8722-6-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=23360755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVyjtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=12&author=N.+Anauthor=A.+S.+Kraftauthor=Y.+Kang&title=Abnormal+hematopoietic+phenotypes+in+Pim+kinase+triple+knockout+mice&doi=10.1186%2F1756-8722-6-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice</span></div><div class="casAuthors">An, Ningfei; Kraft, Andrew S.; Kang, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Pim (proviral insertion in murine lymphoma) kinases are a small family of constitutively active, highly conservative serine/threonine oncogenic kinases and have 3 members: Pim1, Pim2, and Pim3.  Pim kinases are also implicated in the regulation of B- and T-cell responses to cytokines and hematopoietic growth factors.  The roles of Pim kinases in the regulation of primitive hematopoietic stem cells (HSCs) are largely unknown.  Methods: In the current study, Pim1-/-2-/-3-/- triple knockout (TKO) mice were used to det. the role of Pim kinases in hematopoiesis.  Peripheral blood hematol. parameters were measured in Pim TKO mice and age-matched wild-type (WT) controls.  Primary, secondary, and competitive transplantations were performed to assay the long-term repopulating HSCs in Pim TKO mice.  In vivo BrdU incorporation assay and ex vivo Ki67 staining and caspase 3 labeling were performed to evaluate the proliferation and apoptosis of HSCs in Pim TKO mice.  Results: Compared to age-matched WT controls, Pim TKO mice had lower peripheral blood platelet count and exhibited erythrocyte hypochromic microcytosis.  The bone marrow cells from Pim TKO mice demonstrated decreased hematopoietic progenitor colony-forming ability.  Importantly, Pim TKO bone marrow cells had significantly impaired capacity in rescuing lethally irradiated mice and reconstituting hematopoiesis in primary, secondary and competitive transplant models.  In vivo BrdU incorporation in long-term HSCs was reduced in Pim TKO mice.  Finally, cultured HSCs from Pim TKO mice showed reduced proliferation evaluated by Ki67 staining and higher rate of apoptosis via caspase 3 activation.  Conclusions: Pim kinases are not only essential in the hematopoietic lineage cell development, but also important in HSC expansion, self-renewal, and long-term repopulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvaxaUvRqoRbVg90H21EOLACvtfcHk0lhKeklBBoaMvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVyjtb8%253D&md5=c9a44f6b790facfbdea9e8a0d0915b97</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-12%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DN.%26aulast%3DKraft%26aufirst%3DA.%2BS.%26aulast%3DKang%26aufirst%3DY.%26atitle%3DAbnormal%2520hematopoietic%2520phenotypes%2520in%2520Pim%2520kinase%2520triple%2520knockout%2520mice%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D12%26doi%3D10.1186%2F1756-8722-6-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mikkers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawijn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoeven, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berns, A.</span><span> </span><span class="NLM_article-title">Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">6104</span><span class="NLM_x">â</span> <span class="NLM_lpage">6115</span><span class="refDoi">Â DOI: 10.1128/MCB.24.13.6104-6115.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1128%2FMCB.24.13.6104-6115.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=15199164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1aqtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=6104-6115&author=H.+Mikkersauthor=M.+Nawijnauthor=J.+Allenauthor=C.+Brouwersauthor=E.+Verhoevenauthor=J.+Jonkersauthor=A.+Berns&title=Mice+Deficient+for+All+PIM+Kinases+Display+Reduced+Body+Size+and+Impaired+Responses+to+Hematopoietic+Growth+Factors&doi=10.1128%2FMCB.24.13.6104-6115.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mice deficient for All PIM kinases display reduced body size and impaired responses to hematopoietic growth factors</span></div><div class="casAuthors">Mikkers, Harald; Nawijn, Martijn; Allen, John; Brouwers, Conny; Verhoeven, Els; Jonkers, Jos; Berns, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6104-6115</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Pim family of proto-oncogenes encodes a distinct class of serine/threonine kinases consisting of PIM1, PIM2, and PIM3.  Although the Pim genes are evolutionarily highly conserved, the contribution of PIM proteins to mammalian development is unclear.  PIM1-deficient mice were previously described but showed only minor phenotypic aberrations.  To assess the role of PIM proteins in mammalian physiol., compd. Pim knockout mice were generated.  Mice lacking expression of Pim1, Pim2, and Pim3 are viable and fertile.  However, PIM-deficient mice show a profound redn. in body size at birth and throughout postnatal life.  In addn., the in vitro response of distinct hematopoietic cell populations to growth factors is severely impaired.  In particular, PIM proteins are required for the efficient proliferation of peripheral T lymphocytes mediated by synergistic T-cell receptor and interleukin-2 signaling.  These results indicate that members of the PIM family of proteins are important but dispensable factors for growth factor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY6XNolLKGDrVg90H21EOLACvtfcHk0lhKeklBBoaMvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1aqtbo%253D&md5=f062c37a554b2541dad2d03715b7f65d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.13.6104-6115.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.13.6104-6115.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMikkers%26aufirst%3DH.%26aulast%3DNawijn%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBrouwers%26aufirst%3DC.%26aulast%3DVerhoeven%26aufirst%3DE.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DBerns%26aufirst%3DA.%26atitle%3DMice%2520Deficient%2520for%2520All%2520PIM%2520Kinases%2520Display%2520Reduced%2520Body%2520Size%2520and%2520Impaired%2520Responses%2520to%2520Hematopoietic%2520Growth%2520Factors%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D6104%26epage%3D6115%26doi%3D10.1128%2FMCB.24.13.6104-6115.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Qian, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barringer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kronkaitis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mische, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, B.</span><span> </span><span class="NLM_article-title">Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">6130</span><span class="NLM_x">â</span> <span class="NLM_lpage">6137</span><span class="refDoi">Â DOI: 10.1074/jbc.M409123200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1074%2Fjbc.M409123200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=6130-6137&author=K.+C.+Qianauthor=L.+Wangauthor=E.+R.+Hickeyauthor=J.+Studtsauthor=K.+Barringerauthor=C.+Pengauthor=A.+Kronkaitisauthor=J.+Liauthor=A.+Whiteauthor=S.+Mischeauthor=B.+Farmer&title=Structural+Basis+of+Constitutive+Activity+and+a+Unique+Nucleotide+Binding+Mode+of+Human+Pim-1+Kinase&doi=10.1074%2Fjbc.M409123200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M409123200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M409123200%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DStudts%26aufirst%3DJ.%26aulast%3DBarringer%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DKronkaitis%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DMische%26aufirst%3DS.%26aulast%3DFarmer%26aufirst%3DB.%26atitle%3DStructural%2520Basis%2520of%2520Constitutive%2520Activity%2520and%2520a%2520Unique%2520Nucleotide%2520Binding%2520Mode%2520of%2520Human%2520Pim-1%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D6130%26epage%3D6137%26doi%3D10.1074%2Fjbc.M409123200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Blanco-Aparicio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnero, A.</span><span> </span><span class="NLM_article-title">Pim kinases in cancer: diagnostic, prognostic and treatment opportunities</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">â</span> <span class="NLM_lpage">643</span><span class="refDoi">Â DOI: 10.1016/j.bcp.2012.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bcp.2012.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=23041228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Sht7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=629-643&author=C.+Blanco-Aparicioauthor=A.+Carnero&title=Pim+kinases+in+cancer%3A+diagnostic%2C+prognostic+and+treatment+opportunities&doi=10.1016%2Fj.bcp.2012.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities</span></div><div class="casAuthors">Blanco-Aparicio, Carmen; Carnero, Amancio</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-643</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  PIM proteins belong to a family of ser/thr kinases composed of 3 members, PIM1, PIM2 and PIM3, with greatly overlapping functions.  PIM kinases are mainly responsible for cell cycle regulation, antiapoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway.  PIM kinases have been found to be upregulated in many hematol. malignancies and solid tumors.  Although these kinases have been described as weak oncogenes, they are heavily targeted for anticancer drug discovery.  The present review summarizes the discoveries made to date regarding PIM kinases as driving oncogenes in the process of tumorigenesis and their validation as drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtbg06YAgnArVg90H21EOLACvtfcHk0lj4A9kRcj3CFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Sht7nK&md5=63957a55b281d4bbc8c4843249d30273</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Aparicio%26aufirst%3DC.%26aulast%3DCarnero%26aufirst%3DA.%26atitle%3DPim%2520kinases%2520in%2520cancer%253A%2520diagnostic%252C%2520prognostic%2520and%2520treatment%2520opportunities%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D629%26epage%3D643%26doi%3D10.1016%2Fj.bcp.2012.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Garcia, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langowski, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavorotinskaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narberes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellamacina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holash, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, M. T.</span><span> </span><span class="NLM_article-title">Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1834</span><span class="NLM_x">â</span> <span class="NLM_lpage">1845</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-2062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1158%2F1078-0432.CCR-13-2062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=24474669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1eiu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1834-1845&author=P.+D.+Garciaauthor=J.+L.+Langowskiauthor=Y.+Wangauthor=M.+Chenauthor=J.+Castilloauthor=C.+Fantonauthor=M.+Isonauthor=T.+Zavorotinskayaauthor=Y.+Daiauthor=J.+Luauthor=X.+Niuauthor=S.+Bashamauthor=J.+Chanauthor=J.+Yuauthor=M.+Doyleauthor=P.+Feuchtauthor=R.+Warneauthor=J.+Narberesauthor=T.+Tsangauthor=C.+Fritschauthor=A.+Kauffmannauthor=E.+Pfisterauthor=P.+Drueckesauthor=J.+Trappeauthor=C.+Wilsonauthor=W.+Hanauthor=J.+Lanauthor=G.+Nishiguchiauthor=M.+Lindvallauthor=C.+Bellamacinaauthor=A.+Aycinenaauthor=R.+Zangauthor=J.+Holashauthor=M.+T.+Burger&title=Pan-PIM+Kinase+Inhibition+Provides+a+Novel+Therapy+for+Treating+Hematologic+Cancers&doi=10.1158%2F1078-0432.CCR-13-2062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers</span></div><div class="casAuthors">Garcia, Pablo D.; Langowski, John L.; Wang, Yingyun; Chen, Min; Castillo, Joseph; Fanton, Christie; Ison, Marjorie; Zavorotinskaya, Tatiana; Dai, Yumin; Lu, Jing; Niu, Xiao-Hong; Basham, Stephen; Chan, Julie; Yu, Jianjun; Doyle, Michael; Feucht, Paul; Warne, Robert; Narberes, Jamie; Tsang, Tiffany; Fritsch, Christine; Kauffmann, Audrey; Pfister, Estelle; Drueckes, Peter; Trappe, Joerg; Wilson, Christopher; Han, Wooseok; Lan, Jiong; Nishiguchi, Gisele; Lindvall, Mika; Bellamacina, Cornelia; Aycinena, J. Alex; Zang, Richard; Holash, Jocelyn; Burger, Matthew T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1834-1845</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PIM kinases have been shown to act as oncogenes in mice, with each family member being able to drive progression of hematol. cancers.  Consistent with this, we found that PIMs are highly expressed in human hematol. cancers and show that each isoform has a distinct expression pattern among disease subtypes.  This suggests that inhibitors of all three PIMs would be effective in treating multiple hematol. malignancies.  Pan-PIM inhibitors have proven difficult to develop because PIM2 has a low Km for ATP and, thus, requires a very potent inhibitor to effectively block the kinase activity at the ATP levels in cells.  We developed a potent and specific pan-PIM inhibitor, LGB321, which is active on PIM2 in the cellular context.  LGB321 is active on PIM2-dependent multiple myeloma cell lines, where it inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD.  Broad cancer cell line profiling of LGB321 demonstrates limited activity in cell lines derived from solid tumors.  In contrast, significant activity in cell lines derived from diverse hematol. lineages was obsd., including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), multiple myeloma and non-Hodgkin lymphoma (NHL).  Furthermore, we demonstrate LGB321 activity in the KG-1 AML xenograft model, in which modulation of pharmacodynamics markers is predictive of efficacy.  Finally, we demonstrate that LGB321 synergizes with cytarabine in this model.  We have developed a potent and selective pan-PIM inhibitor with single-agent antiproliferative activity and show that it synergizes with cytarabine in an AML xenograft model.  Our results strongly support the development of Pan-PIM inhibitors to treat hematol. malignancies.  Clin Cancer Res; 20(7); 1834-45. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriy2nkB_psKbVg90H21EOLACvtfcHk0lj4A9kRcj3CFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1eiu7k%253D&md5=c563df328e7af3ebf10c31b1a26faae4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2062%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DP.%2BD.%26aulast%3DLangowski%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCastillo%26aufirst%3DJ.%26aulast%3DFanton%26aufirst%3DC.%26aulast%3DIson%26aufirst%3DM.%26aulast%3DZavorotinskaya%26aufirst%3DT.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DBasham%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDoyle%26aufirst%3DM.%26aulast%3DFeucht%26aufirst%3DP.%26aulast%3DWarne%26aufirst%3DR.%26aulast%3DNarberes%26aufirst%3DJ.%26aulast%3DTsang%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DPfister%26aufirst%3DE.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DBellamacina%26aufirst%3DC.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26atitle%3DPan-PIM%2520Kinase%2520Inhibition%2520Provides%2520a%2520Novel%2520Therapy%2520for%2520Treating%2520Hematologic%2520Cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D1834%26epage%3D1845%26doi%3D10.1158%2F1078-0432.CCR-13-2062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Arunesh, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanthi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishna, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanadhan, V. N.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span><span class="refDoi">Â DOI: 10.1517/13543776.2014.848196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1517%2F13543776.2014.848196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=24131033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5-17&author=G.+M.+Aruneshauthor=E.+Shanthiauthor=M.+H.+Krishnaauthor=J.+S.+Kumarauthor=V.+N.+Viswanadhan&title=Small+molecule+inhibitors+of+PIM1+kinase%3A+July+2009+to+February+2013+patent+update&doi=10.1517%2F13543776.2014.848196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update</span></div><div class="casAuthors">Arunesh, Gubbi M.; Shanthi, Ekambaram; Krishna, Mudeenahally H.; Sooriya Kumar, Jegatheesan; Viswanadhan, Vellarkad N.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-17</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The proviral insertion in murine (PIM) lymphoma proteins for which three isoforms, PIM1, PIM2 and PIM3 have been identified, belonging to the family of serine/threonine kinases has emerged recently as an important therapeutic target for the development of selective inhibitors as the new drugs for treating hematol. malignancies and solid tumors.  The small mols. developed by academia and the pharmaceutical industry have steadily increased in the last few years.  Several drug discovery groups focus on treating disorders, such as cancer mediated by PIM kinase, have provided preclin. evidence suggesting that PIM inhibitor provides anti-apoptotic activity, inhibit cell survival and cell proliferation.  Areas covered: This article discloses recent reviews on research and advances published in the patent literature and scientific publications from July 2009 to Feb. 2013, highlighting discoveries on PIM1 kinase.  Expert opinion: Several PIM1 kinase small mol. inhibitors are now at the pre-clin. research stage, development and testing.  Though nearly 40 patents emerged in the last 3 years, greater efforts towards addnl. designs and medicinal chem. continues for developing clin. efficacious PIM1 inhibitors, due to the significance of the target for cancer and the potential for novel and diverse inhibitors as drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWHvcymSiEcLVg90H21EOLACvtfcHk0liQzvkFVMVw8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvM&md5=3980e3504d9f044196cc167a37762b9b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.848196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.848196%26sid%3Dliteratum%253Aachs%26aulast%3DArunesh%26aufirst%3DG.%2BM.%26aulast%3DShanthi%26aufirst%3DE.%26aulast%3DKrishna%26aufirst%3DM.%2BH.%26aulast%3DKumar%26aufirst%3DJ.%2BS.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520PIM1%2520kinase%253A%2520July%25202009%2520to%2520February%25202013%2520patent%2520update%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D5%26epage%3D17%26doi%3D10.1517%2F13543776.2014.848196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Merkel, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meggers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocker, M.</span><span> </span><span class="NLM_article-title">PIM1 kinase as a target for cancer therapy</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">â</span> <span class="NLM_lpage">436</span><span class="refDoi">Â DOI: 10.1517/13543784.2012.668527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1517%2F13543784.2012.668527" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=425-436&author=A.+L.+Merkelauthor=E.+Meggersauthor=M.+Ocker&title=PIM1+kinase+as+a+target+for+cancer+therapy&doi=10.1517%2F13543784.2012.668527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.668527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.668527%26sid%3Dliteratum%253Aachs%26aulast%3DMerkel%26aufirst%3DA.%2BL.%26aulast%3DMeggers%26aufirst%3DE.%26aulast%3DOcker%26aufirst%3DM.%26atitle%3DPIM1%2520kinase%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D425%26epage%3D436%26doi%3D10.1517%2F13543784.2012.668527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Drygin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryckman, D. M.</span><span> </span><span class="NLM_article-title">Potential Use of Selective and Nonselective Pim Kinase Inhibitors for Cancer Therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8199</span><span class="NLM_x">â</span> <span class="NLM_lpage">8208</span><span class="refDoi">Â DOI: 10.1021/jm3009234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8199-8208&author=D.+Dryginauthor=M.+Haddachauthor=F.+Pierreauthor=D.+M.+Ryckman&title=Potential+Use+of+Selective+and+Nonselective+Pim+Kinase+Inhibitors+for+Cancer+Therapy&doi=10.1021%2Fjm3009234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm3009234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009234%26sid%3Dliteratum%253Aachs%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DPotential%2520Use%2520of%2520Selective%2520and%2520Nonselective%2520Pim%2520Kinase%2520Inhibitors%2520for%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8199%26epage%3D8208%26doi%3D10.1021%2Fjm3009234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G. K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span> </span><span class="NLM_article-title">Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5258</span><span class="NLM_x">â</span> <span class="NLM_lpage">5264</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.09.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2015.09.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5258-5264&author=H.+Huauthor=X.+Wangauthor=G.+K.+Y.+Chanauthor=J.+H.+Changauthor=S.+Doauthor=J.+Drummondauthor=A.+Ebensauthor=W.+Leeauthor=J.+Lyauthor=J.+P.+Lyssikatosauthor=J.+Murrayauthor=J.+G.+Moffatauthor=Q.+Chaoauthor=V.+Tsuiauthor=H.+Wallweberauthor=A.+Kolesnikov&title=Discovery+of+3%2C5-substituted+6-azaindazoles+as+potent+pan-Pim+inhibitors&doi=10.1016%2Fj.bmcl.2015.09.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.052%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DKolesnikov%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25203%252C5-substituted%25206-azaindazoles%2520as%2520potent%2520pan-Pim%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5258%26epage%3D5264%26doi%3D10.1016%2Fj.bmcl.2015.09.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Burger, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atallah, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellamacina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavorotinskaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holash, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langowski, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanasse, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, P. D.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8373</span><span class="NLM_x">â</span> <span class="NLM_lpage">8386</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8373-8386&author=M.+T.+Burgerauthor=G.+Nishiguchiauthor=W.+Hanauthor=J.+Lanauthor=R.+Simmonsauthor=G.+Atallahauthor=Y.+Dingauthor=V.+Tamezauthor=Y.+Zhangauthor=M.+Mathurauthor=K.+Mullerauthor=C.+Bellamacinaauthor=M.+K.+Lindvallauthor=R.+Zangauthor=K.+Huhauthor=P.+Feuchtauthor=T.+Zavorotinskayaauthor=Y.+Daiauthor=S.+Bashamauthor=J.+Chanauthor=E.+Ginnauthor=A.+Aycinenaauthor=J.+Holashauthor=J.+Castilloauthor=J.+L.+Langowskiauthor=Y.+Wangauthor=M.+Y.+Chenauthor=A.+Lambertauthor=C.+Fritschauthor=A.+Kauffmannauthor=E.+Pfisterauthor=K.+G.+Vanasseauthor=P.+D.+Garcia&title=Identification+of+N-%284-%28%281R%2C3S%2C5S%29-3-Amino-5-methylcyclohexyl%29pyridin-3-yl%29-6-%282%2C6-difluorophenyl%29-5-fluoropicolinamide+%28PIM447%29%2C+a+Potent+and+Selective+Proviral+Insertion+Site+of+Moloney+Murine+Leukemia+%28PIM%29+1%2C+2%2C+and+3+Kinase+Inhibitor+in+Clinical+Trials+for+Hematological+Malignancies&doi=10.1021%2Facs.jmedchem.5b01275"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01275%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DR.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMathur%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DBellamacina%26aufirst%3DC.%26aulast%3DLindvall%26aufirst%3DM.%2BK.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DFeucht%26aufirst%3DP.%26aulast%3DZavorotinskaya%26aufirst%3DT.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DBasham%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DGinn%26aufirst%3DE.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DCastillo%26aufirst%3DJ.%26aulast%3DLangowski%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%2BY.%26aulast%3DLambert%26aufirst%3DA.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DPfister%26aufirst%3DE.%26aulast%3DVanasse%26aufirst%3DK.%2BG.%26aulast%3DGarcia%26aufirst%3DP.%2BD.%26atitle%3DIdentification%2520of%2520N-%25284-%2528%25281R%252C3S%252C5S%2529-3-Amino-5-methylcyclohexyl%2529pyridin-3-yl%2529-6-%25282%252C6-difluorophenyl%2529-5-fluoropicolinamide%2520%2528PIM447%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Proviral%2520Insertion%2520Site%2520of%2520Moloney%2520Murine%2520Leukemia%2520%2528PIM%2529%25201%252C%25202%252C%2520and%25203%2520Kinase%2520Inhibitor%2520in%2520Clinical%2520Trials%2520for%2520Hematological%2520Malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8373%26epage%3D8386%26doi%3D10.1021%2Facs.jmedchem.5b01275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Mumenthaler, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, P. Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanekal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taverna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agus, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, A.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2882</span><span class="NLM_x">â</span> <span class="NLM_lpage">2893</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1158%2F1535-7163.MCT-09-0293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=19825806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2882-2893&author=S.+M.+Mumenthalerauthor=P.+Y.+B.+Ngauthor=A.+Hodgeauthor=D.+Bearssauthor=G.+Berkauthor=S.+Kanekalauthor=S.+Redkarauthor=P.+Tavernaauthor=D.+B.+Agusauthor=A.+Jain&title=Pharmacologic+inhibition+of+Pim+kinases+alters+prostate+cancer+cell+growth+and+resensitizes+chemoresistant+cells+to+taxanes&doi=10.1158%2F1535-7163.MCT-09-0293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes</span></div><div class="casAuthors">Mumenthaler, Shannon M.; Ng, Patricia Y. B.; Hodge, Amanda; Bearss, David; Berk, Gregory; Kanekal, Sarath; Redkar, Sanjeev; Taverna, Pietro; Agus, David B.; Jain, Anjali</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2882-2893</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine family of Pim kinases function as oncogenes and have been implicated in prostate cancer progression, particularly in hormone-refractory prostate disease, as a result of their antiapoptotic function.  In this study, we used a pharmacol. inhibitor targeting the Pim family members, SGI-1776, to det. whether modulation of Pim kinase activity could alter prostate cancer cell survival and modulate chemotherapy resistance.  Extensive biochem. characterization of SGI-1776 confirmed its specificity for the three isoforms of the Pim family.  Treatment of prostate cancer cells with SGI-1776 resulted in a dose-dependent redn. in phosphorylation of known Pim kinase substrates that are involved in cell cycle progression and apoptosis (p21Cip1/WAF1 and Bad).  Consequently, SGI-1776 compromised overall cell viability by inducing G1 cell cycle arrest and triggering apoptosis.  Overexpression of recombinant Pim-1 markedly increased sensitivity of SGI-1776-mediated prostate cancer cell apoptosis and p21Cip1/WAF1 phosphorylation inhibition, reinforcing the specificity of SGI-1776.  An addnl. cytotoxic effect was obsd. when SGI-1776 was combined with taxane-based chemotherapy agents.  SGI-1776 was able to reduce cell viability in a multidrug resistance 1 protein-based taxane-refractory prostate cancer cell line.  In addn., SGI-1776 treatment was able to resensitize chemoresistant cells to taxane-based therapies by inhibiting multidrug resistance 1 activity and inducing apoptosis.  These findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clin. problem of chemoresistance. [Mol Cancer Ther 2009;8(10):2882-93].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnGQXKbXm4Y7Vg90H21EOLACvtfcHk0liV1j62Tm1gAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7E&md5=b6353cdc3b367e336a707147e5c99a4c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0293%26sid%3Dliteratum%253Aachs%26aulast%3DMumenthaler%26aufirst%3DS.%2BM.%26aulast%3DNg%26aufirst%3DP.%2BY.%2BB.%26aulast%3DHodge%26aufirst%3DA.%26aulast%3DBearss%26aufirst%3DD.%26aulast%3DBerk%26aufirst%3DG.%26aulast%3DKanekal%26aufirst%3DS.%26aulast%3DRedkar%26aufirst%3DS.%26aulast%3DTaverna%26aufirst%3DP.%26aulast%3DAgus%26aufirst%3DD.%2BB.%26aulast%3DJain%26aufirst%3DA.%26atitle%3DPharmacologic%2520inhibition%2520of%2520Pim%2520kinases%2520alters%2520prostate%2520cancer%2520cell%2520growth%2520and%2520resensitizes%2520chemoresistant%2520cells%2520to%2520taxanes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2882%26epage%3D2893%26doi%3D10.1158%2F1535-7163.MCT-09-0293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Keeton, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEachern, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillman, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palakurthi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grondine, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platanias, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span> </span><span class="NLM_article-title">AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">â</span> <span class="NLM_lpage">913</span><span class="refDoi">Â DOI: 10.1182/blood-2013-04-495366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1182%2Fblood-2013-04-495366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=24363397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFaqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=905-913&author=E.+K.+Keetonauthor=K.+McEachernauthor=K.+S.+Dillmanauthor=S.+Palakurthiauthor=Y.+Caoauthor=M.+R.+Grondineauthor=S.+Kaurauthor=S.+Wangauthor=Y.+Chenauthor=A.+Wuauthor=M.+Shenauthor=F.+D.+Gibbonsauthor=M.+L.+Lambauthor=X.+Zhengauthor=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=L.+C.+Plataniasauthor=L.+A.+Dakinauthor=H.+Chenauthor=P.+D.+Lyneauthor=D.+Huszar&title=AZD1208%2C+a+potent+and+selective+pan-Pim+kinase+inhibitor%2C+demonstrates+efficacy+in+preclinical+models+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-04-495366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia</span></div><div class="casAuthors">Keeton, Erika K.; McEachern, Kristen; Dillman, Keith S.; Palakurthi, Sangeetha; Cao, Yichen; Grondine, Michael R.; Kaur, Surinder; Wang, Suping; Chen, Yuching; Wu, Allan; Shen, Minhui; Gibbson, Francis D.; Lamb, Michelle L.; Zheng, Xiaolan; Stone, Richard M.; DeAngelo, Daniel J.; Platanias, Leonidas C.; Dakin, Les A.; Chen, Huawei; Lyne, Paul D.; Huszar, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">905-913</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Upregulation of Pim kinases is obsd. in several types of leukemias and lymphomas.  Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways.  AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at <5 nM or <150 nM in enzyme and cell assays, resp.  AZD1208 inhibited the growth of 5 of 14 acute myeloid leukemia (AML) cell lines tested, and sensitivity correlates with Pim-1 expression and STAT5 activation.  AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells, accompanied by a dose-dependent redn. in phosphorylation of Bcl-2 antagonist of cell death, 4EBP1, p70S6K, and S6, as well as increases in cleaved caspase 3 and p27.  Inhibition of p4EBP1 and p-p70S6K and suppression of translation are the most representative effects of Pim inhibition in sensitive AML cell lines.  AZD1208 inhibits the growth of MOLM-16 and KG-1a xenograft tumors in vivo with a clear pharmacodynamic-pharmacokinetic relationship.  AZD1208 also potently inhibits colony growth and Pim signaling substrates in primary AML cells from bone marrow that are Flt3 wild-type or Flt3 internal tandem duplication mutant.  These results underscore the therapeutic potential of Pim kinase inhibition for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGYuN7tp7NrVg90H21EOLACvtfcHk0lgd8u6fzt2vhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFaqs7o%253D&md5=4277790b53c9064787cbd68c159e552b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-04-495366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-04-495366%26sid%3Dliteratum%253Aachs%26aulast%3DKeeton%26aufirst%3DE.%2BK.%26aulast%3DMcEachern%26aufirst%3DK.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DGrondine%26aufirst%3DM.%2BR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DGibbons%26aufirst%3DF.%2BD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DPlatanias%26aufirst%3DL.%2BC.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DHuszar%26aufirst%3DD.%26atitle%3DAZD1208%252C%2520a%2520potent%2520and%2520selective%2520pan-Pim%2520kinase%2520inhibitor%252C%2520demonstrates%2520efficacy%2520in%2520preclinical%2520models%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D905%26epage%3D913%26doi%3D10.1182%2Fblood-2013-04-495366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Code, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hird, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeton, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span> </span><span class="NLM_article-title">Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4599</span><span class="NLM_x">â</span> <span class="NLM_lpage">4604</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.05.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2012.05.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=22727640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1Shtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4599-4604&author=L.+A.+Dakinauthor=M.+H.+Blockauthor=H.+Chenauthor=E.+Codeauthor=J.+E.+Dowlingauthor=X.+Fengauthor=A.+D.+Fergusonauthor=I.+Greenauthor=A.+W.+Hirdauthor=T.+Howardauthor=E.+K.+Keetonauthor=M.+L.+Lambauthor=P.+D.+Lyneauthor=H.+Pollardauthor=J.+Readauthor=A.+J.+Wuauthor=T.+Zhangauthor=X.+Zheng&title=Discovery+of+novel+benzylidene-1%2C3-thiazolidine-2%2C4-diones+as+potent+and+selective+inhibitors+of+the+PIM-1%2C+PIM-2%2C+and+PIM-3+protein+kinases&doi=10.1016%2Fj.bmcl.2012.05.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases</span></div><div class="casAuthors">Dakin, Les A.; Block, Michael H.; Chen, Huawei; Code, Erin; Dowling, James E.; Feng, Xiaomei; Ferguson, Andrew D.; Green, Isabelle; Hird, Alexander W.; Howard, Tina; Keeton, Erika K.; Lamb, Michelle L.; Lyne, Paul D.; Pollard, Hannah; Read, Jon; Wu, Allan J.; Zhang, Tao; Zheng, Xiaolan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4599-4604</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel substituted benzylidene-1,3-thiazolidine-2,4-diones (TZDs) have been identified as potent and highly selective inhibitors of the PIM kinases.  The synthesis and SAR of these compds. are described, along with x-ray crystallog. of deriv. I, anti-proliferative, and selectivity data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLer-JRufp_rVg90H21EOLACvtfcHk0lgd8u6fzt2vhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1Shtb4%253D&md5=cd1570938d48864bb739d2ccc37888f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.098%26sid%3Dliteratum%253Aachs%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCode%26aufirst%3DE.%26aulast%3DDowling%26aufirst%3DJ.%2BE.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHird%26aufirst%3DA.%2BW.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DKeeton%26aufirst%3DE.%2BK.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DA.%2BJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520benzylidene-1%252C3-thiazolidine-2%252C4-diones%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520PIM-1%252C%2520PIM-2%252C%2520and%2520PIM-3%2520protein%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4599%26epage%3D4604%26doi%3D10.1016%2Fj.bmcl.2012.05.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herberich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurz, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laszlo, J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattson, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastri, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winston, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-L.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">â</span> <span class="NLM_lpage">412</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00403</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00403" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVSjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=408-412&author=V.+J.+Ceeauthor=F.+Chavezauthor=B.+Herberichauthor=B.+A.+Lanmanauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=B.+Wuauthor=R.+P.+Wurzauthor=K.+L.+Andrewsauthor=J.+Chenauthor=D.+Hickmanauthor=J.+Laszloauthor=M.+R.+Leeauthor=N.+Guerreroauthor=B.+K.+Mattsonauthor=Y.+Nguyenauthor=C.+Mohrauthor=K.+Rexauthor=C.+E.+Sastriauthor=P.+Wangauthor=Q.+Wuauthor=T.+Wuauthor=Y.+Xuauthor=Y.+Zhouauthor=J.+T.+Winstonauthor=J.+R.+Lipfordauthor=A.+S.+Taskerauthor=H.-L.+Wang&title=Discovery+and+Optimization+of+Macrocyclic+Quinoxaline-pyrrolo-dihydropiperidinones+as+Potent+Pim-1%2F2+Kinase+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors</span></div><div class="casAuthors">Cee, Victor J.; Chavez, Frank, Jr.; Herberich, Bradley; Lanman, Brian A.; Pettus, Liping H.; Reed, Anthony B.; Wu, Bin; Wurz, Ryan P.; Andrews, Kristin L.; Chen, Jie; Hickman, Dean; Laszlo, Jimmy, III; Lee, Matthew R.; Guerrero, Nadia; Mattson, Bethany K.; Nguyen, Yen; Mohr, Christopher; Rex, Karen; Sastri, Christine E.; Wang, Paul; Wu, Qiong; Wu, Tian; Xu, Yang; Zhou, Yihong; Winston, Jeffrey T.; Lipford, J. Russell; Tasker, Andrew S.; Wang, Hui-Ling</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">408-412</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of Pim-1/2 kinase overexpression in B-cell malignancies suggests that Pim kinase inhibitors will have utility in the treatment of lymphoma, leukemia, and multiple myeloma.  Starting from a moderately potent quinoxaline-dihydropyrrolopiperidinone lead, the authors recognized the potential for macrocyclization and developed a series of 13-membered macrocycles.  The structure-activity relationships of the macrocyclic linker were systematically explored, leading to the identification of I as a potent, subnanomolar inhibitor of Pim-1 and -2.  This mol. also potently inhibited Pim kinase activity in I, a multiple myeloma cell line with relatively high endogenous levels of Pim-1/2, both in vitro (pBAD IC50 = 25 nM) and in vivo (pBAD EC50 = 30 nM, unbound), and a 100 mg/kg daily dose was found to completely arrest the growth of I xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqakxW_TAberrVg90H21EOLACvtfcHk0ljWMZy6YIi0rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVSjsrk%253D&md5=cd64db700aa01012b74e33ba2cbaf501</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00403%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLaszlo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DMattson%26aufirst%3DB.%2BK.%26aulast%3DNguyen%26aufirst%3DY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSastri%26aufirst%3DC.%2BE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWinston%26aufirst%3DJ.%2BT.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DH.-L.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Macrocyclic%2520Quinoxaline-pyrrolo-dihydropiperidinones%2520as%2520Potent%2520Pim-1%252F2%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D408%26epage%3D412%26doi%3D10.1021%2Facsmedchemlett.5b00403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cee, V. J.; Chavez, F.,  Jr.; Chen, J. J.; Harrington, E. H.; Herberich, B.; Jackson, C. L. M.; Lanman, B. A.; Nguyen, T. T.; Norman, M. H.; Pettus, L. H.; Reed, A. B.; Smith, A. L.; Tamayo, N. A.; Tasker, A. S.; Wang, H.-L.; Wu, B.; Wurz, R. P.</span><span> </span><span class="NLM_article-title">Preparation of fused pyridinones and related compounds as Pim kinase inhibitors and their use in the treatment of cancer</span>. US 20150329538, November 19,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=V.+J.+Cee&author=F.+Chavez&author=J.+J.+Chen&author=E.+H.+Harrington&author=B.+Herberich&author=C.+L.+M.+Jackson&author=B.+A.+Lanman&author=T.+T.+Nguyen&author=M.+H.+Norman&author=L.+H.+Pettus&author=A.+B.+Reed&author=A.+L.+Smith&author=N.+A.+Tamayo&author=A.+S.+Tasker&author=H.-L.+Wang&author=B.+Wu&author=R.+P.+Wurz&title=Preparation+of+fused+pyridinones+and+related+compounds+as+Pim+kinase+inhibitors+and+their+use+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26atitle%3DPreparation%2520of%2520fused%2520pyridinones%2520and%2520related%2520compounds%2520as%2520Pim%2520kinase%2520inhibitors%2520and%2520their%2520use%2520in%2520the%2520treatment%2520of%2520cancer%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wang, H.-L.; Cee, V. J.; Chavez, F.,  Jr.; Herberich, B.; Lanman, B. A.; Pettus, L. H.; Reed, A. B.; Wu, B.; Wurz, R. P.; Andrews, K. L.; Chen, J.; Hickman, D.; Huang, X.; Laszlo, J.,  III; Lee, M. R.; Guerrero, N.; Mattson, B. K.; Nguyen, Y.; Mohr, C.; Rex, K.; Lipford, J. R.; Tasker, A. S.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Quinoxaline-pyrrolodihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors</span>. 35th National Medicinal Chemistry Symposium, Chicago, IL, United States, June 26â29, 2016,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>Poster Session.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.-L.+Wang&author=V.+J.+Cee&author=F.+Chavez&author=B.+Herberich&author=B.+A.+Lanman&author=L.+H.+Pettus&author=A.+B.+Reed&author=B.+Wu&author=R.+P.+Wurz&author=K.+L.+Andrews&author=J.+Chen&author=D.+Hickman&author=X.+Huang&author=J.+Laszlo&author=M.+R.+Lee&author=N.+Guerrero&author=B.+K.+Mattson&author=Y.+Nguyen&author=C.+Mohr&author=K.+Rex&author=J.+R.+Lipford&author=A.+S.+Tasker&title=Discovery+and+Optimization+of+Quinoxaline-pyrrolodihydropiperidinones+as+Potent+Pim-1%2F2+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.-L.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Quinoxaline-pyrrolodihydropiperidinones%2520as%2520Potent%2520Pim-1%252F2%2520Kinase%2520Inhibitors%26jtitle%3D35th%2520National%2520Medicinal%2520Chemistry%2520Symposium%252C%2520Chicago%252C%2520IL%252C%2520United%2520States%252C%2520June%252026%25E2%2580%259329%252C%25202016%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">Microsome stability studies: the parent compound (1 Î¼M) was incubated in liver microsomes (rat, dog, and human, 0.25 mg/mL) in potassium phosphate (66.7 mM, pH 7.4) buffered with NADPH (1 mM) at 37 Â°C for 30 min. Intrinsic clearance, CL<sub>int</sub> (Î¼L/min/mg), was estimated from the amount of parent compound remaining. Under these conditions, a cutoff of CL<sub>int</sub> < 100 Î¼L/min/mg of protein was considered desirable.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurz, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winston, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span> </span><span class="NLM_article-title">Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">780</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.12.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2014.12.091" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=775-780&author=B.+Wuauthor=H.-L.+Wangauthor=V.+J.+Ceeauthor=B.+J.+Lanmanauthor=T.+Nixeyauthor=L.+Pettusauthor=A.+B.+Reedauthor=R.+P.+Wurzauthor=N.+Guerreroauthor=C.+Sastriauthor=J.+Winstonauthor=J.+R.+Lipfordauthor=M.+R.+Leeauthor=C.+Mohrauthor=K.+L.+Andrewsauthor=A.+S.+Tasker&title=Discovery+of+5-%281H-indol-5-yl%29-1%2C3%2C4-thiadiazol-2-amines+as+potent+PIM+inhibitors&doi=10.1016%2Fj.bmcl.2014.12.091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.091%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.-L.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DLanman%26aufirst%3DB.%2BJ.%26aulast%3DNixey%26aufirst%3DT.%26aulast%3DPettus%26aufirst%3DL.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DWinston%26aufirst%3DJ.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26atitle%3DDiscovery%2520of%25205-%25281H-indol-5-yl%2529-1%252C3%252C4-thiadiazol-2-amines%2520as%2520potent%2520PIM%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D775%26epage%3D780%26doi%3D10.1016%2Fj.bmcl.2014.12.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wang, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winston, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span> </span><span class="NLM_article-title">The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">840</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.12.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2014.12.068" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=834-840&author=H.-L.+Wangauthor=V.+J.+Ceeauthor=F.+Chavezauthor=B.+J.+Lanmanauthor=A.+B.+Reedauthor=B.+Wuauthor=N.+Guerreroauthor=J.+R.+Lipfordauthor=C.+Sastriauthor=J.+Winstonauthor=K.+L.+Andrewsauthor=X.+Huangauthor=M.+R.+Leeauthor=C.+Mohrauthor=Y.+Xuauthor=Y.+Zhouauthor=A.+S.+Tasker&title=The+discovery+of+novel+3-%28pyrazin-2-yl%29-1H-indazoles+as+potent+pan-Pim+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2014.12.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.068%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.-L.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DLanman%26aufirst%3DB.%2BJ.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DWinston%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26atitle%3DThe%2520discovery%2520of%2520novel%25203-%2528pyrazin-2-yl%2529-1H-indazoles%2520as%2520potent%2520pan-Pim%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D834%26epage%3D840%26doi%3D10.1016%2Fj.bmcl.2014.12.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ohtsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yawata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namba, M.</span><span> </span><span class="NLM_article-title">Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)</span> <span class="citation_source-journal">br J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">â</span> <span class="NLM_lpage">204</span><span class="refDoi">Â DOI: 10.1111/j.1365-2141.1989.tb00252.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1111%2Fj.1365-2141.1989.tb00252.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=2479409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A280%3ADyaK3c%252FlslagtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1989&pages=199-204&author=T.+Ohtsukiauthor=Y.+Yawataauthor=H.+Wadaauthor=T.+Sugiharaauthor=M.+Moriauthor=M.+Namba&title=Two+human+myeloma+cell+lines%2C+amylase-producing+KMS-12-PE+and+amylase-non-producing+KMS-12-BM%2C+were+established+from+a+patient%2C+having+the+same+chromosome+marker%2C+t%2811%3B14%29%28q13%3Bq32%29&doi=10.1111%2Fj.1365-2141.1989.tb00252.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)</span></div><div class="casAuthors">Ohtsuki T; Yawata Y; Wada H; Sugihara T; Mori M; Namba M</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-204</span>
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    </div><div class="casAbstract">Two human myeloma cell lines, KMS-12-PE and KMS-12-BM, were established from a 64-year-old woman with a non-producing type of multiple myeloma.  The KMS-12-PE line originated from the pleural effusion and the KMS-12-BM from the bone marrow.  These two lines showed the same chromosome marker, t(11:14)(q13:q32).  However, their phenotypes of surface markers differed from each other.  KMS-12-BM cells were positive to CD20, CD38 and PCA-1. showing the plasmacytoid (immature plasma cell) stage of B-cell differentiation, while KMS-12-PE cells were positive to CD38 and PCA-1, but not to CD20, indicating the terminal differentiated stage of B-cells.  As seen in the pleural effusion of the patient.  KMS-12-PE cells ectopically produced a salivary type of amylase, but KMS-12-BM cells did not.  Interestingly, the chromosome abnormality of del(1)(p22----pter) near the region of 1p21, where the amylase gene was assigned, was noticed in as many as 76% of KMS-12-PE cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa-mt51XJz39TiMd2aNQVUfW6udTcc2eZnainfqXCDgrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c%252FlslagtQ%253D%253D&md5=fdebafb9ae219b198515126be2c0e364</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.1989.tb00252.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.1989.tb00252.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhtsuki%26aufirst%3DT.%26aulast%3DYawata%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DSugihara%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DNamba%26aufirst%3DM.%26atitle%3DTwo%2520human%2520myeloma%2520cell%2520lines%252C%2520amylase-producing%2520KMS-12-PE%2520and%2520amylase-non-producing%2520KMS-12-BM%252C%2520were%2520established%2520from%2520a%2520patient%252C%2520having%2520the%2520same%2520chromosome%2520marker%252C%2520t%252811%253B14%2529%2528q13%253Bq32%2529%26jtitle%3Dbr%2520J.%2520Haematol.%26date%3D1989%26volume%3D73%26spage%3D199%26epage%3D204%26doi%3D10.1111%2Fj.1365-2141.1989.tb00252.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><div class="note"><p class="first last">Metabolites identified in human hepatocytes for compound <b>17</b> were consistent with oxidation which supported using microsomes for a mechanistic clearance prediction. The predicted clearance was based on in vitro in vivo extrapolation using the well stirred model of hepatic clearance incorporating plasma and microsomal binding. For more about in vitro in vivo extrapolation, please see:</p></div><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">â</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lhaaATm9St6dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">Human Pregnane X Receptor (hPXR) Assay (1 pt): HepG2 cells were transfected with a luciferase reporter construct driven by human CYP3A4 gene and human PXR cDNA. Cells were exposed to test article for 1 day and the luciferase activity was determined by chemiluminescence.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span>I1-receptor Bovine _TO_1 (POC% < 1). For more information on Cerep panel, please visit: <a href="http://www.cerep.fr" class="extLink">http://www.cerep.fr</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=I1-receptor+Bovine+_TO_1+%28POC%25+%3C+1%29.+For+more+information+on+Cerep+panel%2C+please+visit%3A+http%3A%2F%2Fwww.cerep.fr."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span>For kinase profiling protocols, please visit: <a href="http://www.discoverx.com" class="extLink">http://www.discoverx.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+kinase+profiling+protocols%2C+please+visit%3A+http%3A%2F%2Fwww.discoverx.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Amaravadi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">The survival kinases Akt and Pim as potential pharmacological targets</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2618</span><span class="NLM_x">â</span> <span class="NLM_lpage">2624</span><span class="refDoi">Â DOI: 10.1172/JCI26273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1172%2FJCI26273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=16200194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2618-2624&author=R.+Amaravadiauthor=C.+B.+Thompson&title=The+survival+kinases+Akt+and+Pim+as+potential+pharmacological+targets&doi=10.1172%2FJCI26273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The survival kinases Akt and Pim as potential pharmacological targets</span></div><div class="casAuthors">Amaravadi, Ravi; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2618-2624</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  The Akt and Pim kinases are cytoplasmic protein serine/threonine kinases that control programmed cell death (apoptosis) by phosphorylating substrates that regulate both apoptosis and cellular metab.  The phosphatidylinositol 3-kinase-dependent activation of the Akt kinases and the JAK/STAT-dependent induction of the Pim kinases are examples of partially overlapping survival kinase pathways.  Pharmacol. manipulation of such kinases could have a major impact on the treatment of a wide variety of human diseases including cancer, inflammatory disorders, and ischemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUNe0bt5gIJrVg90H21EOLACvtfcHk0lhaaATm9St6dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vL&md5=d501bb9ac92d6d2674d09e6375acb57e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1172%2FJCI26273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI26273%26sid%3Dliteratum%253Aachs%26aulast%3DAmaravadi%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520survival%2520kinases%2520Akt%2520and%2520Pim%2520as%2520potential%2520pharmacological%2520targets%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2618%26epage%3D2624%26doi%3D10.1172%2FJCI26273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargiotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthelsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavolella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAlessio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibolla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santocanale, C.</span><span> </span><span class="NLM_article-title">Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure-Activity Relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">â</span> <span class="NLM_lpage">501</span><span class="refDoi">Â DOI: 10.1021/jm700956r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700956r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFCrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=487-501&author=E.+Vanottiauthor=R.+Amiciauthor=A.+Bargiottiauthor=J.+Berthelsenauthor=R.+Bosottiauthor=A.+Ciavolellaauthor=A.+Cirlaauthor=C.+Cristianiauthor=R.+D%E2%80%99Alessioauthor=B.+Forteauthor=A.+Isacchiauthor=K.+Martinaauthor=M.+Menichincheriauthor=A.+Molinariauthor=A.+Montagnoliauthor=P.+Orsiniauthor=A.+Pillanauthor=F.+Rolettoauthor=A.+Scolaroauthor=M.+Tibollaauthor=B.+Valsasinaauthor=M.+Varasiauthor=D.+Volpiauthor=C.+Santocanale&title=Cdc7+Kinase+Inhibitors%3A+Pyrrolopyridinones+as+Potential+Antitumor+Agents.+1.+Synthesis+and+Structure-Activity+Relationships&doi=10.1021%2Fjm700956r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure-Activity Relationships</span></div><div class="casAuthors">Vanotti, Ermes; Amici, Raffaella; Bargiotti, Alberto; Berthelsen, Jens; Bosotti, Roberta; Ciavolella, Antonella; Cirla, Alessandra; Cristiani, Cinzia; D'Alessio, Roberto; Forte, Barbara; Isacchi, Antonella; Martina, Katia; Menichincheri, Maria; Molinari, Antonio; Montagnoli, Alessia; Orsini, Paolo; Pillan, Antonio; Roletto, Fulvia; Scolaro, Alessandra; Tibolla, Marcellino; Valsasina, Barbara; Varasi, Mario; Volpi, Daniele; Santocanale, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">487-501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cdc7 kinase is an essential protein promoting DNA replication in eukaryotic organisms, inhibition of which can cause selective tumor-cell death in a p53-independent manner, supporting the rationale for developing Cdc7 small-mol. inhibitors for the treatment of cancers.  Herein, the synthesis and structure-activity relationships of 2-heteroaryl-substituted pyrrolopyridinones, e.g. I (R1 = H, Me, Et, HOCH2CH2, F3CCH2, cyclopropylmethyl, etc.; R2 = 3-pyridyl, 4-pyridyl, 2-amino-4-pyrimidinyl, purin-9-yl, etc.), the first potent Cdc7 kinase inhibitors, are described.  Starting from 2-(heteroaryl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, progress toward a simple scaffold, tailored for Cdc7 inhibition, is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUMnkXSdra97Vg90H21EOLACvtfcHk0lgbK64gPCoWyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFCrtQ%253D%253D&md5=211646b7b60414b32e8f85b38706ee10</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm700956r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700956r%26sid%3Dliteratum%253Aachs%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DBargiotti%26aufirst%3DA.%26aulast%3DBerthelsen%26aufirst%3DJ.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DCiavolella%26aufirst%3DA.%26aulast%3DCirla%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DMolinari%26aufirst%3DA.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPillan%26aufirst%3DA.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DTibolla%26aufirst%3DM.%26aulast%3DValsasina%26aufirst%3DB.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVolpi%26aufirst%3DD.%26aulast%3DSantocanale%26aufirst%3DC.%26atitle%3DCdc7%2520Kinase%2520Inhibitors%253A%2520Pyrrolopyridinones%2520as%2520Potential%2520Antitumor%2520Agents.%25201.%2520Synthesis%2520and%2520Structure-Activity%2520Relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D487%26epage%3D501%26doi%3D10.1021%2Fjm700956r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Carpenter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadwick, D. J.</span><span> </span><span class="NLM_article-title">The Scope and Limitations of Carboxamide-Induced Î²-Directed Metalation of 2-Substituted Furan, Thiophene, and 1-Methylpyrrole derivatives. Application of the Method to Syntheses of 2,3-Disubstituted Thiophenes and Furans</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4362</span><span class="NLM_x">â</span> <span class="NLM_lpage">4368</span><span class="refDoi">Â DOI: 10.1021/jo00222a032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00222a032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1985&pages=4362-4368&author=A.+J.+Carpenterauthor=D.+J.+Chadwick&title=The+Scope+and+Limitations+of+Carboxamide-Induced+%CE%B2-Directed+Metalation+of+2-Substituted+Furan%2C+Thiophene%2C+and+1-Methylpyrrole+derivatives.+Application+of+the+Method+to+Syntheses+of+2%2C3-Disubstituted+Thiophenes+and+Furans&doi=10.1021%2Fjo00222a032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo00222a032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00222a032%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DA.%2BJ.%26aulast%3DChadwick%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Scope%2520and%2520Limitations%2520of%2520Carboxamide-Induced%2520%25CE%25B2-Directed%2520Metalation%2520of%25202-Substituted%2520Furan%252C%2520Thiophene%252C%2520and%25201-Methylpyrrole%2520derivatives.%2520Application%2520of%2520the%2520Method%2520to%2520Syntheses%2520of%25202%252C3-Disubstituted%2520Thiophenes%2520and%2520Furans%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1985%26volume%3D50%26spage%3D4362%26epage%3D4368%26doi%3D10.1021%2Fjo00222a032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':[],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kerstin Hiesinger, Dmitry Darâin, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Mikhail Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">Spirocyclic Scaffolds in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 150-183. <a href="https://doi.org/10.1021/acs.jmedchem.0c01473" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSpirocyclic%252BScaffolds%252Bin%252BMedicinal%252BChemistry%26aulast%3DHiesinger%26aufirst%3DKerstin%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24082020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D150%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wooseok Han, Yu Ding, Zheng Chen, John L. Langowski, Cornelia Bellamacina, Alice Rico, Gisele A. Nishiguchi, Jiong Lan, Gordana Atallah, Mika Lindvall, Song Lin, Richard Zang, Paul Feucht, Tatiana Zavorotinskaya, Yumin Dai, Pablo Garcia, <span class="NLM_string-name hlFld-ContribAuthor">Matthew T. Burger</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and StructureâActivity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14885-14904. <a href="https://doi.org/10.1021/acs.jmedchem.0c01279" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01279%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252Bof%252BTetra-Substituted%252BCyclohexyl%252BDiol%252BInhibitors%252Bof%252BProviral%252BInsertion%252Bof%252BMoloney%252BVirus%252B%252528PIM%252529%252BKinases%26aulast%3DHan%26aufirst%3DWooseok%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11082020%26date%3D01122020%26volume%3D63%26issue%3D23%26spage%3D14885%26epage%3D14904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaojing Wang, Wesley Blackaby, Vivienne Allen, Grace Ka Yan Chan, Jae H. Chang, Po-Chang Chiang, Coura DiÃ¨ne, Jason Drummond, Steven Do, Eric Fan, Eric B. Harstad, Alastair Hodges, Huiyong Hu, Wei Jia, William Kofie, Aleksandr Kolesnikov, Joseph P. Lyssikatos, Justin Ly, Mizio Matteucci, John G. Moffat, Veerendra Munugalavadla, Jeremy Murray, David Nash, Cameron L. Noland, Geoff Del Rosario, Leanne Ross, Craig Rouse, Andrew Sharpe, Dionysos Slaga, Minghua Sun, Vickie Tsui, Heidi Wallweber, Shang-Fan Yu, <span class="NLM_string-name hlFld-ContribAuthor">Allen J. Ebens</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (4)
                                     , 2140-2153. <a href="https://doi.org/10.1021/acs.jmedchem.8b01857" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01857</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01857%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252BPan-Pim%252BKinase%252BActivity%252Band%252BOral%252BBioavailability%252BLeading%252Bto%252BDiaminopyrazole%252B%252528GDC-0339%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BMultiple%252BMyeloma%26aulast%3DWang%26aufirst%3DXiaojing%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D27112018%26date%3D20022019%26date%3D04022019%26volume%3D62%26issue%3D4%26spage%3D2140%26epage%3D2153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hui-Ling Wang, Kristin L. Andrews, Shon K. Booker, Jude Canon, Victor J. Cee, Frank Chavez, Jr., Yuping Chen, Heather Eastwood, Nadia Guerrero, Brad Herberich, Dean Hickman, Brian A. Lanman, Jimmy Laszlo, III, Matthew R. Lee, J. Russell Lipford, Bethany Mattson, Christopher Mohr, Yen Nguyen, Mark H. Norman, Liping H. Pettus, David Powers, Anthony B. Reed, Karen Rex, Christine Sastri, Nuria Tamayo, Paul Wang, Jeffrey T. Winston, Bin Wu, Qiong Wu, Tian Wu, Ryan P. Wurz, Yang Xu, Yihong Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Andrew S. Tasker</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1523-1540. <a href="https://doi.org/10.1021/acs.jmedchem.8b01733" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01733</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01733%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-8-%2525286-Methyl-4-oxo-1%25252C4%25252C5%25252C6-tetrahydropyrrolo%25255B3%25252C4-b%25255Dpyrrol-2-yl%252529-3-%2525281-methylcyclopropyl%252529-2-%252528%2525281-methylcyclopropyl%252529amino%252529quinazolin-4%2525283H%252529-one%25252C%252Ba%252BPotent%252Band%252BSelective%252BPim-1%25252F2%252BKinase%252BInhibitor%252Bfor%252BHematological%252BMalignancies%26aulast%3DWang%26aufirst%3DHui-Ling%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D06112018%26date%3D17012019%26date%3D09012019%26volume%3D62%26issue%3D3%26spage%3D1523%26epage%3D1540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">Aleksandr  Kolesnikov</span>, <span class="hlFld-ContribAuthor ">Suzanne  Tay</span>, <span class="hlFld-ContribAuthor ">Grace  Chan</span>, <span class="hlFld-ContribAuthor ">Qi  Chao</span>, <span class="hlFld-ContribAuthor ">Steven  Do</span>, <span class="hlFld-ContribAuthor ">Jason  Drummond</span>, <span class="hlFld-ContribAuthor ">Allen J.  Ebens</span>, <span class="hlFld-ContribAuthor ">Ning  Liu</span>, <span class="hlFld-ContribAuthor ">Justin  Ly</span>, <span class="hlFld-ContribAuthor ">Eric  Harstad</span>, <span class="hlFld-ContribAuthor ">Huiyong  Hu</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, <span class="hlFld-ContribAuthor ">Veerendra  Munugalavadla</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">Dionysos  Slaga</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>, <span class="hlFld-ContribAuthor ">Matthew  Volgraf</span>, <span class="hlFld-ContribAuthor ">Heidi  Wallweber</span>, and <span class="hlFld-ContribAuthor ">Jae H.  Chang</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (10)
                                     , 4458-4473. <a href="https://doi.org/10.1021/acs.jmedchem.7b00418" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00418%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B5-Azaindazole%252B%252528GNE-955%252529%252Bas%252Ba%252BPotent%252BPan-Pim%252BInhibitor%252Bwith%252BOptimized%252BBioavailability%26aulast%3DWang%26aufirst%3DXiaojing%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21032017%26date%3D05052017%26date%3D25052017%26date%3D26042017%26volume%3D60%26issue%3D10%26spage%3D4458%26epage%3D4473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jimil  George</span>, <span class="hlFld-ContribAuthor ">Hun Young  Kim</span>, and <span class="hlFld-ContribAuthor ">Kyungsoo  Oh</span>  . </span><span class="cited-content_cbyCitation_article-title">Substituted Pyrrololactams via Ring Expansion of Spiro-2H-pyrroles from Intermolecular AlkyneâIsocyanide Click Reactions. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (3)
                                     , 628-631. <a href="https://doi.org/10.1021/acs.orglett.6b03786" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b03786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b03786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b03786%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSubstituted%252BPyrrololactams%252Bvia%252BRing%252BExpansion%252Bof%252BSpiro-2H-pyrroles%252Bfrom%252BIntermolecular%252BAlkyne%2525E2%252580%252593Isocyanide%252BClick%252BReactions%26aulast%3DGeorge%26aufirst%3DJimil%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D20122016%26date%3D20012017%26date%3D03022017%26volume%3D19%26issue%3D3%26spage%3D628%26epage%3D631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marion  Peyressatre</span>, <span class="hlFld-ContribAuthor ">Dominique Patomo  Arama</span>, <span class="hlFld-ContribAuthor ">Arthur  Laure</span>, <span class="hlFld-ContribAuthor ">Juan A.  GonzÃ¡lez-Vera</span>, <span class="hlFld-ContribAuthor ">Morgan  Pellerano</span>, <span class="hlFld-ContribAuthor ">Nicolas  Masurier</span>, <span class="hlFld-ContribAuthor ">Vincent  Lisowski</span>, <span class="hlFld-ContribAuthor ">May C.  Morris</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00691" title="DOI URL">https://doi.org/10.3389/fchem.2020.00691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00691%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DIdentification%252Bof%252BQuinazolinone%252BAnalogs%252BTargeting%252BCDK5%252BKinase%252BActivity%252Band%252BGlioblastoma%252BCell%252BProliferation%26aulast%3DPeyressatre%26aufirst%3DMarion%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rabdan M.  Tikhov</span>, <span class="hlFld-ContribAuthor ">Nikolai Yu.  Kuznetsov</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of piperidine-2,4-dione-type azaheterocycles and their application in modern drug development and natural product synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (15)
                                     , 2793-2812. <a href="https://doi.org/10.1039/D0OB00287A" title="DOI URL">https://doi.org/10.1039/D0OB00287A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00287A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00287A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConstruction%252Bof%252Bpiperidine-2%25252C4-dione-type%252Bazaheterocycles%252Band%252Btheir%252Bapplication%252Bin%252Bmodern%252Bdrug%252Bdevelopment%252Band%252Bnatural%252Bproduct%252Bsynthesis%26aulast%3DTikhov%26aufirst%3DRabdan%2BM.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D15%26spage%3D2793%26epage%3D2812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zahra  Rezaei</span>, <span class="hlFld-ContribAuthor ">Mir  Mahdi Didehvar</span>, <span class="hlFld-ContribAuthor ">Mohammad  Mahdavi</span>, <span class="hlFld-ContribAuthor ">Homa  Azizian</span>, <span class="hlFld-ContribAuthor ">Haleh  Hamedifar</span>, <span class="hlFld-ContribAuthor ">Eman H.M.  Mohammed</span>, <span class="hlFld-ContribAuthor ">Sayednaser  Ostad</span>, <span class="hlFld-ContribAuthor ">Mohsen  Amini</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer properties of N-alkyl-2, 4-diphenylimidazo [1, 2-a] quinoxalin-1-amine derivatives; kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>90 </em>, 103055. <a href="https://doi.org/10.1016/j.bioorg.2019.103055" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103055%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAnticancer%252Bproperties%252Bof%252BN-alkyl-2%25252C%252B4-diphenylimidazo%252B%25255B1%25252C%252B2-a%25255D%252Bquinoxalin-1-amine%252Bderivatives%25253B%252Bkinase%252Binhibitors%26aulast%3DRezaei%26aufirst%3DZahra%26date%3D2019%26volume%3D90%26spage%3D103055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohd  Salman</span>, <span class="hlFld-ContribAuthor ">Sarfaraz  Ahmed</span>, <span class="hlFld-ContribAuthor ">Sisir  Nandi</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR and Anticancer Drug Design on Benzothienopyrimidinones as Promising Pim Kinase Inhibitors Utilizing Structural Descriptors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Quantitative Structure-Property Relationships</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 82-99. <a href="https://doi.org/10.4018/IJQSPR.2019040104" title="DOI URL">https://doi.org/10.4018/IJQSPR.2019040104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4018/IJQSPR.2019040104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4018%2FIJQSPR.2019040104%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Quantitative%2520Structure-Property%2520Relationships%26atitle%3DQSAR%252Band%252BAnticancer%252BDrug%252BDesign%252Bon%252BBenzothienopyrimidinones%252Bas%252BPromising%252BPim%252BKinase%252BInhibitors%252BUtilizing%252BStructural%252BDescriptors%26aulast%3DSalman%26aufirst%3DMohd%26date%3D2019%26volume%3D4%26issue%3D2%26spage%3D82%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claude  Barberis</span>, <span class="hlFld-ContribAuthor ">James  Pribish</span>, <span class="hlFld-ContribAuthor ">Elina  Tserlin</span>, <span class="hlFld-ContribAuthor ">Alexandre  Gross</span>, <span class="hlFld-ContribAuthor ">Mark  Czekaj</span>, <span class="hlFld-ContribAuthor ">Matthieu  BarraguÃ©</span>, <span class="hlFld-ContribAuthor ">Paul  Erdman</span>, <span class="hlFld-ContribAuthor ">Sachin  Maniar</span>, <span class="hlFld-ContribAuthor ">John  Jiang</span>, <span class="hlFld-ContribAuthor ">Luke  Fire</span>, <span class="hlFld-ContribAuthor ">Vinod  Patel</span>, <span class="hlFld-ContribAuthor ">Andrew  Hebert</span>, <span class="hlFld-ContribAuthor ">Mikhail  Levit</span>, <span class="hlFld-ContribAuthor ">Anlai  Wang</span>, <span class="hlFld-ContribAuthor ">Frank  Sun</span>, <span class="hlFld-ContribAuthor ">Shih-Min A.  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors â Lead optimization â Part III. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (3)
                                     , 491-495. <a href="https://doi.org/10.1016/j.bmcl.2018.12.015" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.12.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.12.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BN-substituted%252B7-azaindoles%252Bas%252BPan-PIM%252Bkinases%252Binhibitors%252B%2525E2%252580%252593%252BLead%252Boptimization%252B%2525E2%252580%252593%252BPart%252BIII%26aulast%3DBarberis%26aufirst%3DClaude%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D491%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew D.  Harper</span>, <span class="hlFld-ContribAuthor ">R. Alan  Aitken</span>. </span><span class="cited-content_cbyCitation_article-title">The Chemistry of Thieno[c]pyrrolones, Dihydrothieno[c]pyrrolones, and Their Fused Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 227-314. <a href="https://doi.org/10.1016/bs.aihch.2018.09.001" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.09.001%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BChemistry%252Bof%252BThieno%25255Bc%25255Dpyrrolones%25252C%252BDihydrothieno%25255Bc%25255Dpyrrolones%25252C%252Band%252BTheir%252BFused%252BDerivatives%26aulast%3DHarper%26aufirst%3DAndrew%2BD.%26date%3D2019%26spage%3D227%26epage%3D314%26pub%3DElsevier%26date%3D2019%26volume%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claude  Barberis</span>, <span class="hlFld-ContribAuthor ">Neil  Moorcroft</span>, <span class="hlFld-ContribAuthor ">James  Pribish</span>, <span class="hlFld-ContribAuthor ">Elina  Tserlin</span>, <span class="hlFld-ContribAuthor ">Alexandre  Gross</span>, <span class="hlFld-ContribAuthor ">Mark  Czekaj</span>, <span class="hlFld-ContribAuthor ">Matthieu  Barrague</span>, <span class="hlFld-ContribAuthor ">Paul  Erdman</span>, <span class="hlFld-ContribAuthor ">Tahir  Majid</span>, <span class="hlFld-ContribAuthor ">Joseph  Batchelor</span>, <span class="hlFld-ContribAuthor ">Mikhail  Levit</span>, <span class="hlFld-ContribAuthor ">Andrew  Hebert</span>, <span class="hlFld-ContribAuthor ">Liduo  Shen</span>, <span class="hlFld-ContribAuthor ">Sandra  Moreno-Mazza</span>, <span class="hlFld-ContribAuthor ">Anlai  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N -substituted 7-azaindoles as Pan-PIM kinase inhibitors â Lead series identification â Part II. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (20)
                                     , 4735-4740. <a href="https://doi.org/10.1016/j.bmcl.2017.08.068" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.08.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.08.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.08.068%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BN%252B-substituted%252B7-azaindoles%252Bas%252BPan-PIM%252Bkinase%252Binhibitors%252B%2525E2%252580%252593%252BLead%252Bseries%252Bidentification%252B%2525E2%252580%252593%252BPart%252BII%26aulast%3DBarberis%26aufirst%3DClaude%26date%3D2017%26volume%3D27%26issue%3D20%26spage%3D4735%26epage%3D4740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claude  Barberis</span>, <span class="hlFld-ContribAuthor ">Neil  Moorcroft</span>, <span class="hlFld-ContribAuthor ">Chris  Arendt</span>, <span class="hlFld-ContribAuthor ">Mikhail  Levit</span>, <span class="hlFld-ContribAuthor ">Sandra  Moreno-Mazza</span>, <span class="hlFld-ContribAuthor ">Joseph  Batchelor</span>, <span class="hlFld-ContribAuthor ">Ingrid  Mechin</span>, <span class="hlFld-ContribAuthor ">Tahir  Majid</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N -substituted 7-azaindoles as PIM1 kinase inhibitors â Part I. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (20)
                                     , 4730-4734. <a href="https://doi.org/10.1016/j.bmcl.2017.08.069" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.08.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.08.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.08.069%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BN%252B-substituted%252B7-azaindoles%252Bas%252BPIM1%252Bkinase%252Binhibitors%252B%2525E2%252580%252593%252BPart%252BI%26aulast%3DBarberis%26aufirst%3DClaude%26date%3D2017%26volume%3D27%26issue%3D20%26spage%3D4730%26epage%3D4734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Yu  Yu</span>, <span class="hlFld-ContribAuthor ">Mei-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Jun-Xiong  He</span>, <span class="hlFld-ContribAuthor ">Duan-Jian  Tao</span>, <span class="hlFld-ContribAuthor ">Jian-Jun  Yuan</span>, <span class="hlFld-ContribAuthor ">Yi-Yuan  Peng</span>, <span class="hlFld-ContribAuthor ">Zhi-Bin  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Controllable BrÃ¸nsted acid-promoted aerobic oxidation via solvation-induced proton transfer: Metal-free construction of quinazolinones and dihydroquinazolinones. </span><span class="cited-content_cbyCitation_journal-name">Molecular Catalysis</span><span> <strong>2017,</strong> <em>434 </em>, 134-139. <a href="https://doi.org/10.1016/j.mcat.2017.03.006" title="DOI URL">https://doi.org/10.1016/j.mcat.2017.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mcat.2017.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mcat.2017.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Catalysis%26atitle%3DControllable%252BBr%2525C3%2525B8nsted%252Bacid-promoted%252Baerobic%252Boxidation%252Bvia%252Bsolvation-induced%252Bproton%252Btransfer%25253A%252BMetal-free%252Bconstruction%252Bof%252Bquinazolinones%252Band%252Bdihydroquinazolinones%26aulast%3DYu%26aufirst%3DZhi-Yu%26date%3D2017%26volume%3D434%26spage%3D134%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan  Greenwood</span>, <span class="hlFld-ContribAuthor ">Kay  Yeung</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis of novel pyrrololactams and their boronate ester derivatives. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2016,</strong> <em>57 </em>
                                    (51)
                                     , 5812-5814. <a href="https://doi.org/10.1016/j.tetlet.2016.11.047" title="DOI URL">https://doi.org/10.1016/j.tetlet.2016.11.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2016.11.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2016.11.047%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DThe%252Bsynthesis%252Bof%252Bnovel%252Bpyrrololactams%252Band%252Btheir%252Bboronate%252Bester%252Bderivatives%26aulast%3DGreenwood%26aufirst%3DRyan%26date%3D2016%26volume%3D57%26issue%3D51%26spage%3D5812%26epage%3D5814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Christine  Sastri</span>, <span class="hlFld-ContribAuthor ">Derin C.  DâAmico</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Claire L.M.  Jackson</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>, <span class="hlFld-ContribAuthor ">Bin  Wu</span>, <span class="hlFld-ContribAuthor ">Nadia  Guerrero</span>, <span class="hlFld-ContribAuthor ">J. Russell  Lipford</span>, <span class="hlFld-ContribAuthor ">Jeffrey T.  Winston</span>, <span class="hlFld-ContribAuthor ">Yajing  Yang</span>, <span class="hlFld-ContribAuthor ">Paul  Wang</span>, <span class="hlFld-ContribAuthor ">Yen  Nguyen</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Lee</span>, <span class="hlFld-ContribAuthor ">Christopher  Mohr</span>, <span class="hlFld-ContribAuthor ">J.D.  Zhang</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Yang  Xu</span>, <span class="hlFld-ContribAuthor ">Yihong  Zhou</span>, <span class="hlFld-ContribAuthor ">Hui-Ling  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (22)
                                     , 5580-5590. <a href="https://doi.org/10.1016/j.bmcl.2016.09.067" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.09.067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.09.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.09.067%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bimidazopyridazines%252Bas%252Bpotent%252BPim-1%25252F2%252Bkinase%252Binhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2016%26volume%3D26%26issue%3D22%26spage%3D5580%26epage%3D5590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nehad A.  El Sayed</span>, <span class="hlFld-ContribAuthor ">Amal A.  Eissa</span>, <span class="hlFld-ContribAuthor ">Ghada F.  El Masry</span>, <span class="hlFld-ContribAuthor ">MohamedÂ M.  Abdullah</span>, <span class="hlFld-ContribAuthor ">Reem K.  Arafa</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinazolinones and their acyclic analogues as multi-kinase inhibitors: design, synthesis, SAR analysis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (113)
                                     , 111767-111786. <a href="https://doi.org/10.1039/C6RA19137A" title="DOI URL">https://doi.org/10.1039/C6RA19137A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA19137A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA19137A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinazolinones%252Band%252Btheir%252Bacyclic%252Banalogues%252Bas%252Bmulti-kinase%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%25252C%252BSAR%252Banalysis%252Band%252Bbiological%252Bevaluation%26aulast%3DEl%2BSayed%26aufirst%3DNehad%2BA.%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D113%26spage%3D111767%26epage%3D111786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and potency of publicly disclosed Pim kinases inhibitors. *Data from ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">14</a>; <sup>#</sup>data from ref <a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">18</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. In Vitro Metabolism of Compound <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of <b>17</b>/Pim-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ">5IPJ</a>). (a) Inhibitor <b>17</b> occupies the ATP-binding site; hydrogen bond contacts are shown with dashed lines; the red dots represent water molecules; the top of the ATP-binding pocket is omitted for clarity. (b) CPK (CoreyâPaulingâKoltun) rendering of <b>17</b> illustrating that the alkyl substituents form a complementary hydrophobic surface to Leu44, Gly45, Val52, Phe49, and Ile185. The figures were generated with the PyMOL Molecular Graphics System, version 1.7.0.1 SchrÃ¶dinger, LLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) The effect of <b>17</b> on tumor growth in mouse KMS-12 BM xenograft model. (b) The concentration of <b>17</b> in plasma. Data represent the mean (<i>n</i> = 10) Â± SEM for the xenograft study and (<i>n</i> = 2/time point) for the concentration of <b>17</b> in plasma. Statistical significance (*) was determined by repeated measures analysis of variance (RMANOVA) followed by Dunnettâs post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>17</b> on BAD phosphorylation in terminal KMS-12 BM xenograft tumors. Data represent the mean (<i>n</i> = 2) Â± standard deviation. Bars represent levels of pBAD and are expressed as percent of vehicle (POV) of pBAD/total BAD (tBAD). Red dots represent the mean total plasma concentration of <b>17</b>. Statistical significance was evaluated by analysis of variance (ANOVA), followed by the Bonferroni/Dunn post hoc test. * <i>p</i> < 0.0001, ** <i>p</i> < 0.001, *** <i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Structures of Amino-quinoxaline Intermediates <b>AQ1</b>, <b>AQ2</b>, and <b>AQ3</b>, and Synthesis of Boronic Ester <b>BE1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) CDI, THF, (2) mono-<i>t</i>-butyl malonate, MgCl<sub>2</sub>, KO<i>t</i>Bu, 75%; (b) NH<sub>4</sub>OAc, NH<sub>3</sub> in MeOH, chloroacetaldehyde, 63%; (c) NaO<i>t</i>Bu, <i>p</i>TsCl, THF, 70%; (d) TFA, DCM, 50 Â°C; (e) T3P, DIPEA, EtOAc >95% (2 steps); (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, SFC chiral purification, 73%; (g) (BPin)<sub>2</sub>, bis(1,5-cyclooctadiene)di-Î¼-methoxydiiridium(I), 4,4â²-di-<i>t</i>-butyl-2,2â²-dipyridyl, MTBE.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, DMF, 1,2-dibromoethane, 0â70 Â°C, 46%; (b) (2,4-dimethoxyphenyl)methanamine, DMSO, 150 Â°C, 85%; (c) <b>AQ2</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>3</sub>PO<sub>4</sub>, 135 Â°C; (d) TFA, DCM, 22% (2 steps); (e) 1,3-dibromo-5,5-dimethylhydantoin, DMF, 60 Â°C, 83%; (f) hydroxylamine hydrochloride, NaOAc, MeOH, 50 Â°C; (g) SOCl<sub>2</sub>, 55% (2 steps); (h) <b>AQ2</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>3</sub>PO<sub>4</sub>, 105 Â°C, 96%.</p></p></figure><figure data-id="sch4A" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0008.jpeg" id="rightTab-GRAPHIC-d3161e2046-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Aminoquinoxaline-pyrrolopyrrolones <b>7</b>â<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch4A"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>AQ3</b>, K<sub>2</sub>CO<sub>3</sub>, THF, EtOH, RT; (b) AcONH<sub>4</sub>, EtOH, AcOH, 50 Â°C; (c) LiOH then HCl; (d) PyBop or HATU or EDCI, DIPEA; (e) 1) BCl<sub>3</sub>; 2) MsCl, Et<sub>3</sub>N; 3) NaN<sub>3</sub>; 4) PMe<sub>3</sub>; (f) NCS, CHCl<sub>3</sub>, 70%.</p></p></figure><figure data-id="sch4B" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0009.jpeg" id="rightTab-GRAPHIC-d3161e2112-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Aminoquinoxaline-pyrrolopyrrolone <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch4B"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (NH<sub>4</sub>)<sub>2</sub>CO<sub>3</sub>, Et<sub>3</sub>N, DMF, 97%; (b) Pt/C, H<sub>2</sub>, EtOH, 99%; (c) ethyl 2-bromopropionate, 120 Â°C, 96%; (d) H<sub>2</sub>O<sub>2</sub>, NaOH, 85 Â°C, 80%; (e) POCl<sub>3</sub>, 90 Â°C, 49%; (f) <i>t</i>-butylamine, DMSO, 100 Â°C, 83%; (g) <b>BE1</b>, XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, 54%.</p></p></figure><figure data-id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>14</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) NaBH<sub>4</sub>, (2) MsCl, DIPEA, (3) LiHMDS, 77% for <b>14b</b> and 60% for <b>15b</b>; (b) NBS, 34%; (c) H<sub>2</sub>SO<sub>4</sub>, 25%; (d) <b>AQ2</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>3</sub>PO<sub>4</sub>, 26% for <b>14</b> and 52% for <b>15</b>; (e) Br<sub>2</sub>, HOAc; (f) H<sub>2</sub>SO<sub>4</sub>, 130 Â°C, 68% for two steps.</p></p></figure><figure data-id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>16</b>, <b>19</b>, <b>20</b>, and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) diethyl methylmalonate, 220 Â°C; (b) BOP, <i>t</i>-butyl amine, DBU, 21%; (c) <b>BE1</b>, XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, 40% for <b>16</b>, 21% for <b>19</b>, 62% for <b>20</b>, 71% for <b>21</b>; (d) triphosgene, MeNH<sub>2</sub>, 44%; (e) BOP, <i>t</i>-butyl amine, 41%; (f) T3P, CH<sub>3</sub>NH<sub>2</sub>, 62%; (g) <i>t</i>-butylacetyl chloride, 100 Â°C, quant; (h) NaNO<sub>2</sub>, concentrated HCl, CuSO<sub>4</sub>; (i) CH<sub>3</sub>NH<sub>2</sub>, DIPEA, 26% for two steps; (j) Pt/C, H<sub>2</sub>, MeOH, 95%; (k) <i>t</i>-butyl nitrite, TMSN<sub>3</sub>, MeCN, 20%; (l) PPh<sub>3</sub>, <i>t</i>-butyl isocyanate, DBU, 120 Â°C, 45%.</p></p></figure><figure data-id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/medium/jm-2016-00610h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0012.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>17</b>, <b>18</b>, and <b>22</b>â<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00610/20160708/images/large/jm-2016-00610h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00610&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeNH<sub>2</sub>, T3P, EtOAc; 92% for <b>17b</b>, 78% for <b>18b</b>; (b) triphosgene, DIPEA, >95% for both <b>17c</b> and <b>18c</b>; (c) POCl<sub>3</sub>, DIPEA, 84% for <b>17d</b>, 80% for <b>18d,</b> 77% for <b>22d</b>; (d) HNRR<sup>2</sup>; (e) <b>BE1</b>, XPhos Pd G2 or Pd<sub>2</sub>(dba)<sub>3</sub>/X-phos, K<sub>3</sub>PO<sub>4</sub>; (f) (1) MeNCS, (2) MeI, K<sub>2</sub>CO<sub>3</sub>, 97%; (g) <i>m</i>CPBA; (h) LiOH, 94% for two steps; (i) NaH, MeI, 85%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i118">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Brault, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span> </span><span class="NLM_article-title">PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">â</span> <span class="NLM_lpage">1015</span><span class="refDoi">Â DOI: 10.3324/haematol.2009.017079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.3324%2Fhaematol.2009.017079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=20145274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlShu7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=1004-1015&author=L.+Braultauthor=C.+Gasserauthor=F.+Bracherauthor=K.+Huberauthor=S.+Knappauthor=J.+Schwaller&title=PIM+serine%2Fthreonine+kinases+in+the+pathogenesis+and+therapy+of+hematologic+malignancies+and+solid+cancers&doi=10.3324%2Fhaematol.2009.017079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers</span></div><div class="casAuthors">Brault, Laurent; Gasser, Christelle; Bracher, Franz; Huber, Kilian; Knapp, Stefan; Schwaller, Jurg</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1004-1015</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">A review.  The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biol.  Whereas elevated levels of PIM1 and PIM2 were mostly found in hematol. malignancies and prostate cancer, increased PIM3 expression was obsd. in different solid tumors.  PIM kinases are constitutively active and their activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing no. of common as well as isoform-specific substrates including several cell cycle regulators and apoptosis mediators.  PIM1 but not PIM2 seems also to mediate homing and migration of normal and malignant hematopoietic cells by regulating chemokine receptor surface expression.  Knockdown expts. by RNA interference or dominant-neg. acting mutants suggested that PIM kinases are important for maintenance of a transformed phenotype and therefore potential therapeutic targets.  Detn. of the protein structure facilitated identification of an increasing no. of potent small mol. PIM kinase inhibitors with in vitro and in vivo anticancer activity.  Ongoing efforts aim to identify isoform-specific PIM inhibitors that would not only help to dissect the kinase function but hopefully also provide targeted therapeutics.  Here, we summarize the current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematol. malignancies and solid cancers, and we highlight structural principles and recent progress on small mol. PIM kinase inhibitors that are on their way into first clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM0F0X8PArhLVg90H21EOLACvtfcHk0lhhaD4v_WlFag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlShu7%252FO&md5=241c17f65ee9203be2a6ee138a914781</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2009.017079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2009.017079%26sid%3Dliteratum%253Aachs%26aulast%3DBrault%26aufirst%3DL.%26aulast%3DGasser%26aufirst%3DC.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSchwaller%26aufirst%3DJ.%26atitle%3DPIM%2520serine%252Fthreonine%2520kinases%2520in%2520the%2520pathogenesis%2520and%2520therapy%2520of%2520hematologic%2520malignancies%2520and%2520solid%2520cancers%26jtitle%3DHaematologica%26date%3D2010%26volume%3D95%26spage%3D1004%26epage%3D1015%26doi%3D10.3324%2Fhaematol.2009.017079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Nawijn, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alendar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berns, A.</span><span> </span><span class="NLM_article-title">For better or for worse: the role of Pim oncogenes in tumorigenesis</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span><span class="refDoi">Â DOI: 10.1038/nrc2986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1038%2Fnrc2986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=21150935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCjsrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=23-34&author=M.+C.+Nawijnauthor=A.+Alendarauthor=A.+Berns&title=For+better+or+for+worse%3A+the+role+of+Pim+oncogenes+in+tumorigenesis&doi=10.1038%2Fnrc2986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">For better or for worse: the role of Pim oncogenes in tumorigenesis</span></div><div class="casAuthors">Nawijn, Martijn C.; Alendar, Andrej; Berns, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Pim oncogenes are overexpressed in a wide range of tumors from a hematol. and epithelial origin.  Pim genes encode serine/threonine kinases that have been shown to counteract the increased sensitivity to apoptosis induction that is assocd. with MYC-driven tumorigenesis.  Recently, considerable progress has been made in characterizing the pathways of PIM-mediated survival signalling.  Given the unique structure of their active site and the minimal phenotype of mice mutant for all Pim family members, these oncogenes might be promising targets for highly specific and selective drugs with favorable toxicity profiles.  In this Review, we discuss the physiol. functions and oncogenic activities of Pim kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu23UDfObMZrVg90H21EOLACvtfcHk0ljpSyhMQr-kWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCjsrjE&md5=fe08e70454ca8c4d808715db87d195e1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2986%26sid%3Dliteratum%253Aachs%26aulast%3DNawijn%26aufirst%3DM.%2BC.%26aulast%3DAlendar%26aufirst%3DA.%26aulast%3DBerns%26aufirst%3DA.%26atitle%3DFor%2520better%2520or%2520for%2520worse%253A%2520the%2520role%2520of%2520Pim%2520oncogenes%2520in%2520tumorigenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D23%26epage%3D34%26doi%3D10.1038%2Fnrc2986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Yan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemskova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskinen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilly, M.</span><span> </span><span class="NLM_article-title">The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">45358</span><span class="NLM_x">â</span> <span class="NLM_lpage">45367</span><span class="refDoi">Â DOI: 10.1074/jbc.M307933200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1074%2Fjbc.M307933200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=45358-45367&author=B.+Yanauthor=M.+Zemskovaauthor=S.+Holderauthor=V.+Chinauthor=A.+Kraftauthor=P.+J.+Koskinenauthor=M.+Lilly&title=The+PIM-2+kinase+phosphorylates+BAD+on+serine+112+and+reverses+BAD-induced+cell+death&doi=10.1074%2Fjbc.M307933200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307933200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307933200%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DB.%26aulast%3DZemskova%26aufirst%3DM.%26aulast%3DHolder%26aufirst%3DS.%26aulast%3DChin%26aufirst%3DV.%26aulast%3DKraft%26aufirst%3DA.%26aulast%3DKoskinen%26aufirst%3DP.%2BJ.%26aulast%3DLilly%26aufirst%3DM.%26atitle%3DThe%2520PIM-2%2520kinase%2520phosphorylates%2520BAD%2520on%2520serine%2520112%2520and%2520reverses%2520BAD-induced%2520cell%2520death%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D45358%26epage%3D45367%26doi%3D10.1074%2Fjbc.M307933200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Fox, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammerman, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinalli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Master, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodosh, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">â</span> <span class="NLM_lpage">1854</span><span class="refDoi">Â DOI: 10.1101/gad.1105003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1101%2Fgad.1105003" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=1841-1854&author=C.+J.+Foxauthor=P.+S.+Hammermanauthor=R.+M.+Cinalliauthor=S.+R.+Masterauthor=L.+A.+Chodoshauthor=C.+B.+Thompson&title=The+serine%2Fthreonine+kinase+Pim-2+is+a+transcriptionally+regulated+apoptotic+inhibitor&doi=10.1101%2Fgad.1105003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fgad.1105003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1105003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DC.%2BJ.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DCinalli%26aufirst%3DR.%2BM.%26aulast%3DMaster%26aufirst%3DS.%2BR.%26aulast%3DChodosh%26aufirst%3DL.%2BA.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520serine%252Fthreonine%2520kinase%2520Pim-2%2520is%2520a%2520transcriptionally%2520regulated%2520apoptotic%2520inhibitor%26jtitle%3DGenes%2520Dev.%26date%3D2003%26volume%3D17%26spage%3D1841%26epage%3D1854%26doi%3D10.1101%2Fgad.1105003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">An, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.</span><span> </span><span class="NLM_article-title">Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="refDoi">Â DOI: 10.1186/1756-8722-6-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1186%2F1756-8722-6-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=23360755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVyjtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=12&author=N.+Anauthor=A.+S.+Kraftauthor=Y.+Kang&title=Abnormal+hematopoietic+phenotypes+in+Pim+kinase+triple+knockout+mice&doi=10.1186%2F1756-8722-6-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice</span></div><div class="casAuthors">An, Ningfei; Kraft, Andrew S.; Kang, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Pim (proviral insertion in murine lymphoma) kinases are a small family of constitutively active, highly conservative serine/threonine oncogenic kinases and have 3 members: Pim1, Pim2, and Pim3.  Pim kinases are also implicated in the regulation of B- and T-cell responses to cytokines and hematopoietic growth factors.  The roles of Pim kinases in the regulation of primitive hematopoietic stem cells (HSCs) are largely unknown.  Methods: In the current study, Pim1-/-2-/-3-/- triple knockout (TKO) mice were used to det. the role of Pim kinases in hematopoiesis.  Peripheral blood hematol. parameters were measured in Pim TKO mice and age-matched wild-type (WT) controls.  Primary, secondary, and competitive transplantations were performed to assay the long-term repopulating HSCs in Pim TKO mice.  In vivo BrdU incorporation assay and ex vivo Ki67 staining and caspase 3 labeling were performed to evaluate the proliferation and apoptosis of HSCs in Pim TKO mice.  Results: Compared to age-matched WT controls, Pim TKO mice had lower peripheral blood platelet count and exhibited erythrocyte hypochromic microcytosis.  The bone marrow cells from Pim TKO mice demonstrated decreased hematopoietic progenitor colony-forming ability.  Importantly, Pim TKO bone marrow cells had significantly impaired capacity in rescuing lethally irradiated mice and reconstituting hematopoiesis in primary, secondary and competitive transplant models.  In vivo BrdU incorporation in long-term HSCs was reduced in Pim TKO mice.  Finally, cultured HSCs from Pim TKO mice showed reduced proliferation evaluated by Ki67 staining and higher rate of apoptosis via caspase 3 activation.  Conclusions: Pim kinases are not only essential in the hematopoietic lineage cell development, but also important in HSC expansion, self-renewal, and long-term repopulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvaxaUvRqoRbVg90H21EOLACvtfcHk0ljpSyhMQr-kWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVyjtb8%253D&md5=c9a44f6b790facfbdea9e8a0d0915b97</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-12%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DN.%26aulast%3DKraft%26aufirst%3DA.%2BS.%26aulast%3DKang%26aufirst%3DY.%26atitle%3DAbnormal%2520hematopoietic%2520phenotypes%2520in%2520Pim%2520kinase%2520triple%2520knockout%2520mice%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D12%26doi%3D10.1186%2F1756-8722-6-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mikkers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawijn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoeven, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berns, A.</span><span> </span><span class="NLM_article-title">Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">6104</span><span class="NLM_x">â</span> <span class="NLM_lpage">6115</span><span class="refDoi">Â DOI: 10.1128/MCB.24.13.6104-6115.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1128%2FMCB.24.13.6104-6115.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=15199164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1aqtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=6104-6115&author=H.+Mikkersauthor=M.+Nawijnauthor=J.+Allenauthor=C.+Brouwersauthor=E.+Verhoevenauthor=J.+Jonkersauthor=A.+Berns&title=Mice+Deficient+for+All+PIM+Kinases+Display+Reduced+Body+Size+and+Impaired+Responses+to+Hematopoietic+Growth+Factors&doi=10.1128%2FMCB.24.13.6104-6115.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mice deficient for All PIM kinases display reduced body size and impaired responses to hematopoietic growth factors</span></div><div class="casAuthors">Mikkers, Harald; Nawijn, Martijn; Allen, John; Brouwers, Conny; Verhoeven, Els; Jonkers, Jos; Berns, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6104-6115</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Pim family of proto-oncogenes encodes a distinct class of serine/threonine kinases consisting of PIM1, PIM2, and PIM3.  Although the Pim genes are evolutionarily highly conserved, the contribution of PIM proteins to mammalian development is unclear.  PIM1-deficient mice were previously described but showed only minor phenotypic aberrations.  To assess the role of PIM proteins in mammalian physiol., compd. Pim knockout mice were generated.  Mice lacking expression of Pim1, Pim2, and Pim3 are viable and fertile.  However, PIM-deficient mice show a profound redn. in body size at birth and throughout postnatal life.  In addn., the in vitro response of distinct hematopoietic cell populations to growth factors is severely impaired.  In particular, PIM proteins are required for the efficient proliferation of peripheral T lymphocytes mediated by synergistic T-cell receptor and interleukin-2 signaling.  These results indicate that members of the PIM family of proteins are important but dispensable factors for growth factor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY6XNolLKGDrVg90H21EOLACvtfcHk0licEY_7fHX6Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1aqtbo%253D&md5=f062c37a554b2541dad2d03715b7f65d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.13.6104-6115.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.13.6104-6115.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMikkers%26aufirst%3DH.%26aulast%3DNawijn%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBrouwers%26aufirst%3DC.%26aulast%3DVerhoeven%26aufirst%3DE.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DBerns%26aufirst%3DA.%26atitle%3DMice%2520Deficient%2520for%2520All%2520PIM%2520Kinases%2520Display%2520Reduced%2520Body%2520Size%2520and%2520Impaired%2520Responses%2520to%2520Hematopoietic%2520Growth%2520Factors%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D6104%26epage%3D6115%26doi%3D10.1128%2FMCB.24.13.6104-6115.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Qian, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barringer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kronkaitis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mische, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, B.</span><span> </span><span class="NLM_article-title">Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">6130</span><span class="NLM_x">â</span> <span class="NLM_lpage">6137</span><span class="refDoi">Â DOI: 10.1074/jbc.M409123200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1074%2Fjbc.M409123200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=6130-6137&author=K.+C.+Qianauthor=L.+Wangauthor=E.+R.+Hickeyauthor=J.+Studtsauthor=K.+Barringerauthor=C.+Pengauthor=A.+Kronkaitisauthor=J.+Liauthor=A.+Whiteauthor=S.+Mischeauthor=B.+Farmer&title=Structural+Basis+of+Constitutive+Activity+and+a+Unique+Nucleotide+Binding+Mode+of+Human+Pim-1+Kinase&doi=10.1074%2Fjbc.M409123200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M409123200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M409123200%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DStudts%26aufirst%3DJ.%26aulast%3DBarringer%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DKronkaitis%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DMische%26aufirst%3DS.%26aulast%3DFarmer%26aufirst%3DB.%26atitle%3DStructural%2520Basis%2520of%2520Constitutive%2520Activity%2520and%2520a%2520Unique%2520Nucleotide%2520Binding%2520Mode%2520of%2520Human%2520Pim-1%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D6130%26epage%3D6137%26doi%3D10.1074%2Fjbc.M409123200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Blanco-Aparicio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnero, A.</span><span> </span><span class="NLM_article-title">Pim kinases in cancer: diagnostic, prognostic and treatment opportunities</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">â</span> <span class="NLM_lpage">643</span><span class="refDoi">Â DOI: 10.1016/j.bcp.2012.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bcp.2012.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=23041228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Sht7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=629-643&author=C.+Blanco-Aparicioauthor=A.+Carnero&title=Pim+kinases+in+cancer%3A+diagnostic%2C+prognostic+and+treatment+opportunities&doi=10.1016%2Fj.bcp.2012.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities</span></div><div class="casAuthors">Blanco-Aparicio, Carmen; Carnero, Amancio</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-643</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  PIM proteins belong to a family of ser/thr kinases composed of 3 members, PIM1, PIM2 and PIM3, with greatly overlapping functions.  PIM kinases are mainly responsible for cell cycle regulation, antiapoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway.  PIM kinases have been found to be upregulated in many hematol. malignancies and solid tumors.  Although these kinases have been described as weak oncogenes, they are heavily targeted for anticancer drug discovery.  The present review summarizes the discoveries made to date regarding PIM kinases as driving oncogenes in the process of tumorigenesis and their validation as drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtbg06YAgnArVg90H21EOLACvtfcHk0licEY_7fHX6Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Sht7nK&md5=63957a55b281d4bbc8c4843249d30273</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Aparicio%26aufirst%3DC.%26aulast%3DCarnero%26aufirst%3DA.%26atitle%3DPim%2520kinases%2520in%2520cancer%253A%2520diagnostic%252C%2520prognostic%2520and%2520treatment%2520opportunities%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D629%26epage%3D643%26doi%3D10.1016%2Fj.bcp.2012.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Garcia, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langowski, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavorotinskaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narberes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellamacina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holash, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, M. T.</span><span> </span><span class="NLM_article-title">Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1834</span><span class="NLM_x">â</span> <span class="NLM_lpage">1845</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-2062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1158%2F1078-0432.CCR-13-2062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=24474669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1eiu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1834-1845&author=P.+D.+Garciaauthor=J.+L.+Langowskiauthor=Y.+Wangauthor=M.+Chenauthor=J.+Castilloauthor=C.+Fantonauthor=M.+Isonauthor=T.+Zavorotinskayaauthor=Y.+Daiauthor=J.+Luauthor=X.+Niuauthor=S.+Bashamauthor=J.+Chanauthor=J.+Yuauthor=M.+Doyleauthor=P.+Feuchtauthor=R.+Warneauthor=J.+Narberesauthor=T.+Tsangauthor=C.+Fritschauthor=A.+Kauffmannauthor=E.+Pfisterauthor=P.+Drueckesauthor=J.+Trappeauthor=C.+Wilsonauthor=W.+Hanauthor=J.+Lanauthor=G.+Nishiguchiauthor=M.+Lindvallauthor=C.+Bellamacinaauthor=A.+Aycinenaauthor=R.+Zangauthor=J.+Holashauthor=M.+T.+Burger&title=Pan-PIM+Kinase+Inhibition+Provides+a+Novel+Therapy+for+Treating+Hematologic+Cancers&doi=10.1158%2F1078-0432.CCR-13-2062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers</span></div><div class="casAuthors">Garcia, Pablo D.; Langowski, John L.; Wang, Yingyun; Chen, Min; Castillo, Joseph; Fanton, Christie; Ison, Marjorie; Zavorotinskaya, Tatiana; Dai, Yumin; Lu, Jing; Niu, Xiao-Hong; Basham, Stephen; Chan, Julie; Yu, Jianjun; Doyle, Michael; Feucht, Paul; Warne, Robert; Narberes, Jamie; Tsang, Tiffany; Fritsch, Christine; Kauffmann, Audrey; Pfister, Estelle; Drueckes, Peter; Trappe, Joerg; Wilson, Christopher; Han, Wooseok; Lan, Jiong; Nishiguchi, Gisele; Lindvall, Mika; Bellamacina, Cornelia; Aycinena, J. Alex; Zang, Richard; Holash, Jocelyn; Burger, Matthew T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1834-1845</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PIM kinases have been shown to act as oncogenes in mice, with each family member being able to drive progression of hematol. cancers.  Consistent with this, we found that PIMs are highly expressed in human hematol. cancers and show that each isoform has a distinct expression pattern among disease subtypes.  This suggests that inhibitors of all three PIMs would be effective in treating multiple hematol. malignancies.  Pan-PIM inhibitors have proven difficult to develop because PIM2 has a low Km for ATP and, thus, requires a very potent inhibitor to effectively block the kinase activity at the ATP levels in cells.  We developed a potent and specific pan-PIM inhibitor, LGB321, which is active on PIM2 in the cellular context.  LGB321 is active on PIM2-dependent multiple myeloma cell lines, where it inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD.  Broad cancer cell line profiling of LGB321 demonstrates limited activity in cell lines derived from solid tumors.  In contrast, significant activity in cell lines derived from diverse hematol. lineages was obsd., including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), multiple myeloma and non-Hodgkin lymphoma (NHL).  Furthermore, we demonstrate LGB321 activity in the KG-1 AML xenograft model, in which modulation of pharmacodynamics markers is predictive of efficacy.  Finally, we demonstrate that LGB321 synergizes with cytarabine in this model.  We have developed a potent and selective pan-PIM inhibitor with single-agent antiproliferative activity and show that it synergizes with cytarabine in an AML xenograft model.  Our results strongly support the development of Pan-PIM inhibitors to treat hematol. malignancies.  Clin Cancer Res; 20(7); 1834-45. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriy2nkB_psKbVg90H21EOLACvtfcHk0ljqbWhL4nPSeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1eiu7k%253D&md5=c563df328e7af3ebf10c31b1a26faae4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2062%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DP.%2BD.%26aulast%3DLangowski%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCastillo%26aufirst%3DJ.%26aulast%3DFanton%26aufirst%3DC.%26aulast%3DIson%26aufirst%3DM.%26aulast%3DZavorotinskaya%26aufirst%3DT.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DBasham%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDoyle%26aufirst%3DM.%26aulast%3DFeucht%26aufirst%3DP.%26aulast%3DWarne%26aufirst%3DR.%26aulast%3DNarberes%26aufirst%3DJ.%26aulast%3DTsang%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DPfister%26aufirst%3DE.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DBellamacina%26aufirst%3DC.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26atitle%3DPan-PIM%2520Kinase%2520Inhibition%2520Provides%2520a%2520Novel%2520Therapy%2520for%2520Treating%2520Hematologic%2520Cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D1834%26epage%3D1845%26doi%3D10.1158%2F1078-0432.CCR-13-2062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Arunesh, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanthi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishna, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanadhan, V. N.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span><span class="refDoi">Â DOI: 10.1517/13543776.2014.848196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1517%2F13543776.2014.848196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=24131033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5-17&author=G.+M.+Aruneshauthor=E.+Shanthiauthor=M.+H.+Krishnaauthor=J.+S.+Kumarauthor=V.+N.+Viswanadhan&title=Small+molecule+inhibitors+of+PIM1+kinase%3A+July+2009+to+February+2013+patent+update&doi=10.1517%2F13543776.2014.848196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update</span></div><div class="casAuthors">Arunesh, Gubbi M.; Shanthi, Ekambaram; Krishna, Mudeenahally H.; Sooriya Kumar, Jegatheesan; Viswanadhan, Vellarkad N.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-17</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The proviral insertion in murine (PIM) lymphoma proteins for which three isoforms, PIM1, PIM2 and PIM3 have been identified, belonging to the family of serine/threonine kinases has emerged recently as an important therapeutic target for the development of selective inhibitors as the new drugs for treating hematol. malignancies and solid tumors.  The small mols. developed by academia and the pharmaceutical industry have steadily increased in the last few years.  Several drug discovery groups focus on treating disorders, such as cancer mediated by PIM kinase, have provided preclin. evidence suggesting that PIM inhibitor provides anti-apoptotic activity, inhibit cell survival and cell proliferation.  Areas covered: This article discloses recent reviews on research and advances published in the patent literature and scientific publications from July 2009 to Feb. 2013, highlighting discoveries on PIM1 kinase.  Expert opinion: Several PIM1 kinase small mol. inhibitors are now at the pre-clin. research stage, development and testing.  Though nearly 40 patents emerged in the last 3 years, greater efforts towards addnl. designs and medicinal chem. continues for developing clin. efficacious PIM1 inhibitors, due to the significance of the target for cancer and the potential for novel and diverse inhibitors as drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWHvcymSiEcLVg90H21EOLACvtfcHk0ljqbWhL4nPSeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvM&md5=3980e3504d9f044196cc167a37762b9b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.848196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.848196%26sid%3Dliteratum%253Aachs%26aulast%3DArunesh%26aufirst%3DG.%2BM.%26aulast%3DShanthi%26aufirst%3DE.%26aulast%3DKrishna%26aufirst%3DM.%2BH.%26aulast%3DKumar%26aufirst%3DJ.%2BS.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520PIM1%2520kinase%253A%2520July%25202009%2520to%2520February%25202013%2520patent%2520update%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D5%26epage%3D17%26doi%3D10.1517%2F13543776.2014.848196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Merkel, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meggers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocker, M.</span><span> </span><span class="NLM_article-title">PIM1 kinase as a target for cancer therapy</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">â</span> <span class="NLM_lpage">436</span><span class="refDoi">Â DOI: 10.1517/13543784.2012.668527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1517%2F13543784.2012.668527" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=425-436&author=A.+L.+Merkelauthor=E.+Meggersauthor=M.+Ocker&title=PIM1+kinase+as+a+target+for+cancer+therapy&doi=10.1517%2F13543784.2012.668527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.668527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.668527%26sid%3Dliteratum%253Aachs%26aulast%3DMerkel%26aufirst%3DA.%2BL.%26aulast%3DMeggers%26aufirst%3DE.%26aulast%3DOcker%26aufirst%3DM.%26atitle%3DPIM1%2520kinase%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D425%26epage%3D436%26doi%3D10.1517%2F13543784.2012.668527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Drygin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryckman, D. M.</span><span> </span><span class="NLM_article-title">Potential Use of Selective and Nonselective Pim Kinase Inhibitors for Cancer Therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8199</span><span class="NLM_x">â</span> <span class="NLM_lpage">8208</span><span class="refDoi">Â DOI: 10.1021/jm3009234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8199-8208&author=D.+Dryginauthor=M.+Haddachauthor=F.+Pierreauthor=D.+M.+Ryckman&title=Potential+Use+of+Selective+and+Nonselective+Pim+Kinase+Inhibitors+for+Cancer+Therapy&doi=10.1021%2Fjm3009234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm3009234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009234%26sid%3Dliteratum%253Aachs%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DPotential%2520Use%2520of%2520Selective%2520and%2520Nonselective%2520Pim%2520Kinase%2520Inhibitors%2520for%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8199%26epage%3D8208%26doi%3D10.1021%2Fjm3009234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G. K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span> </span><span class="NLM_article-title">Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5258</span><span class="NLM_x">â</span> <span class="NLM_lpage">5264</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.09.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2015.09.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5258-5264&author=H.+Huauthor=X.+Wangauthor=G.+K.+Y.+Chanauthor=J.+H.+Changauthor=S.+Doauthor=J.+Drummondauthor=A.+Ebensauthor=W.+Leeauthor=J.+Lyauthor=J.+P.+Lyssikatosauthor=J.+Murrayauthor=J.+G.+Moffatauthor=Q.+Chaoauthor=V.+Tsuiauthor=H.+Wallweberauthor=A.+Kolesnikov&title=Discovery+of+3%2C5-substituted+6-azaindazoles+as+potent+pan-Pim+inhibitors&doi=10.1016%2Fj.bmcl.2015.09.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.052%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DKolesnikov%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25203%252C5-substituted%25206-azaindazoles%2520as%2520potent%2520pan-Pim%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5258%26epage%3D5264%26doi%3D10.1016%2Fj.bmcl.2015.09.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Burger, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atallah, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellamacina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavorotinskaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holash, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langowski, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanasse, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, P. D.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8373</span><span class="NLM_x">â</span> <span class="NLM_lpage">8386</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8373-8386&author=M.+T.+Burgerauthor=G.+Nishiguchiauthor=W.+Hanauthor=J.+Lanauthor=R.+Simmonsauthor=G.+Atallahauthor=Y.+Dingauthor=V.+Tamezauthor=Y.+Zhangauthor=M.+Mathurauthor=K.+Mullerauthor=C.+Bellamacinaauthor=M.+K.+Lindvallauthor=R.+Zangauthor=K.+Huhauthor=P.+Feuchtauthor=T.+Zavorotinskayaauthor=Y.+Daiauthor=S.+Bashamauthor=J.+Chanauthor=E.+Ginnauthor=A.+Aycinenaauthor=J.+Holashauthor=J.+Castilloauthor=J.+L.+Langowskiauthor=Y.+Wangauthor=M.+Y.+Chenauthor=A.+Lambertauthor=C.+Fritschauthor=A.+Kauffmannauthor=E.+Pfisterauthor=K.+G.+Vanasseauthor=P.+D.+Garcia&title=Identification+of+N-%284-%28%281R%2C3S%2C5S%29-3-Amino-5-methylcyclohexyl%29pyridin-3-yl%29-6-%282%2C6-difluorophenyl%29-5-fluoropicolinamide+%28PIM447%29%2C+a+Potent+and+Selective+Proviral+Insertion+Site+of+Moloney+Murine+Leukemia+%28PIM%29+1%2C+2%2C+and+3+Kinase+Inhibitor+in+Clinical+Trials+for+Hematological+Malignancies&doi=10.1021%2Facs.jmedchem.5b01275"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01275%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DR.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMathur%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DBellamacina%26aufirst%3DC.%26aulast%3DLindvall%26aufirst%3DM.%2BK.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DFeucht%26aufirst%3DP.%26aulast%3DZavorotinskaya%26aufirst%3DT.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DBasham%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DGinn%26aufirst%3DE.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DCastillo%26aufirst%3DJ.%26aulast%3DLangowski%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%2BY.%26aulast%3DLambert%26aufirst%3DA.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DPfister%26aufirst%3DE.%26aulast%3DVanasse%26aufirst%3DK.%2BG.%26aulast%3DGarcia%26aufirst%3DP.%2BD.%26atitle%3DIdentification%2520of%2520N-%25284-%2528%25281R%252C3S%252C5S%2529-3-Amino-5-methylcyclohexyl%2529pyridin-3-yl%2529-6-%25282%252C6-difluorophenyl%2529-5-fluoropicolinamide%2520%2528PIM447%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Proviral%2520Insertion%2520Site%2520of%2520Moloney%2520Murine%2520Leukemia%2520%2528PIM%2529%25201%252C%25202%252C%2520and%25203%2520Kinase%2520Inhibitor%2520in%2520Clinical%2520Trials%2520for%2520Hematological%2520Malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8373%26epage%3D8386%26doi%3D10.1021%2Facs.jmedchem.5b01275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Mumenthaler, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, P. Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanekal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taverna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agus, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, A.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2882</span><span class="NLM_x">â</span> <span class="NLM_lpage">2893</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1158%2F1535-7163.MCT-09-0293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=19825806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2882-2893&author=S.+M.+Mumenthalerauthor=P.+Y.+B.+Ngauthor=A.+Hodgeauthor=D.+Bearssauthor=G.+Berkauthor=S.+Kanekalauthor=S.+Redkarauthor=P.+Tavernaauthor=D.+B.+Agusauthor=A.+Jain&title=Pharmacologic+inhibition+of+Pim+kinases+alters+prostate+cancer+cell+growth+and+resensitizes+chemoresistant+cells+to+taxanes&doi=10.1158%2F1535-7163.MCT-09-0293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes</span></div><div class="casAuthors">Mumenthaler, Shannon M.; Ng, Patricia Y. B.; Hodge, Amanda; Bearss, David; Berk, Gregory; Kanekal, Sarath; Redkar, Sanjeev; Taverna, Pietro; Agus, David B.; Jain, Anjali</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2882-2893</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine family of Pim kinases function as oncogenes and have been implicated in prostate cancer progression, particularly in hormone-refractory prostate disease, as a result of their antiapoptotic function.  In this study, we used a pharmacol. inhibitor targeting the Pim family members, SGI-1776, to det. whether modulation of Pim kinase activity could alter prostate cancer cell survival and modulate chemotherapy resistance.  Extensive biochem. characterization of SGI-1776 confirmed its specificity for the three isoforms of the Pim family.  Treatment of prostate cancer cells with SGI-1776 resulted in a dose-dependent redn. in phosphorylation of known Pim kinase substrates that are involved in cell cycle progression and apoptosis (p21Cip1/WAF1 and Bad).  Consequently, SGI-1776 compromised overall cell viability by inducing G1 cell cycle arrest and triggering apoptosis.  Overexpression of recombinant Pim-1 markedly increased sensitivity of SGI-1776-mediated prostate cancer cell apoptosis and p21Cip1/WAF1 phosphorylation inhibition, reinforcing the specificity of SGI-1776.  An addnl. cytotoxic effect was obsd. when SGI-1776 was combined with taxane-based chemotherapy agents.  SGI-1776 was able to reduce cell viability in a multidrug resistance 1 protein-based taxane-refractory prostate cancer cell line.  In addn., SGI-1776 treatment was able to resensitize chemoresistant cells to taxane-based therapies by inhibiting multidrug resistance 1 activity and inducing apoptosis.  These findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clin. problem of chemoresistance. [Mol Cancer Ther 2009;8(10):2882-93].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnGQXKbXm4Y7Vg90H21EOLACvtfcHk0lj529QHvKswgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7E&md5=b6353cdc3b367e336a707147e5c99a4c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0293%26sid%3Dliteratum%253Aachs%26aulast%3DMumenthaler%26aufirst%3DS.%2BM.%26aulast%3DNg%26aufirst%3DP.%2BY.%2BB.%26aulast%3DHodge%26aufirst%3DA.%26aulast%3DBearss%26aufirst%3DD.%26aulast%3DBerk%26aufirst%3DG.%26aulast%3DKanekal%26aufirst%3DS.%26aulast%3DRedkar%26aufirst%3DS.%26aulast%3DTaverna%26aufirst%3DP.%26aulast%3DAgus%26aufirst%3DD.%2BB.%26aulast%3DJain%26aufirst%3DA.%26atitle%3DPharmacologic%2520inhibition%2520of%2520Pim%2520kinases%2520alters%2520prostate%2520cancer%2520cell%2520growth%2520and%2520resensitizes%2520chemoresistant%2520cells%2520to%2520taxanes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2882%26epage%3D2893%26doi%3D10.1158%2F1535-7163.MCT-09-0293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Keeton, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEachern, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillman, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palakurthi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grondine, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platanias, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span> </span><span class="NLM_article-title">AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">â</span> <span class="NLM_lpage">913</span><span class="refDoi">Â DOI: 10.1182/blood-2013-04-495366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1182%2Fblood-2013-04-495366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=24363397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFaqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=905-913&author=E.+K.+Keetonauthor=K.+McEachernauthor=K.+S.+Dillmanauthor=S.+Palakurthiauthor=Y.+Caoauthor=M.+R.+Grondineauthor=S.+Kaurauthor=S.+Wangauthor=Y.+Chenauthor=A.+Wuauthor=M.+Shenauthor=F.+D.+Gibbonsauthor=M.+L.+Lambauthor=X.+Zhengauthor=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=L.+C.+Plataniasauthor=L.+A.+Dakinauthor=H.+Chenauthor=P.+D.+Lyneauthor=D.+Huszar&title=AZD1208%2C+a+potent+and+selective+pan-Pim+kinase+inhibitor%2C+demonstrates+efficacy+in+preclinical+models+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-04-495366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia</span></div><div class="casAuthors">Keeton, Erika K.; McEachern, Kristen; Dillman, Keith S.; Palakurthi, Sangeetha; Cao, Yichen; Grondine, Michael R.; Kaur, Surinder; Wang, Suping; Chen, Yuching; Wu, Allan; Shen, Minhui; Gibbson, Francis D.; Lamb, Michelle L.; Zheng, Xiaolan; Stone, Richard M.; DeAngelo, Daniel J.; Platanias, Leonidas C.; Dakin, Les A.; Chen, Huawei; Lyne, Paul D.; Huszar, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">905-913</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Upregulation of Pim kinases is obsd. in several types of leukemias and lymphomas.  Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways.  AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at <5 nM or <150 nM in enzyme and cell assays, resp.  AZD1208 inhibited the growth of 5 of 14 acute myeloid leukemia (AML) cell lines tested, and sensitivity correlates with Pim-1 expression and STAT5 activation.  AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells, accompanied by a dose-dependent redn. in phosphorylation of Bcl-2 antagonist of cell death, 4EBP1, p70S6K, and S6, as well as increases in cleaved caspase 3 and p27.  Inhibition of p4EBP1 and p-p70S6K and suppression of translation are the most representative effects of Pim inhibition in sensitive AML cell lines.  AZD1208 inhibits the growth of MOLM-16 and KG-1a xenograft tumors in vivo with a clear pharmacodynamic-pharmacokinetic relationship.  AZD1208 also potently inhibits colony growth and Pim signaling substrates in primary AML cells from bone marrow that are Flt3 wild-type or Flt3 internal tandem duplication mutant.  These results underscore the therapeutic potential of Pim kinase inhibition for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGYuN7tp7NrVg90H21EOLACvtfcHk0lhPFa-TPpUk0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFaqs7o%253D&md5=4277790b53c9064787cbd68c159e552b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-04-495366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-04-495366%26sid%3Dliteratum%253Aachs%26aulast%3DKeeton%26aufirst%3DE.%2BK.%26aulast%3DMcEachern%26aufirst%3DK.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DGrondine%26aufirst%3DM.%2BR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DGibbons%26aufirst%3DF.%2BD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DPlatanias%26aufirst%3DL.%2BC.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DHuszar%26aufirst%3DD.%26atitle%3DAZD1208%252C%2520a%2520potent%2520and%2520selective%2520pan-Pim%2520kinase%2520inhibitor%252C%2520demonstrates%2520efficacy%2520in%2520preclinical%2520models%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D905%26epage%3D913%26doi%3D10.1182%2Fblood-2013-04-495366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Code, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hird, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeton, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span> </span><span class="NLM_article-title">Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4599</span><span class="NLM_x">â</span> <span class="NLM_lpage">4604</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.05.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2012.05.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=22727640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1Shtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4599-4604&author=L.+A.+Dakinauthor=M.+H.+Blockauthor=H.+Chenauthor=E.+Codeauthor=J.+E.+Dowlingauthor=X.+Fengauthor=A.+D.+Fergusonauthor=I.+Greenauthor=A.+W.+Hirdauthor=T.+Howardauthor=E.+K.+Keetonauthor=M.+L.+Lambauthor=P.+D.+Lyneauthor=H.+Pollardauthor=J.+Readauthor=A.+J.+Wuauthor=T.+Zhangauthor=X.+Zheng&title=Discovery+of+novel+benzylidene-1%2C3-thiazolidine-2%2C4-diones+as+potent+and+selective+inhibitors+of+the+PIM-1%2C+PIM-2%2C+and+PIM-3+protein+kinases&doi=10.1016%2Fj.bmcl.2012.05.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases</span></div><div class="casAuthors">Dakin, Les A.; Block, Michael H.; Chen, Huawei; Code, Erin; Dowling, James E.; Feng, Xiaomei; Ferguson, Andrew D.; Green, Isabelle; Hird, Alexander W.; Howard, Tina; Keeton, Erika K.; Lamb, Michelle L.; Lyne, Paul D.; Pollard, Hannah; Read, Jon; Wu, Allan J.; Zhang, Tao; Zheng, Xiaolan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4599-4604</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel substituted benzylidene-1,3-thiazolidine-2,4-diones (TZDs) have been identified as potent and highly selective inhibitors of the PIM kinases.  The synthesis and SAR of these compds. are described, along with x-ray crystallog. of deriv. I, anti-proliferative, and selectivity data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLer-JRufp_rVg90H21EOLACvtfcHk0lhPFa-TPpUk0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1Shtb4%253D&md5=cd1570938d48864bb739d2ccc37888f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.098%26sid%3Dliteratum%253Aachs%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCode%26aufirst%3DE.%26aulast%3DDowling%26aufirst%3DJ.%2BE.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHird%26aufirst%3DA.%2BW.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DKeeton%26aufirst%3DE.%2BK.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DA.%2BJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520benzylidene-1%252C3-thiazolidine-2%252C4-diones%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520PIM-1%252C%2520PIM-2%252C%2520and%2520PIM-3%2520protein%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4599%26epage%3D4604%26doi%3D10.1016%2Fj.bmcl.2012.05.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herberich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurz, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laszlo, J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattson, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastri, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winston, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-L.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">â</span> <span class="NLM_lpage">412</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00403</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00403" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVSjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=408-412&author=V.+J.+Ceeauthor=F.+Chavezauthor=B.+Herberichauthor=B.+A.+Lanmanauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=B.+Wuauthor=R.+P.+Wurzauthor=K.+L.+Andrewsauthor=J.+Chenauthor=D.+Hickmanauthor=J.+Laszloauthor=M.+R.+Leeauthor=N.+Guerreroauthor=B.+K.+Mattsonauthor=Y.+Nguyenauthor=C.+Mohrauthor=K.+Rexauthor=C.+E.+Sastriauthor=P.+Wangauthor=Q.+Wuauthor=T.+Wuauthor=Y.+Xuauthor=Y.+Zhouauthor=J.+T.+Winstonauthor=J.+R.+Lipfordauthor=A.+S.+Taskerauthor=H.-L.+Wang&title=Discovery+and+Optimization+of+Macrocyclic+Quinoxaline-pyrrolo-dihydropiperidinones+as+Potent+Pim-1%2F2+Kinase+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors</span></div><div class="casAuthors">Cee, Victor J.; Chavez, Frank, Jr.; Herberich, Bradley; Lanman, Brian A.; Pettus, Liping H.; Reed, Anthony B.; Wu, Bin; Wurz, Ryan P.; Andrews, Kristin L.; Chen, Jie; Hickman, Dean; Laszlo, Jimmy, III; Lee, Matthew R.; Guerrero, Nadia; Mattson, Bethany K.; Nguyen, Yen; Mohr, Christopher; Rex, Karen; Sastri, Christine E.; Wang, Paul; Wu, Qiong; Wu, Tian; Xu, Yang; Zhou, Yihong; Winston, Jeffrey T.; Lipford, J. Russell; Tasker, Andrew S.; Wang, Hui-Ling</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">408-412</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of Pim-1/2 kinase overexpression in B-cell malignancies suggests that Pim kinase inhibitors will have utility in the treatment of lymphoma, leukemia, and multiple myeloma.  Starting from a moderately potent quinoxaline-dihydropyrrolopiperidinone lead, the authors recognized the potential for macrocyclization and developed a series of 13-membered macrocycles.  The structure-activity relationships of the macrocyclic linker were systematically explored, leading to the identification of I as a potent, subnanomolar inhibitor of Pim-1 and -2.  This mol. also potently inhibited Pim kinase activity in I, a multiple myeloma cell line with relatively high endogenous levels of Pim-1/2, both in vitro (pBAD IC50 = 25 nM) and in vivo (pBAD EC50 = 30 nM, unbound), and a 100 mg/kg daily dose was found to completely arrest the growth of I xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqakxW_TAberrVg90H21EOLACvtfcHk0ljImvcUj_Jhiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVSjsrk%253D&md5=cd64db700aa01012b74e33ba2cbaf501</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00403%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLaszlo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DMattson%26aufirst%3DB.%2BK.%26aulast%3DNguyen%26aufirst%3DY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSastri%26aufirst%3DC.%2BE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWinston%26aufirst%3DJ.%2BT.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DH.-L.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Macrocyclic%2520Quinoxaline-pyrrolo-dihydropiperidinones%2520as%2520Potent%2520Pim-1%252F2%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D408%26epage%3D412%26doi%3D10.1021%2Facsmedchemlett.5b00403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cee, V. J.; Chavez, F.,  Jr.; Chen, J. J.; Harrington, E. H.; Herberich, B.; Jackson, C. L. M.; Lanman, B. A.; Nguyen, T. T.; Norman, M. H.; Pettus, L. H.; Reed, A. B.; Smith, A. L.; Tamayo, N. A.; Tasker, A. S.; Wang, H.-L.; Wu, B.; Wurz, R. P.</span><span> </span><span class="NLM_article-title">Preparation of fused pyridinones and related compounds as Pim kinase inhibitors and their use in the treatment of cancer</span>. US 20150329538, November 19,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=V.+J.+Cee&author=F.+Chavez&author=J.+J.+Chen&author=E.+H.+Harrington&author=B.+Herberich&author=C.+L.+M.+Jackson&author=B.+A.+Lanman&author=T.+T.+Nguyen&author=M.+H.+Norman&author=L.+H.+Pettus&author=A.+B.+Reed&author=A.+L.+Smith&author=N.+A.+Tamayo&author=A.+S.+Tasker&author=H.-L.+Wang&author=B.+Wu&author=R.+P.+Wurz&title=Preparation+of+fused+pyridinones+and+related+compounds+as+Pim+kinase+inhibitors+and+their+use+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26atitle%3DPreparation%2520of%2520fused%2520pyridinones%2520and%2520related%2520compounds%2520as%2520Pim%2520kinase%2520inhibitors%2520and%2520their%2520use%2520in%2520the%2520treatment%2520of%2520cancer%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wang, H.-L.; Cee, V. J.; Chavez, F.,  Jr.; Herberich, B.; Lanman, B. A.; Pettus, L. H.; Reed, A. B.; Wu, B.; Wurz, R. P.; Andrews, K. L.; Chen, J.; Hickman, D.; Huang, X.; Laszlo, J.,  III; Lee, M. R.; Guerrero, N.; Mattson, B. K.; Nguyen, Y.; Mohr, C.; Rex, K.; Lipford, J. R.; Tasker, A. S.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Quinoxaline-pyrrolodihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors</span>. 35th National Medicinal Chemistry Symposium, Chicago, IL, United States, June 26â29, 2016,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>Poster Session.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.-L.+Wang&author=V.+J.+Cee&author=F.+Chavez&author=B.+Herberich&author=B.+A.+Lanman&author=L.+H.+Pettus&author=A.+B.+Reed&author=B.+Wu&author=R.+P.+Wurz&author=K.+L.+Andrews&author=J.+Chen&author=D.+Hickman&author=X.+Huang&author=J.+Laszlo&author=M.+R.+Lee&author=N.+Guerrero&author=B.+K.+Mattson&author=Y.+Nguyen&author=C.+Mohr&author=K.+Rex&author=J.+R.+Lipford&author=A.+S.+Tasker&title=Discovery+and+Optimization+of+Quinoxaline-pyrrolodihydropiperidinones+as+Potent+Pim-1%2F2+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.-L.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Quinoxaline-pyrrolodihydropiperidinones%2520as%2520Potent%2520Pim-1%252F2%2520Kinase%2520Inhibitors%26jtitle%3D35th%2520National%2520Medicinal%2520Chemistry%2520Symposium%252C%2520Chicago%252C%2520IL%252C%2520United%2520States%252C%2520June%252026%25E2%2580%259329%252C%25202016%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">Microsome stability studies: the parent compound (1 Î¼M) was incubated in liver microsomes (rat, dog, and human, 0.25 mg/mL) in potassium phosphate (66.7 mM, pH 7.4) buffered with NADPH (1 mM) at 37 Â°C for 30 min. Intrinsic clearance, CL<sub>int</sub> (Î¼L/min/mg), was estimated from the amount of parent compound remaining. Under these conditions, a cutoff of CL<sub>int</sub> < 100 Î¼L/min/mg of protein was considered desirable.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurz, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winston, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span> </span><span class="NLM_article-title">Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">780</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.12.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2014.12.091" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=775-780&author=B.+Wuauthor=H.-L.+Wangauthor=V.+J.+Ceeauthor=B.+J.+Lanmanauthor=T.+Nixeyauthor=L.+Pettusauthor=A.+B.+Reedauthor=R.+P.+Wurzauthor=N.+Guerreroauthor=C.+Sastriauthor=J.+Winstonauthor=J.+R.+Lipfordauthor=M.+R.+Leeauthor=C.+Mohrauthor=K.+L.+Andrewsauthor=A.+S.+Tasker&title=Discovery+of+5-%281H-indol-5-yl%29-1%2C3%2C4-thiadiazol-2-amines+as+potent+PIM+inhibitors&doi=10.1016%2Fj.bmcl.2014.12.091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.091%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.-L.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DLanman%26aufirst%3DB.%2BJ.%26aulast%3DNixey%26aufirst%3DT.%26aulast%3DPettus%26aufirst%3DL.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DWinston%26aufirst%3DJ.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26atitle%3DDiscovery%2520of%25205-%25281H-indol-5-yl%2529-1%252C3%252C4-thiadiazol-2-amines%2520as%2520potent%2520PIM%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D775%26epage%3D780%26doi%3D10.1016%2Fj.bmcl.2014.12.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wang, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winston, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span> </span><span class="NLM_article-title">The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">840</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.12.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1016%2Fj.bmcl.2014.12.068" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=834-840&author=H.-L.+Wangauthor=V.+J.+Ceeauthor=F.+Chavezauthor=B.+J.+Lanmanauthor=A.+B.+Reedauthor=B.+Wuauthor=N.+Guerreroauthor=J.+R.+Lipfordauthor=C.+Sastriauthor=J.+Winstonauthor=K.+L.+Andrewsauthor=X.+Huangauthor=M.+R.+Leeauthor=C.+Mohrauthor=Y.+Xuauthor=Y.+Zhouauthor=A.+S.+Tasker&title=The+discovery+of+novel+3-%28pyrazin-2-yl%29-1H-indazoles+as+potent+pan-Pim+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2014.12.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.068%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.-L.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DLanman%26aufirst%3DB.%2BJ.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DWinston%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26atitle%3DThe%2520discovery%2520of%2520novel%25203-%2528pyrazin-2-yl%2529-1H-indazoles%2520as%2520potent%2520pan-Pim%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D834%26epage%3D840%26doi%3D10.1016%2Fj.bmcl.2014.12.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ohtsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yawata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namba, M.</span><span> </span><span class="NLM_article-title">Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)</span> <span class="citation_source-journal">br J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">â</span> <span class="NLM_lpage">204</span><span class="refDoi">Â DOI: 10.1111/j.1365-2141.1989.tb00252.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1111%2Fj.1365-2141.1989.tb00252.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=2479409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A280%3ADyaK3c%252FlslagtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1989&pages=199-204&author=T.+Ohtsukiauthor=Y.+Yawataauthor=H.+Wadaauthor=T.+Sugiharaauthor=M.+Moriauthor=M.+Namba&title=Two+human+myeloma+cell+lines%2C+amylase-producing+KMS-12-PE+and+amylase-non-producing+KMS-12-BM%2C+were+established+from+a+patient%2C+having+the+same+chromosome+marker%2C+t%2811%3B14%29%28q13%3Bq32%29&doi=10.1111%2Fj.1365-2141.1989.tb00252.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)</span></div><div class="casAuthors">Ohtsuki T; Yawata Y; Wada H; Sugihara T; Mori M; Namba M</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-204</span>
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    </div><div class="casAbstract">Two human myeloma cell lines, KMS-12-PE and KMS-12-BM, were established from a 64-year-old woman with a non-producing type of multiple myeloma.  The KMS-12-PE line originated from the pleural effusion and the KMS-12-BM from the bone marrow.  These two lines showed the same chromosome marker, t(11:14)(q13:q32).  However, their phenotypes of surface markers differed from each other.  KMS-12-BM cells were positive to CD20, CD38 and PCA-1. showing the plasmacytoid (immature plasma cell) stage of B-cell differentiation, while KMS-12-PE cells were positive to CD38 and PCA-1, but not to CD20, indicating the terminal differentiated stage of B-cells.  As seen in the pleural effusion of the patient.  KMS-12-PE cells ectopically produced a salivary type of amylase, but KMS-12-BM cells did not.  Interestingly, the chromosome abnormality of del(1)(p22----pter) near the region of 1p21, where the amylase gene was assigned, was noticed in as many as 76% of KMS-12-PE cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa-mt51XJz39TiMd2aNQVUfW6udTcc2ebbprpqWFBD_rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c%252FlslagtQ%253D%253D&md5=fdebafb9ae219b198515126be2c0e364</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.1989.tb00252.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.1989.tb00252.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhtsuki%26aufirst%3DT.%26aulast%3DYawata%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DSugihara%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DNamba%26aufirst%3DM.%26atitle%3DTwo%2520human%2520myeloma%2520cell%2520lines%252C%2520amylase-producing%2520KMS-12-PE%2520and%2520amylase-non-producing%2520KMS-12-BM%252C%2520were%2520established%2520from%2520a%2520patient%252C%2520having%2520the%2520same%2520chromosome%2520marker%252C%2520t%252811%253B14%2529%2528q13%253Bq32%2529%26jtitle%3Dbr%2520J.%2520Haematol.%26date%3D1989%26volume%3D73%26spage%3D199%26epage%3D204%26doi%3D10.1111%2Fj.1365-2141.1989.tb00252.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><div class="note"><p class="first last">Metabolites identified in human hepatocytes for compound <b>17</b> were consistent with oxidation which supported using microsomes for a mechanistic clearance prediction. The predicted clearance was based on in vitro in vivo extrapolation using the well stirred model of hepatic clearance incorporating plasma and microsomal binding. For more about in vitro in vivo extrapolation, please see:</p></div><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">â</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0liMp9sZHUw4eA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">Human Pregnane X Receptor (hPXR) Assay (1 pt): HepG2 cells were transfected with a luciferase reporter construct driven by human CYP3A4 gene and human PXR cDNA. Cells were exposed to test article for 1 day and the luciferase activity was determined by chemiluminescence.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span>I1-receptor Bovine _TO_1 (POC% < 1). For more information on Cerep panel, please visit: <a href="http://www.cerep.fr" class="extLink">http://www.cerep.fr</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=I1-receptor+Bovine+_TO_1+%28POC%25+%3C+1%29.+For+more+information+on+Cerep+panel%2C+please+visit%3A+http%3A%2F%2Fwww.cerep.fr."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span>For kinase profiling protocols, please visit: <a href="http://www.discoverx.com" class="extLink">http://www.discoverx.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+kinase+profiling+protocols%2C+please+visit%3A+http%3A%2F%2Fwww.discoverx.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Amaravadi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">The survival kinases Akt and Pim as potential pharmacological targets</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2618</span><span class="NLM_x">â</span> <span class="NLM_lpage">2624</span><span class="refDoi">Â DOI: 10.1172/JCI26273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=10.1172%2FJCI26273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=16200194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2618-2624&author=R.+Amaravadiauthor=C.+B.+Thompson&title=The+survival+kinases+Akt+and+Pim+as+potential+pharmacological+targets&doi=10.1172%2FJCI26273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The survival kinases Akt and Pim as potential pharmacological targets</span></div><div class="casAuthors">Amaravadi, Ravi; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2618-2624</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  The Akt and Pim kinases are cytoplasmic protein serine/threonine kinases that control programmed cell death (apoptosis) by phosphorylating substrates that regulate both apoptosis and cellular metab.  The phosphatidylinositol 3-kinase-dependent activation of the Akt kinases and the JAK/STAT-dependent induction of the Pim kinases are examples of partially overlapping survival kinase pathways.  Pharmacol. manipulation of such kinases could have a major impact on the treatment of a wide variety of human diseases including cancer, inflammatory disorders, and ischemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUNe0bt5gIJrVg90H21EOLACvtfcHk0liMp9sZHUw4eA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vL&md5=d501bb9ac92d6d2674d09e6375acb57e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1172%2FJCI26273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI26273%26sid%3Dliteratum%253Aachs%26aulast%3DAmaravadi%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520survival%2520kinases%2520Akt%2520and%2520Pim%2520as%2520potential%2520pharmacological%2520targets%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2618%26epage%3D2624%26doi%3D10.1172%2FJCI26273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargiotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthelsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavolella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAlessio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibolla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santocanale, C.</span><span> </span><span class="NLM_article-title">Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure-Activity Relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">â</span> <span class="NLM_lpage">501</span><span class="refDoi">Â DOI: 10.1021/jm700956r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700956r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFCrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=487-501&author=E.+Vanottiauthor=R.+Amiciauthor=A.+Bargiottiauthor=J.+Berthelsenauthor=R.+Bosottiauthor=A.+Ciavolellaauthor=A.+Cirlaauthor=C.+Cristianiauthor=R.+D%E2%80%99Alessioauthor=B.+Forteauthor=A.+Isacchiauthor=K.+Martinaauthor=M.+Menichincheriauthor=A.+Molinariauthor=A.+Montagnoliauthor=P.+Orsiniauthor=A.+Pillanauthor=F.+Rolettoauthor=A.+Scolaroauthor=M.+Tibollaauthor=B.+Valsasinaauthor=M.+Varasiauthor=D.+Volpiauthor=C.+Santocanale&title=Cdc7+Kinase+Inhibitors%3A+Pyrrolopyridinones+as+Potential+Antitumor+Agents.+1.+Synthesis+and+Structure-Activity+Relationships&doi=10.1021%2Fjm700956r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure-Activity Relationships</span></div><div class="casAuthors">Vanotti, Ermes; Amici, Raffaella; Bargiotti, Alberto; Berthelsen, Jens; Bosotti, Roberta; Ciavolella, Antonella; Cirla, Alessandra; Cristiani, Cinzia; D'Alessio, Roberto; Forte, Barbara; Isacchi, Antonella; Martina, Katia; Menichincheri, Maria; Molinari, Antonio; Montagnoli, Alessia; Orsini, Paolo; Pillan, Antonio; Roletto, Fulvia; Scolaro, Alessandra; Tibolla, Marcellino; Valsasina, Barbara; Varasi, Mario; Volpi, Daniele; Santocanale, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">487-501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cdc7 kinase is an essential protein promoting DNA replication in eukaryotic organisms, inhibition of which can cause selective tumor-cell death in a p53-independent manner, supporting the rationale for developing Cdc7 small-mol. inhibitors for the treatment of cancers.  Herein, the synthesis and structure-activity relationships of 2-heteroaryl-substituted pyrrolopyridinones, e.g. I (R1 = H, Me, Et, HOCH2CH2, F3CCH2, cyclopropylmethyl, etc.; R2 = 3-pyridyl, 4-pyridyl, 2-amino-4-pyrimidinyl, purin-9-yl, etc.), the first potent Cdc7 kinase inhibitors, are described.  Starting from 2-(heteroaryl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, progress toward a simple scaffold, tailored for Cdc7 inhibition, is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUMnkXSdra97Vg90H21EOLACvtfcHk0liMp9sZHUw4eA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFCrtQ%253D%253D&md5=211646b7b60414b32e8f85b38706ee10</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm700956r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700956r%26sid%3Dliteratum%253Aachs%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DBargiotti%26aufirst%3DA.%26aulast%3DBerthelsen%26aufirst%3DJ.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DCiavolella%26aufirst%3DA.%26aulast%3DCirla%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DMolinari%26aufirst%3DA.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPillan%26aufirst%3DA.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DTibolla%26aufirst%3DM.%26aulast%3DValsasina%26aufirst%3DB.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVolpi%26aufirst%3DD.%26aulast%3DSantocanale%26aufirst%3DC.%26atitle%3DCdc7%2520Kinase%2520Inhibitors%253A%2520Pyrrolopyridinones%2520as%2520Potential%2520Antitumor%2520Agents.%25201.%2520Synthesis%2520and%2520Structure-Activity%2520Relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D487%26epage%3D501%26doi%3D10.1021%2Fjm700956r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Carpenter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadwick, D. J.</span><span> </span><span class="NLM_article-title">The Scope and Limitations of Carboxamide-Induced Î²-Directed Metalation of 2-Substituted Furan, Thiophene, and 1-Methylpyrrole derivatives. Application of the Method to Syntheses of 2,3-Disubstituted Thiophenes and Furans</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4362</span><span class="NLM_x">â</span> <span class="NLM_lpage">4368</span><span class="refDoi">Â DOI: 10.1021/jo00222a032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00222a032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1985&pages=4362-4368&author=A.+J.+Carpenterauthor=D.+J.+Chadwick&title=The+Scope+and+Limitations+of+Carboxamide-Induced+%CE%B2-Directed+Metalation+of+2-Substituted+Furan%2C+Thiophene%2C+and+1-Methylpyrrole+derivatives.+Application+of+the+Method+to+Syntheses+of+2%2C3-Disubstituted+Thiophenes+and+Furans&doi=10.1021%2Fjo00222a032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo00222a032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00222a032%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DA.%2BJ.%26aulast%3DChadwick%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Scope%2520and%2520Limitations%2520of%2520Carboxamide-Induced%2520%25CE%25B2-Directed%2520Metalation%2520of%25202-Substituted%2520Furan%252C%2520Thiophene%252C%2520and%25201-Methylpyrrole%2520derivatives.%2520Application%2520of%2520the%2520Method%2520to%2520Syntheses%2520of%25202%252C3-Disubstituted%2520Thiophenes%2520and%2520Furans%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1985%26volume%3D50%26spage%3D4362%26epage%3D4368%26doi%3D10.1021%2Fjo00222a032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ','PDB','5IPJ'); return false;">PDB: 5IPJ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i113"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00610">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22076"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00610">10.1021/acs.jmedchem.6b00610</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_002.csv">CSV</a>)</p></li><li><p class="inline">Statistical analysis of data presented in <a class="ref internalNav" href="#tbl1">Tables 1</a> and <a class="ref showTableEvent internalNav" href="#tbl2">2</a>. Atomic coordinates and experimental data of <b>17</b>/Pim-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IPJ">5IPJ</a>). Mouse body weight for the KMS-12 BM xenograft study presented in <a class="ref internalNav" href="#fig3">Figure 3</a>. KINOMEscan data of <b>17</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_002.csv">jm6b00610_si_002.csv (1.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00610/suppl_file/jm6b00610_si_003.pdf">jm6b00610_si_003.pdf (315.26 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00610%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00610" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798983ccf3124c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
